WO1997037967A1 - Calcilytic compounds - Google Patents

Calcilytic compounds Download PDF

Info

Publication number
WO1997037967A1
WO1997037967A1 PCT/US1997/005558 US9705558W WO9737967A1 WO 1997037967 A1 WO1997037967 A1 WO 1997037967A1 US 9705558 W US9705558 W US 9705558W WO 9737967 A1 WO9737967 A1 WO 9737967A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
phenyl
compound
alk
unsubstituted
Prior art date
Application number
PCT/US1997/005558
Other languages
French (fr)
Inventor
Bradford C. Van Wagenen
Eric G. Del Mar
Derek Sheehan
Robert M. Barmore
Richard M. Keenan
Nikesh R. Kotecha
Mervyn Thompson
James F. Callahan
Original Assignee
Nps Pharmaceuticals, Inc.
Smithkline Beecham Plc
Smithkline Beecham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP09536327A priority Critical patent/JP2001501584A/en
Application filed by Nps Pharmaceuticals, Inc., Smithkline Beecham Plc, Smithkline Beecham filed Critical Nps Pharmaceuticals, Inc.
Priority to EP97917848A priority patent/EP0901459B1/en
Priority to PL329314A priority patent/PL191027B1/en
Priority to EA199800913A priority patent/EA002984B1/en
Priority to CA002251331A priority patent/CA2251331C/en
Priority to NZ332068A priority patent/NZ332068A/en
Priority to AT97917848T priority patent/ATE298739T1/en
Priority to IL12645897A priority patent/IL126458A/en
Priority to AU26070/97A priority patent/AU726659B2/en
Priority to BR9708632-0A priority patent/BR9708632A/en
Priority to DE69733649T priority patent/DE69733649T2/en
Publication of WO1997037967A1 publication Critical patent/WO1997037967A1/en
Priority to HK99103964A priority patent/HK1018899A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Definitions

  • the present invention relates to compounds able to inhibit calcium receptor activity and the use of such compounds.
  • the compounds described herein are administered to patients to achieve a therapeutic effect.
  • Extracellular Ca 2 * is under tight homeostatic control and regulates various processes such as blood clotting, nerve and muscle excitability, and proper bone formation.
  • Calcium receptor proteins enable certain specialized cells to respond to changes in extracellular Ca 2 * concentration. For example, extracellular Ca 2 * inhibits the secretion of parathyroid hormone (PTH) from parathyroid cells, inhibits bone resorption by osteoclasts, and stimulates secretion of calcitonin from C-cells.
  • PTH parathyroid hormone
  • PTH is the principal endocrine factor regulating Ca 2 * homeostasis in the blood and extracellular fluids. PTH, by acting on bone and kidney cells, increases the level of Ca 2 * in the blood. This increase in extracellular Ca 2 * then acts as a negative feedback signal, depressing PTH secretion. The reciprocal relationship between extracellular Ca 2 * and PTH secretion forms an important mechanism maintaining bodily Ca 2 * homeostasis.
  • Extracellular Ca 2 * acts directly on parathyroid cells to regulate PTH secretion.
  • the existence of a parathyroid cell surface protein which detects changes in extracellular Ca 2 * has been confirmed. (Brown et al . , Nature 366: 574 , 1993.)
  • this protein the calcium receptor, acts as a receptor for extracellular Ca 2 *, detects changes in the ion concentration of extracellular Ca 2 *, and initiates a functional cellular response, PTH secretion.
  • Extracellular Ca 2 * can exert effects on different cell functions, reviewed in Nemeth et al . , Cell Calcium 11 : 319 , 1990.
  • the role of extracellular Ca 2 * in parafollicular (C- cells) and parathyroid cells is discussed in Nemeth, Cell Calcium 11:323, 1990. These cells were shown to express similar calcium receptors.
  • C- cells parafollicular cells
  • C- cells parafollicular cells
  • parathyroid cells were shown to express similar calcium receptors.
  • These cells were shown to express similar calcium receptors.
  • the role of extracellular Ca 2 * on bone osteoclasts is discussed by Zaidi, Bioscience Reports 10:493, 1990.
  • Applicant is also the first to describe methods by which molecules active at these Ca 2 * receptors can be identified and used as lead molecules in the discovery, development, design, modification and/or construction of useful calcimimetics or calcilytics which are active at Ca 2 * receptors.
  • Such calcimimetics or calcilytics are useful in the treatment of various disease states characterized by abnormal levels of one or more components, e.g.. polypeptides such as hormones, enzymes or growth factors, the expresssion and/or secretion of which is regulated or affected by activity at one or more Ca 2 * receptors.
  • Calcilytic compounds refer to compounds able to inhibit calcium receptor activity.
  • the ability of a compound to "inhibit calcium receptor activity” means that the compound causes a decrease in one or more calcium receptor activities evoked by extracellular Ca 2 *.
  • calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient are described below. Also described below are techniques which can be used to obtain additional calcilytic compounds.
  • R 2 where Rj is selected from the group consisting of: aryl, longer-length alk, and cycloalk;
  • R 3 and R 4 is each independently lower alk or together cyclopropyl
  • Yj is either covalent bond, alkylene, or alkenylene
  • Y 2 is alkylene
  • Y 3 is alkylene
  • Z is selected from the group consisting of: covalent bond, 0, S, NH, N-lower alk, alkylene, alkenylene, and alkynylene, provided that if Z is either 0, S, NH, or N-lower alk, then Y x is not a covalent bond, further provided that Y x and Z may together be a covalent bond; and pharmaceutically acceptable salts and complexes thereof.
  • Section II, infra also provides definitions for other chemical groups described in the present application.
  • Preferred calcilytic compounds have an IC 50 ⁇ . 50 ⁇ M, more preferably an IC 50 ⁇ 10 ⁇ M, and even more preferably an IC 50 ⁇ 1 ⁇ M, as measured using the "Calcium Receptor Inhibitor Assay" described in Example 1, infra.
  • a first aspect of the present invention features a method of treating a patient by administering to the patient a therapeutically effective amount of a Structure I ⁇ , ⁇ -disubstituted arylalkylamine derivative. Treatment can be carried out, for example, to retard the disease in a patient having a disease or to prophylactically retard or prevent the onset of a disease.
  • a therapeutically effective amount is the amount of compound which achieves a therapeutic effect by retarding a disease in a patient having a disease or prophylactically retarding or preventing the onset of a disease.
  • it is an amount which relieves to some extent one or more symptoms of a disease or disorder in a patient; returns to normal either partially or completely one or more physiological or biochemical parameters associated with or causative of the disease or disorder; and/or reduces the likelihood of the onset of the disease of disorder.
  • a "patient” refers to a mammal in which compounds characterized by their ability to inhibit calcium receptor activity, in vivo or in vitro, will have a beneficial effect.
  • the patient is a human being.
  • Patients benefiting from the administration of a therapeutic amount of a calcilytic compound can be identified using standard techniques known to those in the medical profession.
  • Diseases or disorders which can be treated by inhibiting one or more calcium receptor activities include one or more of the following types: (1) those characterized by an abnormal bone and mineral homeostasis; (2) those characterized by an abnormal amount of an extracellular or intracellular messenger whose production can be affected by one or more calcium receptor activities; (3) those characterized by an abnormal effect (e. g.
  • an intracellular or extracellular messenger which can itself be ameliorated by one or more calcium receptor activities; and (4) other diseases or disorders where inhibition of one or more calcium receptor activities exerts a beneficial effect, for example, in diseases or disorders where the production of an intracellular or extracellular messenger stimulated by receptor activity compensates for an abnormal amount of a different messenger.
  • extracellular messengers whose secretion and/or effect can be affected by inhibiting calcium receptor activity are believed to include inorganic ions, hormones, neurotransmitters, growth factors, and chemokines .
  • intracellular messengers include cAMP, cGMP, IP 3 , calcium, magnesium, and diacylglycerol.
  • a patient is a human having a disease or disorder characterized by one or more of the following: (1) an abnormal bone or mineral homeostasis; (2) an abnormal amount of an extracellular or intracellular messenger which is ameliorated by a compound able to effect one or more calcium receptor activities; and (3) an abnormal effect of an intracellular or extracellular messenger which is ameliorated by a compound able to effect one or more calcium receptor activities.
  • the disease or disorder is characterized by an abnormal bone and mineral homeostasis, more preferably calcium homeostasis.
  • Abnormal calcium homeostasis is characterized by one or more of the following activities: (1) an abnormal increase or decrease in serum calcium; (2) an abnormal increase or decrease in urinary excretion of calcium; (3) an abnormal increase or decrease in bone calcium levels, for example, as assessed by bone mineral density measurements; (4) an abnormal absorption of dietary calcium; (5) an abnormal increase or decrease in the production and/or release of messengers which affect serum calcium levels such as PTH and calcitonin; and (6) an abnormal change in the response elicited by messengers which affect serum calcium levels.
  • the abnormal increase or decrease in these different aspects of calcium homeostasis is relative to that occurring in the general population and is generally associated with a disease or disorder.
  • the calcilytic compounds are used to treat diseases or disorders selected from the group consisting of: hypoparathyroidism, osteosarcoma, periodontal disease, fracture healing, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia malignancy, and osteoporosis.
  • Another aspect of the present invention describes a method of treating a patient comprising the step of administering to the patient an amount of a calcilytic compound sufficient to increase serum PTH level.
  • the method is carried out by administering an amount of the compound effective to cause an increase in duration and/or quantity of serum PTH level sufficient to have a therapeutic effect.
  • Increasing serum PTH may be used to achieve a therapeutic effect by retarding a disease in a patient having the disease or prophylactically retarding or preventing the onset of a disease.
  • Prophylactic treatment can be performed, for example, on a person with an abnormally low serum PTH; or on a person without a low serum PTH, but were increasing PTH has a beneficial effect.
  • An abnormally low serum PTH is a serum PTH level lower than that occurring in the general population, and is preferably an amount associated with a disease or the onset of a disease.
  • Increasing serum PTH levels can be used to treat different types of diseases including bone and mineral related diseases.
  • the compound is administered to a patient to cause an increase in serum PTH having a duration up to one hour, about one to about twenty-four hours, about one to about twelve hours, about one to about six hours, about one to about five hours, about one to about four hours, about two to about five hours, about two to about four hours, or about three to about six hours.
  • the compound is administered to a patient to cause an increase in serum PTH up to 0.5 fold, 0.5 to 5 fold, 5 fold to 10 ten fold, and at least 10 fold, greater than peak serum PTH in the patient.
  • the peak serum level is measured with respect to the patient not undergoing treatment.
  • Another aspect of the present invention features Structure I calcilytic compounds.
  • compositions comprising a pharmaceutically acceptable carrier and a calcilytic compound described herein.
  • the pharmaceutical composition contains the calcilytic compound in a form suitable for administration into a mammal, preferably, a human being.
  • the pharmaceutical composition contains an amount of a calcilytic compound in a proper pharmaceutical dosage form sufficient to exert a therapeutic effect on a human being.
  • multiple doses of pharmaceutical compositions may be used to treat a patient. Considerations and factors concerning dosage forms suitable for administration are known in the art and include potential toxic effects, solubility, route of administration, and maintaining activity.
  • pharmaceutical compositions injected into the bloodstream should be soluble.
  • Another aspect of the present invention features a method of screening for Structure I ⁇ , -disubstituted arylalkylamine derivatives able to inhibit calcium receptor activity.
  • the method involves the steps of contacting a cell having a calcium receptor with a Structure I ⁇ , ⁇ -di- substituted arylalkylamine derivative and measuring the ability of the compound to inhibit calcium receptor activity.
  • the screening method can be carried out in vivo or in vitro and is particularly useful to identify those Structure I ⁇ , -disubstituted arylalkylamine derivatives most able to act as calcilytic compounds.
  • In vivo assays include measuring a physiological parameter related to calcium receptor activity, such as serum hormone levels or serum calcium ion concentration.
  • In vitro assays include measuring the ability of the calcilytic compound to affect intracellular calcium concentration, or cellular hormone secretion.
  • hormones levels which can be affected by calcilytic compounds include PTH and calcitonin.
  • the calcilytic compounds described herein can be used as part of in vivo or in vi tro methods. Preferably, the compounds are used in vivo to achieve a beneficial effect in a patient.
  • Examples of in vitro uses, and other in vivo uses include use in a method to identify other calcilytic compounds and use as a tool to investigate calcium receptor activity or the physiological effects of inhibiting calcium receptor activity in different organisms.
  • the present application demonstrates the ability of calcilytic compounds to exert a physiologically relevant effect on a cell by illustrating the ability of such compounds to increase PTH secretion and also identifies a target site for calcilytic compounds.
  • the present application is believed to be the first to demonstrate that calcilytic compounds can increase PTH secretion.
  • Calcium receptors are present on different cell types and can regulate different responses in different cell types. While the calcilytic compounds described herein are believed to act at a calcium receptor through a calcium receptor- activity modulating site, unless otherwise explicitly stated in the claims that a compound exerts an effect by acting at a calcium receptor through such a site, there is no intention to limit the claimed methods or compound to requiring inhibition of calcium receptor activity or any particular mode of action. Rather, the present application demonstrates that compounds able to inhibit calcium receptor activity, whose calcilytic activity can be measured in vivo or in vitro, exert significant physiological effects. For example, the present application demonstrates the ability of different calcilytic compounds to prevent Ca 2 * inhibition of PTH and, thereby, result in an increase in PTH release.
  • Compounds binding at the calcium receptor-activity modulating site can be identified using a labeled compound binding to the site in a competition-binding assay format.
  • Preferred calcilytic compounds described herein are Structure I ⁇ , ⁇ -disubstituted arylalkylamine derivatives able to inhibit calcium receptor activity.
  • Other aspects of the present invention include assays which can be used to identify those Structure I ⁇ , ⁇ -disubstituted arylalkylamine derivatives expected to be effective in inhibiting calcium receptor activity, and/or exerting a therapeutic effect in a patient; preferred groups of Structure I a, ⁇ -disubstituted arylalkylamine derivatives; and the use of the compounds described herein to treat different diseases or disorders.
  • Calcium receptors respond to changes in extracellular calcium levels. The exact changes resulting from calcium receptor activity depend on the particular receptor and the cell containing the receptor. For example, the in vi tro effect of calcium on the calcium receptor in a parathyroid cell includes the following:
  • An increase in internal calcium [Ca 2 *] ⁇ The increase is due to the influx of external calcium and/or to the mobilization of internal calcium. Characteristics of the increase in internal calcium include the following:
  • the transient increase is abolished by pretreatment for 10 minutes with 10 mM sodium fluoride;
  • the transient increase is diminished by pretreatment with an activator of protein kinase C (PKC) , such as phorbol myristate acetate (PMA), mezerein or (-)- indolactam V.
  • PKC protein kinase C
  • PMA phorbol myristate acetate
  • mezerein mezerein
  • - indolactam V The overall effect of the protein kinase C activator is to shift the concentration-response curve of calcium to the right without affecting the maximal response;
  • Pretreatment with pertussis toxin does not affect this increase; 3.
  • the inhibition of dopamine- and isoproterenol- stimulated cyclic AMP formation This effect is blocked by pretreatment with pertussis toxin (100 ng/ml for > 4 hours) ; and 4.
  • the inhibition of PTH secretion Pretreatment with pertussis toxin (100 ng/ml for > 4 hours) does not affect the inhibition of PTH secretion.
  • Calcilytic activity of a compound can be determined using techniques such as those described in the examples below and those described in publications such as Nemeth et al . , PCT/US92/07175, International Publication Number WO 93/04373, Nemeth et al . , PCT/US93/01642, International Publication Number WO 94/18959, and Nemeth et al . , PCT/US94/12117, International Publication Number WO 95/11211 (each of which are hereby incorporated by reference herein) .
  • Calcilytic activity varies depending upon the cell type in which the activity is measured. For example, calcilytic compounds possess one or more, and preferably all, of the following characteristics when tested on parathyroid cells in vitro:
  • the compound blocks, either partially or completely, the ability of increased concentrations of extracellular Ca 2 * to:
  • the compound blocks increases in Cl " current in Xenopus oocytes injected with poly(A) '-mRNA from bovine or human parathyroid cells elicited by extracellular Ca 2 *, but not in Xenopus oocytes injected with water;
  • the compound blocks a response in Xenopus oocytes, injected with cloned nucleic acid expressing the calcium receptor, elicited by extracellular Ca 2 * or a calcimimetic compound (i.e., a compound able to mimic the effect of extracellular Ca 2 *, including compounds potentiating the effect of extracellular Ca 2 *) .
  • a calcimimetic compound i.e., a compound able to mimic the effect of extracellular Ca 2 *, including compounds potentiating the effect of extracellular Ca 2 *
  • Calcium receptors are present in different cells. The pharmacological effects of the following cells, in response to extracellular Ca 2 *, is consistent with the presence of a calcium receptor: parathyroid cell, bone osteoclast, juxtaglomerular kidney cell, proximal tubule kidney cell, distal tubule kidney cell, central nervous system cell, peripheral nervous system cell, cell of the thick ascending limb of Henle's loop and/or collecting duct, keratinocyte in the epidermis, parafollicular cell in the thyroid (C-cell) , intestinal cell, trophoblast in the placenta, platelet, vascular smooth muscle cell, cardiac atrial cell, gastrin- secreting cell, glucagon-secreting cell, kidney mesangial cell, mammary cell, endocrine and exocrine cells in the pancreas, fat/adipose cell, immune cell, GI tract cell, skin cell, -adrenal cell, pituitary cell, hypothalamic cell and cell of
  • a calcium receptor on the following cells have been confirmed using physical data, such as hybridization with nucleic acid encoding a calcium receptor: parathyroid cell, central nervous system cell, peripheral nervous system cell, cell of the thick ascending limb of Henle's loop and/or collecting duct in the kidney, parafollicular cell in the thyroid (C-cell), intestinal cell, GI tract cell, pituitary cell, hypothalamic cell, cell of the subfornical organ, and endocrine and exocrine cells in the pancreas.
  • Rj is selected from the group consisting of: aryl, longer-length alk, and cycloalk.
  • Rj is either optionally substituted phenyl, optionally substituted pyridyl, optionally substituted benzothiopyranyl, optionally substituted carbazole, optionally substituted naphthyl, optionally substituted tetrahydronaphthyl, optionally substituted longer-length alkyl, optionally substituted longer-length alkenyl or optionally substituted cycloalk.
  • R x is either an optionally substituted phenyl; an optionally substituted naphthyl; an optionally substituted pyridyl; an optionally substituted benzothiopyranyl; an optionally substituted carbazole; unsubstituted longer-length alkyl; unsubstituted longer- length alkenyl; or monosubstituted longer-length alkyl or alkenyl, where the monosubstituent is either an optionally substituted phenyl or an optionally substituted cycloalkyl provided that the optionally substituted phenyl or optionally substituted cycloalkyl can have one to four substituents each independently selected from the group consisting of: alkoxy, lower-haloalkyl, S-unsubstituted alkyl, lower-haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, N0 2 , NH 2 and OH;
  • R 2 is OH or alkoxy, even more preferably, R 2 is OH or methoxy;
  • R 3 and R restroom is each independently lower alk or together cyclopropyl.
  • R 3 and R 4 are each independently a lower alkyl, more preferably, R 3 and R 4 are each independently methyl or ethyl;
  • R 5 is aryl.
  • R 5 is either optionally substituted naphthyl or optionally substituted phenyl. More preferably, R 5 is substituted phenyl having a substituent in the meta or para position and optionally containing additional substituents;
  • R 6 is either hydrogen or lower alkyl, more preferably R 6 is hydrogen.
  • Y 1 is either covalent bond, alkylene, or alkenylene.
  • Y x is either covalent bond or lower alkylene. More preferably, Y is methylene;
  • Y 2 is alkylene.
  • Y 2 is lower alkylene. More preferably, Y 2 is methylene;
  • Y 3 is alkylene.
  • Y 3 is lower alkylene. More preferably, Y 3 is methylene;
  • Z is selected from the group consisting of: covalent bond, 0, S, NH, N-lower alk, alkylene, alkenylene, and alkynylene, provided that if Z is either 0, S, NH, or N-lower alk, then Y ⁇ is not a covalent bond, further provided that Y x and Z may together be a covalent bond.
  • Z is selected from the group consisting of: covalent bond, O, S, NH, N-lower alk, and alkylene. More preferably, Z is either O, S, lower alkylene, even more preferably, Z is O; and pharmaceutically acceptable salts and complexes thereof.
  • Alk refers to either alkyl, alkenyl, or alkynyl.
  • Lower alk refers to either lower alkyl, lower alkenyl, or lower alkynyl, preferably, lower alkyl.
  • Alkenyl refers to an optionally substituted hydrocarbon group containing at least one carbon-carbon double bond between the carbon atoms and containing 2-15 carbon atoms joined together.
  • the alkenyl hydrocarbon group may be straight-chain or contain one or more branches. Branched- and straight-chain alkenyl preferably have 2 to 7 carbons, each of which may be optionally substituted.
  • the alkenyl is a lower alkenyl, which is an unsubstituted branched- or straight-chain alkenyl having 2 to 4 carbons.
  • Alkyl refers to an optionally substituted hydrocarbon group joined by single carbon-carbon bonds and having 1-15 carbon atoms joined together.
  • the alkyl hydrocarbon group may be straight-chain or contain one or more branches. Branched- and straight-chain alkyl preferably have 1 to 7 carbons, each of which may be optionally substituted.
  • Alkyl substituents are each independently selected from the substituents described above for alkenyl. Preferably, no more than three substituents are present. More preferably, the alkyl is a lower alkyl, which is an unsubstituted branched- or straight-chain alkyl 1 to 4 carbons in length.
  • Alkynyl refers to an optionally substituted hydrocarbon group containing at least one carbon-carbon triple bond between the carbon atoms and containing 2-15 carbon atoms joined together.
  • the alkynyl hydrocarbon group may be straight-chain or contain one or more branches. Branched- and straight-chain alkynyl preferably have 2 to 7 carbons, each of which may be optionally substituted.
  • Alkynyl substituents are each independently selected from the substituents described above for alkenyl. Preferably, no more than three substituents are present. More preferably, the alkynyl is a lower alkynyl, which is an unsubstituted branched- or straight-chain alkynyl having 2 to 4 carbons.
  • Alkenylene refers to an optionally substituted hydrocarbon chain containing at least one carbon-carbon double bond between the carbon atoms. The alkenylene chain has 2 to 6 carbons and is attached at two locations to other functional groups or structural moieties.
  • the alkenylene substituents are each independently selected from the substituents described above for alkenyl. Preferably, no 18 more than three substituents are present.
  • the alkenylene is a "lower alkenylene,” which is an unsubstituted branched- or straight-chain alkenylene having 2 to 3 carbons.
  • Alkoxy refers to oxygen joined to an unsubstituted alkyl 1 to 12 carbon atoms in length, preferably 1 to 2 carbons in length. More preferably, the alkoxy is methoxy.
  • Alkylene refers to an optionally substituted hydrocarbon chain containing only carbon-carbon single bonds between the carbon atoms.
  • the alkylene chain has 1 to 6 carbons and is attached at two locations to other functional groups or structural moieties.
  • the alkylene substituents are each independently selected from the substituents described above for alkenyl. Preferably, no more than three substituents are present.- More preferably, the alkylene is a "lower alkylene,” which is an unsubstituted branched- or straight-chain alkylene having 1 to 3 carbons.
  • Alkynylene refers to an optionally substituted hydrocarbon chain containing at least one carbon-carbon triple bond between the carbon atoms.
  • the alkynylene chain has 2 to 6 carbons and is attached at two locations to other functional groups or structural moieties.
  • the alkynylene substituents are each independently selected from the substituents described above for alkenyl. More preferably, the alkynylene is a "lower alkynylene,” which is an unsubstituted branched- or straight-chain alkynylene having 2 to 3 carbons.
  • Aryl refers to an optionally substituted aromatic group with at least one ring having a conjugated pi- electron system, containing up to two conjugated or fused ring systems.
  • Aryl includes carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally substituted.
  • the aryl is either optionally substituted phenyl, optionally substituted pyridyl, optionally substituted benzothiopyranyl, optionally substituted carbazole, optionally substituted naphthyl, optionally substituted tetrahydronaphthyl.
  • the aryl has no more than five independently selected substituents.
  • R is an aryl
  • the aryl is either optionally substituted phenyl, optionally substituted pyridyl, optionally substituted benzothiopyranyl, optionally substituted carbazole, optionally substituted naphthyl, or optionally substituted tetrahydronaphthyl.
  • R aryl substituents are each independently selected from the group consisting of: alkoxy, methylene dioxy, N(CH 3 ) 2/ C(0)OCH 3 , phenyl, lower-haloalkyl,
  • each R L aryl substituent is independently selected from the group consisting of: unsubstituted C j. -C 7 alkyl, Ci-C 7 alkoxy, lower haloalkoxy, CF 3 , F, Cl, Br, CN, and N0 2 .
  • R is either 2-CN- phenyl, 2,3-dichloro phenyl, 2-nitro-phenyl, or 2-cyano-3- chloro-phenyl.
  • R 5 right hand aryl substituents are each independently selected from the substituents described above for alkenyl .
  • the R 5 aryl substituents are each independently selected from the group consisting of: methoxy, lower alkyl, lower haloalkoxy, CFH 2 , CHF 2 , CF 3 , OCH 2 CF 3 , F, Cl, Br, I, OH, SH, CN, N0 2 , NH 2 , methylene dioxy, NH-lower alkyl, Ndower alkyl) 2 , C(O) lower alkyl, S-lower alkyl, S(0) lower alkyl, S(0) 2 lower alkyl, 0C(0) lower alkyl, SC(O) lower alkyl, 0C(S) lower alkyl, NHC(O) lower alkyl, Ndower alkyl) C(O) lower alkyl, NHC(S) lower alkyl, Ndower alkyl) C(S) lower alkyl, NHS(0)lower alkyl, Ndower alkyl) S (O) lower alkyl,
  • R 5 aryl substituents are each independently selected from the group consisting of: methylene dioxy, methoxy, lower-haloalkyl, S-lower alkyl, lower-haloalkoxy, lower alkyl, halogen, SH, CN, OH, Cl, F, and Br. Preferred halogens are Cl, F, and Br.
  • Carbocyclic aryl refers to an aromatic ring or ring system having all carbon atoms. The carbon atoms are optionally substituted.
  • Cycloalk refers to an optionally substituted cyclic alkyl or an optionally substituted non-aromatic cyclic alkenyl and includes monocyclic and multiple ring structures such as bicyclic and tricyclic.
  • the cycloalk has 3 to 15 carbon atoms, preferably, 5 to 12 carbon atoms.
  • Optional substituents for the cycloalk are each independently selected from the group described above for alkenyl. Preferably, no more than three substituents are present. More preferably, the cycloalk is unsubstituted, even more preferably it is an unsubstituted cyclic alkyl.
  • Preferred cycloalkyl groups include cyclohexyl and adamantyl.
  • Haloalk refers to substituted alkyl or substituted alkenyl, having no more than 4 carbons, where the substituents are halogens and at least one halogen is present.
  • the haloalk is an alkyl 1 to 3 carbons in length and the halogens are each independently either Cl or F, more preferably the alkyl has 2 carbons, more preferably the haloalkyl is a lower haloalkyl which has 1 carbon.
  • Heterocyclic aryl refers to an aryl having 1 to 3 heteroatoms as ring atoms in the aromatic ring and the remainder of the ring atoms are carbon atoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen. Examples of heterocyclic aryl include indolyl, pyridyl, quinolinyl, and isoquinolinyl.
  • Longer-length alk refers to either longer-length alkyl, longer-length alkenyl, or longer-length alkynyl; preferably, longer-length alkyl or longer-length alkenyl. More preferably a longer-length alk is 4 to 20 carbon atoms.
  • Longer-length alkenyl refers to an optionally substituted hydrocarbon group containing at least one carbon-carbon double bond between the carbon atoms, and which contains 2-20 carbon atoms joined together.
  • the longer-length alkenyl is 4 to 20 carbon atoms.
  • the longer- length alkenyl hydrocarbon group may be straight-chain or contain one or more branches.
  • Longer-length alkenyl substituents are each independently selected from the alkenyl substituent list described above.
  • the longer- length alkenyl is either unsubstituted or has one cycloalk or phenyl substituent. More preferably, the cycloalk substituent, if present, is unsubstituted, and more preferably the cycloalk substituent, if present, is either cyclohexyl or adamantyl.
  • “Longer-length alkyl” refers to an optionally substituted hydrocarbon group joined by single carbon-carbon bonds and which contains 1-20 carbon atoms joined together. Preferably, the longer-length alkyl is 4 to 20 carbon atoms.
  • the longer-length alkyl hydrocarbon group may be straight-chain or contain one or more branches.
  • Longer- length alkyl substituents are each independently selected from the alkenyl substituent list described above.
  • the longer-length alkyl is either unsubstituted or has one cycloalk or phenyl substituent. More preferably, the cycloalk substituent, if present, is unsubstituted, and more preferably the cycloalk substituent, if present, is either cyclohexyl or adamantyl.
  • Longer-length alkynyl refers to an optionally substituted hydrocarbon group containing at least one carbon-carbon triple bond between the carbon atoms, and which contains 2-20 carbon atoms joined together.
  • the longer-length alkynyl is 4 to 20 carbon atoms.
  • the longer- length alkynyl hydrocarbon group may be straight-chain or contain one or more branches.
  • Longer-length alkynyl substituents are each independently selected from the alkenyl substituent list described above.
  • the longer- length alkynyl is either unsubstituted or has one cycloalk or phenyl substituent substituent.
  • the cycloalk substituent if present, is unsubstituted, and more preferably the cycloalk substituent, if present, is either cyclohexyl or adamantyl.
  • “Haloalkoxy” refers to oxygen joined to a "haloalk.”
  • the haloalkoxy is a "lower-haloalkoxy,” which is an oxygen joined to a lower-haloalkyl.
  • More preferred calcilytic compounds are Structure I derivatives where R 3 , R 2 , R 3 , R 4 , R 6 , Z, Y x and Y 2 are as described above for Structure I ⁇ , ⁇ -disubstituted arylalkylamine derivatives, including preferred groups (see, Section II, supra) ; and
  • R 5 is either phenyl substituted with one to four independently selected substituents or an optionally substituted naphthyl having up to four independently selected substituents.
  • R 5 substituents are provided in Section II, supra . , including preferred embodiments. More preferably R 5 is either a substituted phenyl comprising a substituent in a meta or para position, more preferably, the substituent present in a meta or para position is either methyl, ethyl, isopropyl, methoxy, Cl, F, Br, or lower haloalkoxy.
  • Examples of compounds having an IC 50 ⁇ 50 ⁇ include compounds 1, 9, 17, 25, 29, 42, 56, 79, 90, 101 and 164; examples of preferred compounds having an IC 50 ⁇ 10 ⁇ M include compounds 2, 3, 7, 8, 26, 27, 32, 33, 35, 37, 39, 41, 45, 48, 49, 59, 61, 66, 68, 71, 75, 93, 98, 103, 104, 110, 111, 114, 123, 124, 125, 128, 132, 144, 147, 152, 155, 158, 161, 162, 169 and 170; and examples of more preferred compounds having an IC 50 ⁇ than 1 ⁇ M include compounds 5, 6, 19, 20, 21, 28, 38, 40, 43, 44, 46, 47, 50, 51, 63, 64, 65, 67, 69, 72, 74, 96, 105, 106, 109, 112, 113, 115, 116
  • Structure II compounds have the following structure:
  • R 1( R 2 , R 3 , and R 4 are as described above for Structure I ⁇ , ⁇ -disubstituted arylalkylamine derivatives, including preferred groups (see, Section II, supra) ; and R 5 is either an optionally substituted naphthyl having one to four substituents independently selected from the group consisting of methyl, ethyl, isopropyl, methoxy, Cl, F, Br, or lower haloalkoxy, preferably the naphthyl is unsubstituted; or a substituted phenyl having one to four substituent with at least one substituent in a meta or para position selected from the group consisting of: lower alkyl, methoxy, Cl, F, Br, and lower haloalkoxy, more preferably a methoxy is present in the para or meta position; even more preferably, the remaining R 5 substituents are independently selected from the group consisting of: methoxy, lower-haloalkyl, S-lower al
  • R x is not 6-CN-2-pyridyl; and further provided that if R 5 is 3,4 dimethoxy-phenyl, then R ⁇ is not CH 3 (CH 2 ) 5 0-phenyl; 2-cyciopentyl-phenyl; 2-Cl-phenyl; 2-CN-phenyl; 2- (3-furanyl)phenyl; or 4- (1, 2, -benzisothiazol) ; preferably, R 5 is not 3,4 dimethoxy phenyl; further provided that if R 5 is 4-methoxy-phenyl, then R is not 2-cyciopentyl-phenyl; 2-CH 3 -phenyl; 2-benzyl-phenyl; 3- CH 3 , 4-CH 3 S0 2 -phenyl; or 4- (1,2, -benzisothiazol) ; further provided that if R 5 is 4-C1-phenyl, then R x is not 2-CH 3 -phenyl , 5-iso-propyl
  • R 2 , R 3 , and R 4 are as described above for Structure I ⁇ , ⁇ -disubstituted arylalkylamine derivatives, including preferred groups ( see, Section II, supra) , -
  • R 5 is either an optionally substituted naphthyl having one to four substituents independently selected from the group consisting of methyl, ethyl, isopropyl, methoxy, Cl, F, Br, and lower haloalkoxy, preferably the naphthyl is unsubstituted; or a substituted phenyl having one to four substituent with at least one substituent in a meta or para position selected from the group consisting of: methyl, ethyl, isopropyl, methoxy, Cl, F, Br, and lower haloalkoxy, more preferably a methoxy is present in the para or meta position; even more preferably, the remaining R 5 substituents are independently selected from the group consisting of: methoxy, lower-haloalkyl, S-lower alkyl, lower-haloalkoxy, lower alkyl, halogen, SH, CN, OH, Cl, F, and Br; and
  • R x is either 2-CN-phenyl, 2,3-dichloro phenyl, 2-nitro- phenyl, 2-cyano-3-chloro-phenyl, an optionally substituted pyridyl, an optionally substituted benzothiopyranyl, or an optionally substituted carbazole, where the optionally present substituents for the pyridyl, benzothiopyranyl, and carbazole as described in Section II supra, for aryl R x substituents, including preferred substituents, and are even more preferably independently selected from the group consisting of: methoxy, lower-haloalkyl, S-lower alkyl, lower-haloalkoxy, lower alkyl, halogen, SH, CN, OH, Cl, F, and Br.
  • calcilytic compounds described herein can be formulated as a pharmaceutical composition to facilitate the administration of the compound to a patient.
  • Preferred formulations contain a pharmaceutically acceptable carrier and a calcilytic compound as described in Section II, supra . , including the different embodiments.
  • Suitable carriers include calcium carbonate, calcium phosphate, lactose, glucose, sucrose, gelatin, vegetable oils, polyethylene glycols and physiologically compatible solvents.
  • Compounds inhibiting calcium receptor activity can be used to confer beneficial effects to patients suffering from a variety of diseases or disorders.
  • Diseases or disorders which can be treated using a calcilytic compound are known in the art and can be identified using the present application as a guide.
  • diseases or disorders can be identified based on the functional responses of cells regulated by calcium receptor activity.
  • Diseases and disorders which can be treated using the calcilytic compounds described herein include those due to different cellular defects related to calcium receptor activity in different cells, such as a defective calcium receptor or an abnormal number of calcium receptors, a defective intracellular protein acted on by a calcium receptor, or a defective protein or an abnormal number of proteins acting on a calcium receptor.
  • Functional responses of cells regulated by the calcium receptor are known in the art, including PTH secretion by parathyroid cells, calcitonin secretion by C-cells, bone resorption by osteoclasts, and Ca 2 * secretion by kidney cells. Such functional responses are associated with different diseases or disorders.
  • isolated osteoclasts respond to increases in the concentration of extracellular Ca 2 * with corresponding increases in [Ca 2 *]i arising partly from the mobilization of intracellular Ca 2 *.
  • Increases in [Ca 2 *] x in osteoclasts are associated with the inhibition of bone resorption.
  • Renin secretion from juxtaglomerular cells in the kidney is depressed by increased concentrations of extracellular Ca 2 *.
  • Extracellular Ca 2 * causes the mobilization of intracellular Ca 2 * in these cells.
  • Other kidney cells respond to extracellular Ca 2 * as follows: elevated Ca 2 * inhibits formation of 1,25(OH) 2 -vitamin D by proximal tubule cells, stimulates production of calcium-binding protein in distal tubule cells, and inhibits tubular reabsorption of Ca 2 * and Mg 2 * in the thick ascending limb of Henle's loop (MTAL) , and reduces vasopressin action in the cortical collecting duct.
  • MTAL Henle's loop
  • Other examples of functional responses affected by extracellular Ca 2 * include promoting differentiation of intestinal goblet cells, mammary cells, and skin cells; inhibiting atrial natriuretic peptide secretion from cardiac atria; reducing cAMP accumulation in platelets; altering gastrin and glucagon secretion; acting on perivascular nerves to modify cell secretion of vasoactive factors; and affecting cells of the central nervous and peripheral nervous systems.
  • Diseases and disorders which might be treated or prevented, based upon the affected cells include bone and mineral-related diseases or disorders; hypoparathyroidism; those of the central nervous system such as seizures, stroke, head trauma, spinal cord injury, hypoxia-induced nerve cell damage, such as occurs in cardiac arrest or neonatal distress, epilepsy, neurodegenerative diseases such as Alzheimer's disease, Huntington's disease and Parkinson's disease, dementia, muscle tension, depression, anxiety, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, schizophrenia, neuroleptic malignant syndrome, and Tourette's syndrome; diseases involving excess water reabsorption by the kidney, such as syndrome of inappropriate ADH secretion (SIADH) , cirrhosis, congestive heart failure, and nephrosis; hypertension; preventing and/or decreasing renal toxicity from cationic antibiotics (e.
  • SIADH syndrome of inappropriate ADH secretion
  • GI ulcer diseases g. , aminoglycoside antibiotics
  • gut motility disorders such as diarrhea and spastic colon,- GI ulcer diseases
  • GI diseases with excessive calcium absorption such as sarcoidosis
  • autoimmune diseases and organ transplant rejection squamous cell carcinoma
  • pancreatitis g. , aminoglycoside antibiotics
  • calcilytic compounds of the present invention will typically be used to treat human patients, they may also be used to treat similar or identical diseases or disorders in other warm-blooded animal species, such as other primates, farm animals such as swine, cattle, and poultry; and sports animals and pets such as horses, dogs and cats.
  • calcilytic compounds are used in the treatment of bone and mineral-related diseases or disorders.
  • Bone and mineral-related diseases or disorders comprise a diverse class of disorders affecting nearly every major organ system in the body. Examples of bone and mineral-related diseases or disorders include osteosarcoma, periodontal disease, fracture healing, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia malignancy, and osteoporosis.
  • calcilytic compounds are used to treat osteoporosis, a disease characterized by reduced bone density and an increased susceptibility to fractures. Osteoporosis is associated with aging, especially in women.
  • PTH can have a catabolic or an anabolic effect on bone. Whether PTH causes a catabolic effect or an anabolic effect seems to depend on how plasma levels of PTH are altered.
  • plasma levels of PTH are chronically elevated, as in hyperparathyroid states, there is a net loss of bone.
  • intermittent increases in plasma PTH levels, as achieved by administration of exogenous hormone result in new bone formation.
  • Anabolic action of PTH on bone is described, for example, by Dempster et al . , Endocrin . Rev. 14:690-709, 1993.
  • calcilytic compounds stimulate secretion of PTH.
  • Such calcilytic compounds can be used to increase bone formation in a patient, for example, by intermittent dosing, thus achieving intermittent increases in the circulating levels of PTH.
  • calcilytic compounds described by the present invention can be formulated for a variety of modes of administration, including systemic and topical or localized administration. Techniques and formulations generally may be found in Remington's Pharmaceutical Sciences. 18 th ed. , Mack Publishing Co., Easton, PA, 1990 (hereby incorporated by reference herein) . Suitable dosage forms, in part, depend upon the use or the route of entry, for example, oral, transdermal, trans ⁇ mucosal, or by injection (parenteral). Such dosage forms should allow the compound to reach a target cell whether the target cell is present in a multicellular host or in culture. For example, pharmacological compounds or compositions injected into the blood stream should be soluble. Other factors are known in the art, and include considerations such as toxicity and dosage forms which retard the compound or composition from exerting its effect.
  • Compounds can also be formulated as pharmaceutically acceptable salts and complexes thereof.
  • Pharmaceutically acceptable salts are non-toxic salts in the amounts and concentrations at which they are administered. The preparation of such salts can facilitate the pharmacological use by altering the physical characteristics of the compound without preventing it from exerting its physiological effect. Useful alterations in physical properties include lowering the melting point to facilitate transmucosal administration and increasing the solubility to facilitate administering higher concentrations of the drug.
  • the pharmaceutically acceptable salt of the different compounds may be present as a complex.
  • complexes include an 8-chlorotheophylline complex (analogous to, e.g., dimenhydrinate:diphenhydramine 8-chlorotheophylline (1:1) complex; Dramamine) and various cyclodextrin inclusion complexes.
  • Pharmaceutically acceptable salts include acid addition salts such as those containing sulfate, hydrochloride, fumarate, maleate, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate.
  • Pharmaceutically acceptable salts can be obtained from acids such as hydrochloric acid, maleic acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, fumaric acid, and quinic acid.
  • acids such as hydrochloric acid, maleic acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, fumaric acid, and quinic acid.
  • Pharmaceutically acceptable salts also include basic addition salts such as those containing benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium, ammonium, alkylamine, and zinc, when acidic functional groups, such as carboxylic acid or phenol are present.
  • basic addition salts such as those containing benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium, ammonium, alkylamine, and zinc.
  • acidic functional groups such as carboxylic acid or phenol are present.
  • Such salts can be prepared using the appropriate corresponding bases.
  • salts can be prepared by standard techniques. For example, the free-base form of a compound is dissolved in a suitable solvent, such as an aqueous or aqueous-alcohol in solution containing the appropriate acid and then isolated by evaporating the solution. In another example, a salt is prepared by reacting the free base and acid in an organic solvent. (See, e . g. , PCT/US92/03736, hereby incorporated by reference herein.) Carriers or excipients can also be used to facilitate administration of the compound.
  • a suitable solvent such as an aqueous or aqueous-alcohol in solution containing the appropriate acid and then isolated by evaporating the solution.
  • a salt is prepared by reacting the free base and acid in an organic solvent.
  • Carriers or excipients can also be used to facilitate administration of the compound.
  • Examples of carriers include calcium carbonate, calcium phosphate, various sugars such as lactose, glucose, or sucrose, or types of starch, cellulose derivatives, gelatin, vegetable oils, polyethylene glycols and physiologically compatible solvents.
  • physiologically compatible solvents include sterile solutions of water for injection (WFI) , saline solution and dextrose.
  • WFI water for injection
  • the calcilytic compounds can be administered by different routes including intravenous, intraperitoneal, subcutaneous, intramuscular, oral, topical (transdermal), or transmucosal administration. For systemic administration, oral administration is preferred.
  • the compounds can be formulated into conventional oral dosage forms such as capsules, tablets, and liquid preparations such as syrups, elixirs, and concentrated drops.
  • injection parenteral administration
  • the compounds of the invention are formulated in liquid solutions, preferably, in physiologically compatible buffers or solutions, such as saline solution, Hank's solution, or Ringer's solution.
  • the compounds may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms can also be produced.
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, for transmucosal administration, bile salts and fusidic acid derivatives.
  • detergents may be used to facilitate permeation.
  • Transmucosal administration for example, may be through nasal sprays, rectal suppositories, or vaginal suppositories.
  • the compounds of the invention can be formulated into ointments, salves, gels, or creams, as is generally known in the art.
  • the amounts of various calcilytic compounds to be administered can be determined by standard procedures taking into account factors such as the compound IC 50 , EC 50 , the biological half-life of the compound, the age, size and weight of the patient, and the disease or disorder associated with the patient. The importance of these and other factors to be considered are known to those of ordinary skill in the art. Generally, it is an amount between about 0.1 and 50 mg/kg, preferably 0.01 and 20 mg/kg of the animal to be treated.
  • EXAMPLE 1 Calcium Receptor Inhibitor Assay This example illustrates the use of the Calcium Receptor Inhibitor Assay. Calcilytic activity was measured by determining the IC 50 of the test compound for blocking increases of intracellular Ca 2 * elicited by extracellular Ca 2 * in HEK 293 4.0-7 cells stably expressing the human calcium receptor. HEK 293 4.0-7 cells were constructed as described by Rogers et al . , J. Bone Miner. Res . 10 Suppl. 1:S483, 1995 (hereby incorporated by reference herein) . Intracellular Ca 2 * increases were elicited by increasing extracellular Ca 2 * from 1 to 1.75 mM. Intracellular Ca 2 * was measured using fluo-3, a fluorescent calcium indicator.
  • SPF-PCB contains 20 mM Na-Hepes, pH 7.4, 126 mM NaCl, 5 mM KCI, and 1 mM MgCl 2 .
  • SPF-PCB was made up and stored at 4 °C. On the day of use, SPF-PCB was supplemented with 1 mg/mL of D-glucose and 1 mM CaCl 2 and then split into two fractions. To one fraction, bovine serum albumin (BSA; fraction V, ICN) was added at 5 mg/mL (SPF-PCB+) . This buffer was used for washing, loading and maintaining the cells. The BSA-free fraction was used for diluting the cells in the cuvette for measurements of fluorescence. 4. The pellet was resuspended in 10 mL of SPF-PCB+ containing 2.2 ⁇ M fluo-3 (Molecular Probes) and incubated at room temperature for 35 minutes.
  • BSA bovine serum albumin
  • test compound or vehicle as a control
  • Cal ⁇ cilytic compounds were detected by their ability to block, in a concentration-dependent manner, increases in the concentration of intracellular Ca 2 * elicited by extracellular Ca 2 *.
  • those compounds having lower IC 50 values in the Calcium Receptor Inhibitor Assay are more preferred compounds.
  • Compounds having an IC 50 greater than 50 ⁇ M were considered to be inactive.
  • Preferred compounds are those having an IC S0 10-50 ⁇ M, more preferred compounds have an IC 50 1-10 ⁇ M, and most preferred compounds have an IC 50 less than 1 ⁇ M.
  • Examples of compounds having an IC 50 greater than 50 ⁇ M include compounds 22, 24, 34, 36, 52, 53, 54, 55, 58, 60, 62, 70, 84, 92, 99, and 102.
  • ⁇ , ⁇ -disubstituted arylalkylamine derivatives include compounds which have both calcilytic activity and ⁇ -adrenergic receptor activity. If desired, ⁇ - adrenergic activity can be reduced using appropriate functional groups and structural modifications.
  • Modifications which can be carried out to reduce ⁇ -adrenergic receptor activity include using alternative R 2 groups and using absolute stereochemistry opposite to that which occurs in active ⁇ -adrenergic receptor antagonists, which provides compounds corresponding to the R enantiomer when R 2 is OH.
  • ⁇ - adrenergic receptor activity and binding to the ⁇ -adrenergic receptor can be measured using standard techniques. For example, see Riva et al . , Mol . Pharmacol . 35:201-210, 1989.
  • the calcilytic compounds have an IC 50 .> 1.0 nM, at the ⁇ - adrenergic receptor as measured using the " ⁇ -Adrenergic Receptor Binding Assay" described below.
  • using the ⁇ -Adrenergic Receptor Assay calcilytic compounds have an IC 50 >. 1.0 ⁇ M, and IC 50 >. 10.0 ⁇ M.
  • ⁇ -Adrenergic Receptor Binding Assay is carried out as follows: Incubations are performed in polypropylene reaction tubes in a 37 °C water bath. To each tube 50 ⁇ L of test sample is added, followed by 300 ⁇ L of assay buffer (50 mM Tris-HCI, pH 7.5), and 50 ⁇ L of 20 nM [ 3 H] - dihydroalprenolol. The binding reaction is initiated by the addition of 100 ⁇ L of 3.75 mg/mL well-washed rat cortex membranes in assay buffer, and allowed to incubate at 37 °C for 30 minutes. Non-specific binding is determined in the presence of 10 ⁇ M alprenolol.
  • the final concentration of reactants is : 2 nM [ 3 H] -dihydroalprenolol , and 75 mg/mL rat cortex membrane in a reaction volume of 0.5 mL.
  • the binding reaction is terminated by rapid filtration with ice-cold assay buffer onto GF/C filters (Brandel, Gaithersburg, MD) which have been soaked for 15 minutes in assay buffer.
  • the reaction is first diluted with 3 mL of cold assay buffer (4 °C) , then aspirated onto the filter followed by 3 x 3 mL washes.
  • PTH secretion was determined using dissociated bovine parathyroid cells as described below for Compounds 32, 33, and 38.
  • Compounds 32, 33, and 38 all stimulated PTH secretion with an EC 50 of less than 10 ⁇ M.
  • PCB Parathyroid cell buffer
  • BSA fraction V bovine serum albumin
  • ICN Biomedicals, Inc. Costa Mesa, CA; catalog #81-003
  • D-glucose reagent grade
  • Percoll purification buffer was prepared immediately before use by mixing 8 mL of Percoll (Pharmacia LKB, Alameda, CA; catalog #17-0891-01) and 7 mL of a twice- concentrated PCB solution without phosphate and containing 2 mM CaCl 2 .
  • Parathyroid glands were obtained from calves within minutes of slaughter at an abattoir and shipped via overnight express on ice in PCB containing 1.25 mM CaCl 2 . The glands were trimmed and minced in ice-cold PCB containing 1.25 mM CaCl 2 , 1 mg/mL of D-glucose, and 2% BSA. Dissociated cells were obtained by collagenase digestion by vigorously shaking the minced tissue at 37 °C in PCB containing 0.5 to 1.0% Collagenase P (Boehringer Mannheim, Indianapolis, IN; catalog #1249 002), 2 to 5 units of deoxyribonuclease (Sigma, St.
  • Cells were pooled at 1-hour intervals by filtering the cell suspension through a 250- ⁇ m Nitex screen into 15-mL polystyrene centrifuge tubes and spinning at 100 x g for 5 minutes at 22 °C.
  • the pooled cell pellet was resuspended in Percoll purification buffer and purified by centrifugation at 14,500 x g for 20 minutes at 4 °C.
  • Dissociated parathyroid cells equilibrated within a buoyant density of 1.048-1.062 above a dense band of red blood cells and below a diffuse band that contains adipocytes, strands of collagen, and damaged cells.
  • the dissociated parathyroid cells were removed with a sterile pipette and washed 3 to 4 times under sterile conditions in a 1:1 mixture of Ham's F-12 and Dulbecco's modified Eagle's medium (F-12/DMEM, Sigma, St. Louis, MO; catalog #D 8900) supplemented with 0.5% BSA, 100 U/mL of penicillin, 100 ⁇ g/mL of streptomycin (Gibco BRL, Grand Island, NY; catalog #15140-031) , and 20 ⁇ g/mL of gentamicin (Sigma, St. Louis, MO; catalog #G 1397) .
  • the cells were finally resuspended in F-12/DMEM supplemented with lower antibiotic concentrations (10 U/mL of penicillin, 10 ⁇ g/mL of streptomycin, and 4 ⁇ g/mL of gentamicin) .
  • This latter medium lacks serum and contained ITS* (insulin, transferrin, selenous acid, BSA, and linoleic acid; Collaborative Biomedical Products, Bedford, MA; catalog #40352) .
  • PTH Parathyroid Hormone
  • Sulfate, phosphate-free parathyroid cell buffer contains (mM) : NaCl, 126; KCI, 5; MgCl 2 , 1; Na-Hepes, pH 7.45, and variable amounts of CaCl 2 as specified (reagent grade) .
  • SPF-PCB was typically supplemented with bovine serum albumin (BSA fraction V; ICN Biomedicals, Inc., Costa Mesa, CA; catalog #81-003) and 1 mg/mL of D-glucose (reagent grade) as indicated.
  • BSA fraction V bovine serum albumin
  • Incubations were performed in triplicate in 12 x 75 mm polypropylene or polystyrene tubes to which were added 2.5 ⁇ L of test compound.
  • the tubes were kept on ice until the drug additions were completed, then were transferred to a water bath at 37 °C, and the reactions were initiated by the addition of 0.2 mL of a suspension of dissociated cells at a density of 1 to 2 million cells/mL in SPF-PCB containing 0.5 mM Ca 2 *, 1 mg/mL of D-glucose, and 0.1% BSA.
  • Incubation was for 30 minutes and the reaction was terminated by placing the tubes on ice. Cells were pelleted by gentle centrifugation (500 x g for 10 minutes at 4 °C) and 0.1 mL of supernatant was removed and stored at -20 °C.
  • Amino-terminal bovine PTH was measured by radioimmunoassay (RIA) using goat anti-hPTH antiserum H 2 , HPLC-purified 125 I-hPTH (1-34) and bovine PTH (1-84) standards.
  • Serial dilutions of bPTH standards (1,000 pg/25 ⁇ L to 3.8 pg/25 ⁇ L) were done in 50 mM Tris, pH 7.4, containing 0.5 mM Na azide and 2% bovine serum albumin (diluent) .
  • Standards and samples were incubated for 2-3 days at 4 °C in the presence of antiserum after which 1,500-2,000 cpm label/tube was added.
  • dextran-coated charcoal was added to separate bound vs . free label.
  • the contents of each tube were mixed and the charcoal was pelleted by centrifugation.
  • the supematants were decanted into 12 x 75 mm polystyrene tubes and counted in a Packard Cobra gamma counter.
  • the calcilytic compounds described by the present invention can be prepared using standard techniques. For example, an overall strategy for preparing preferred compounds described herein can be carried out as described in this section. The examples which follow illustrate the synthesis of specific compounds. Using the protocols described herein as a model, one of ordinary skill in the art can readily produce other Structure I compounds. All reagents and solvents were obtained from commercial vendors. Starting materials ( e . g. , amines and epoxides) were synthesized using standard techniques and procedures.
  • GC/EI- MS Gas Chromatographic/Electron-Impact Mass Spectrometric analyses were performed on HP-5890 Series II gas chromato- graphs equipped with HP-Ultra-2 or HP-5MS columns (30 mm x 0.25 mm ID) and HP-5971 or HP-5972 Mass Selective Spectrometric Detectors (MSD's) were used.
  • MPLC Medium- Pressure Liquid Chromatography separations were carried out on silica gel (400 mesh) using an FMI pump, ISCO UV-6 detector (254 nm) and FOXY 200 fraction collector.
  • Chiral HPLC separations were carried out using a Beckman System Gold HPLC and UV detector (254 nm) on Diacel ® ChiralCel OD columns (Chiral Technologies, Inc., Exton, PA 19341).
  • NMR Nuclear Magnetic Resonance
  • Proton and carbon spectra were taken at 300 MHz and 75 MHz, respectively.
  • NMR resonances are reported in ppm relative to tetramethylsilane (TMS) with the following descriptors for the observed multiplicities: s (singlet), d (doublet), t (triplet) , q (quartet) , dd (doublet of doublets) and m (multiplet) .
  • J ⁇ coupling constants are reported in Hz. Elemental analyses were performed and FT-IR data were acquired by Oneida Research Services, Inc., Whitesboro, NY 13492.
  • the product is purified by one of three general methods: (1) conversion to the hydrochloride salt, followed by Reversed-Phase High-Performance Liquid Chromatography (RP- HPLC, 0.1% HCl/acetonitrile) ; (2) conversion to the hydrochloride salt, followed by recrystallization from water- methanol or acetonitrile; and (3) purification by normal- phase chromatography (column chromatography or preparative, thin-layer chromatography (TLC)) .
  • Hydrochloride salts were also prepared by treatment of the corresponding free base in diethyl ether with IM HCl (in diethyl ether) .
  • the reaction was stirred for 48 hours at room temperature and treated with 10% HCl (200 mL) .
  • the reaction was concentrated to 300 mL and diluted to 600 mL with water.
  • the resulting solution was extracted with diethyl ether (2 x 300 mL) and the combined ether extracts were washed with 10% HCl (2 x 200 mL) .
  • the ether extract was then extracted with IN NaOH (3 x 200 mL) .
  • the combined IN NaOH washes were made acidic (pH 1) by the addition of concentrated HCl, and the resulting solution was extracted with diethyl ether (3 x 300 mL) .
  • Triethylamine (16.8 g, 166 mmol) and 2, 2-dimethyl-3- (4- methoxyphenyl)propionic acid (32.6 g, 157 mmol) were dissolved in 30 mL of water and enough acetone to maintain solubility at 0 °C.
  • a solution of ethyl chloroformate (20.1 g, 185 mmol) in acetone (100 mL) was then added dropwise.
  • An aqueous solution (95 mL) of sodium azide (12.9 g, 198 mmol) was then added dropwise and the resulting reaction mixture stirred 45 minutes at room temperature.
  • the intermediate acyl azide was then extracted into toluene (200 mL) .
  • the organic extract was washed with water, dried over anhydrous magnesium sulfate, and heated at 100 °C until the evolution of nitrogen ceased (-45 min) .
  • the toluene was removed under vacuum and replaced with benzyl alcohol .
  • the solution was then heated at 100 °C for 16 hours.
  • the excess benzyl alcohol was removed under vacuum.
  • the resulting benzyl carbamate was dissolved in absolute ethanol (200 mL) and reduced in the presence of palladium hydroxide (2 g) under 90 p.s.i. hydrogen for 4 hours at room temperature.
  • the reaction was filtered and concentrated to a yellow oil.
  • hydrochloride salt of each enantiomer was prepared by treatment of the free amine in diethyl ether with excess IM HCl (diethyl ether) . Evaporation of the solvent yielded the hydrochloride product as a solid.
  • the crude mixture (1.47 g, 6 mmol) was dissolved in 6 mL of acetonitrile, to which was added 50% KF-Celite (0.7 g, 12 mmol) and 1, l-dimethyl-2- (4-methoxyphenyl) - ethylamine (0.54 g, 3 mmole) .
  • the mixture was refluxed under nitrogen for 48 hours, and then cooled and filtered. The filtrate was evaporated to dryness, and the residue was taken up in water and ether. The ether layer was dried over sodium sulfate and concentrated to dryness.
  • the reaction was diluted with water, and the product extracted into diethyl ether.
  • the ether layer was washed with saturated NaCl and dried over sodium sulfate.
  • the ether solution was treated with Amberlyst 15 ion-exchange resin to absorb the 2, 4, 6-triphenylpyridine. The resin was filtered and the filtrate evaporated to yield 1.3 g of pure 1- (4- methylphenyl) -2-methyl-2-nitropropane.
  • the 1- (4-methylphenyl) -2-methyl-2-nitropropane (1.3 g) was hydrogenated for 5 hours at 65 p.s.i. hydrogen in ethanol (30 mL) using 1.4 g of Raney nickel as catalyst. Removal of the catalyst by filtration and evaporation of the solvent yielded 1.15 g of 1, l-dimethyl-2- (4-me hoxyphenyl) ethylamine as a clear oil.
  • the aqueous layer was then made acidic with HCl, and the product extracted into ether.
  • the ether layer was dried over anhydrous sodium sulfate, filtered, and concentrated.
  • the resulting solid was crystallized from water/methanol to yield 1.11 g of 3-chloro-2-cyanophenol .
  • Nickel chloride monohydrate (0.107 g, 0.404 mmol) was dissolved in 5 mL of methanol, followed by the addition of sodium borohydride (0.05 g, 1.2 mmol) .
  • sodium borohydride 0.05 g, 1.2 mmol
  • 1-ethyl-l-methyl-2- ( -methoxyphenyl)nitroethane (0.18 g, 0.807 mmol) in 3 mL of methanol was added, and stirred for 5 minutes.
  • Sodium borohydride (0.11 g, 2.83 mmol) was then added in portions over 5 minutes.
  • the reaction was then stirred overnight under a hydrogen balloon.
  • the reaction mixture was filtered, and the methanol was removed on a rotary evaporator.
  • the residue was taken up in ether and dilute sodium hydroxide.
  • the ether layer was separated, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated.
  • Safrole oxide was prepared by stirring a solution of safrole (1.48 mL, 10 mmol) and m-chloroperoxybenzoic acid (2.70 g, 11 mmol) in methylene dichloride (25 L) overnight. The reaction was quenched by pouring into water (50 mL) . The aqueous was extracted with ether (3 x 25 mL) . The organic layers were combined and washed with 10% aqueous sodium sulfate (2 x 25 mL) , saturated aqueous sodium bicarbonate (3 x 25 mL) , and brine (25 mL) . The organic phase was dried over magnesium sulfate and the solvents were removed in vacuo. The resulting yellow oil was used without further purification.
  • the crude orange oil was purified (MPLC, silica gel, 1% MeOH/CHCl 3 ) and dissolved in methylene dichloride (5 mL) .
  • the hydrochloride salt was prepared by adding an excess of 1 M HCl/ether.
  • the solvents were removed in vacuo to yield 139 mg of thick oil: GC/EI-MS, /z (rel. int.) 342 (M + , .l) , 237 (15) , 236 (100) , 163 (5), 136 (6), 135 (61), 121 (23) , 78 (7), 77 (13), 70 (15) , 58 (7) .
  • phenyl glycidyl ether 150 mg, 1.1 mmol
  • 1, l-dimethyl-2- (3-fluoro- 4-methoxyphenyl) ethylamine 197 mg, 1 mmol
  • the title compound crystallized on standing to yield 169 mg of small crystals: GC/EI-MS, m/z (rel. int.) 332 (M* - 15, .1) , 209 (16) , 208 (100), 139 (13) , 133 (5), 114 (7), 107 (6), 77 (11), 71 (12) , 70 (20) , 58 (9) .
  • Potassium carbonate 13 mmol was added to a solution of 1, 5-dihydroxy napthalene (6.2 mmol) in acetone in a sealed vacuum tube. The tube was heated to 70 °C for 30 minutes. lodomethane (9.4 mmol) was added and the tube heated to 70 °C overnight .
  • the reaction mixture was partitioned between ether and 10% aqueous HCl.
  • the ether layer was separated and extracted with 0.5 M KOH.
  • the water layer was separated and acidified with 10% aqueous HCl and extracted into ether.
  • the ether layer was separated and dried over magnesium sulfate and evaporated to a solid.
  • the solid was purified using reverse phase HPLC using a acetonitrile/0.1% HCl gradient yielding 179 mg 1-hydroxy-5-methoxy napthalene.
  • Sodium hydride (60% suspension in mineral oil, 1 mmol) was added to a solution of 1-hydroxy-5-methoxy napthalene (1 mmol) and stirred 10 minutes.
  • EXAMPLE 86 Additional compounds Additional compounds were synthesized using techniques along lines as those described above. Examples of such compounds include the following:
  • Compound 22 N- (3-phenylpropyl) -1, l-dimethyl-2 (4- methoxyphenyl)ethylamine.
  • Compound 24 iV- (4-phenylbutyl) -1, l-dimethyl-2- (4- methoxyphenyl)ethylamine.
  • Compound 54 iV-2-hydroxy-3- (4- tert-butylphenoxy)propyl] - 1, 1-dimethyl-2-phenylethylamine.
  • Compound 55 N- [2-hydroxy-3- (1-naphthoxy)propyl] -1, 1- dimethyl-2-phenylethylamine.
  • Compound 102 N- (2-hydroxy-3-phenoxypropyl) -1, 1- dimethyl-2- (4-ethoxyphenyl)ethylamine.
  • Compound 132 N- [2-hydroxy-3- (3, 4-dimethoxy- phenoxy)propyl] -1, l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 390 (M+,.0) , 269 (17), 268 (100), 163 (6), 153 (5), 121 (21) , 114 (17) , 77 (5) , 71 (19) , 70 (17) , 58 (7) .
  • Compound 152 N- [2-hydroxy-3- (4-trifluoro- methoxyphenoxy)propyl] -1, l-dimethyl-2- (4-methoxy- phenyl) ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 398 (M-15,2) , 293(15), 292 (100) , 121 (20) , 77 (5) .
  • Compound 153 N- [2-hydroxy-3- (2 -iso-propyl- phenoxy)propyl] -1, l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride; GC/EI-MS, m/z (rel.
  • Compound 160 N- [2-hydroxy-3- (3-cyanophenoxy)propyl] - 1, l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 339 (M-15, .l) , 234 (15) , 233 (100) , 121 (21) , 102 (7) , 90 (6) .
  • Compound 161 N- [2-hydroxy-3- (4-cyanophenoxy)propyl] - 1, l-dimethyl-2- (4-methoxyphenyl)ethylamine Hydrochloride; GC/EI-MS, m/z (rel.

Abstract

The present invention features calcilytic compounds. 'Calcilytic compounds' refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.

Description

DESCRIPTIO
CALCILYTIC COMPOUNDS
FIELD OF THE INVENTION The present invention relates to compounds able to inhibit calcium receptor activity and the use of such compounds. Preferably, the compounds described herein are administered to patients to achieve a therapeutic effect.
BACKGROUND OF THE INVENTION Certain cells in the body respond not only to chemical signals, but also to ions such as extracellular calcium ions (Ca2*) . Extracellular Ca2* is under tight homeostatic control and regulates various processes such as blood clotting, nerve and muscle excitability, and proper bone formation. Calcium receptor proteins enable certain specialized cells to respond to changes in extracellular Ca2* concentration. For example, extracellular Ca2* inhibits the secretion of parathyroid hormone (PTH) from parathyroid cells, inhibits bone resorption by osteoclasts, and stimulates secretion of calcitonin from C-cells.
PTH is the principal endocrine factor regulating Ca2* homeostasis in the blood and extracellular fluids. PTH, by acting on bone and kidney cells, increases the level of Ca2* in the blood. This increase in extracellular Ca2* then acts as a negative feedback signal, depressing PTH secretion. The reciprocal relationship between extracellular Ca2* and PTH secretion forms an important mechanism maintaining bodily Ca2* homeostasis.
Extracellular Ca2* acts directly on parathyroid cells to regulate PTH secretion. The existence of a parathyroid cell surface protein which detects changes in extracellular Ca2* has been confirmed. (Brown et al . , Nature 366: 574 , 1993.) In parathyroid cells, this protein, the calcium receptor, acts as a receptor for extracellular Ca2*, detects changes in the ion concentration of extracellular Ca2*, and initiates a functional cellular response, PTH secretion.
Extracellular Ca2* can exert effects on different cell functions, reviewed in Nemeth et al . , Cell Calcium 11 : 319 , 1990. The role of extracellular Ca2* in parafollicular (C- cells) and parathyroid cells is discussed in Nemeth, Cell Calcium 11:323, 1990. These cells were shown to express similar calcium receptors. (See, Brown et al . , Nature 366: 574 , 1993; Mithal et al . , J. Bone Miner. Res . 9 , Suppl . 1, s282, 1994; Rogers et al . , J. Bone Miner. Res . 9, Suppl, 1, S409, 1994; Garrett et al . , Endocrinology 136: 5202 - 5211 , 1995.) The role of extracellular Ca2* on bone osteoclasts is discussed by Zaidi, Bioscience Reports 10:493, 1990.
The ability of various molecules to mimic extracellular Ca2* in vi tro is discussed in references such as Nemeth et al . , in "Calcium-Binding Proteins in Health and Disease," 1987, Academic Press, Inc., pp. 33-35; Brown et al . ,
Endocrinology 128:3047, 1991; Chen et al . , J. Bone Miner. Res . 5.-581, 1990; and Zaidi et al . , Biochem. Biophys . Res . Commun . 157:807, 1990.
Nemeth et al . , PCT/US92/07175, International Publication Number WO 93/04373, Nemeth et al . , PCT/US93/01642,
International Publication Number WO 94/18959, and Nemeth et al . , PCT/US94/12117, International Publication Number WO 95/11211, feature calcium receptor-active molecules and refer to calcilytics as compounds able to inhibit calcium receptor activity. For example, W0 94/18959 on page 8, lines 2-13 asserts:
Applicant is also the first to describe methods by which molecules active at these Ca2* receptors can be identified and used as lead molecules in the discovery, development, design, modification and/or construction of useful calcimimetics or calcilytics which are active at Ca2* receptors. Such calcimimetics or calcilytics are useful in the treatment of various disease states characterized by abnormal levels of one or more components, e.g.. polypeptides such as hormones, enzymes or growth factors, the expresssion and/or secretion of which is regulated or affected by activity at one or more Ca2* receptors.
The references provided in the background are not admitted to be prior art to the pending claims.
SUMMARY OF THE INVENTION The present invention features calcilytic compounds. "Calcilytic compounds" refer to compounds able to inhibit calcium receptor activity. The ability of a compound to "inhibit calcium receptor activity" means that the compound causes a decrease in one or more calcium receptor activities evoked by extracellular Ca2*.
The use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient are described below. Also described below are techniques which can be used to obtain additional calcilytic compounds.
An example of featured calcilytic compounds are Structure I α, -disubstituted arylalkylamine derivatives having the chemical formula:
STRUCTURE I
Figure imgf000005_0001
R2 where Rj is selected from the group consisting of: aryl, longer-length alk, and cycloalk;
R2 is selected from the group consisting of: lower alk, cycloalk, alkoxy, H, OH, =0, C(0)0H, C(0)0-lower alk, C(0)NH- lower alk, C(0)N(lower alk)2, SH, S-lower alk, NH2, NH-lower alk, and N(lower alk)2;
R3 and R4 is each independently lower alk or together cyclopropyl;
R5 is aryl; R6 if present is either hydrogen, lower alkyl or lower alkenyl, wherein R6 is not present if R2 is =0;
Yj. is either covalent bond, alkylene, or alkenylene; Y2 is alkylene; Y3 is alkylene; and Z is selected from the group consisting of: covalent bond, 0, S, NH, N-lower alk, alkylene, alkenylene, and alkynylene, provided that if Z is either 0, S, NH, or N-lower alk, then Yx is not a covalent bond, further provided that Yx and Z may together be a covalent bond; and pharmaceutically acceptable salts and complexes thereof.
The terms aryl, longer-length alk, lower alk, cycloalk, alkoxy, alkylene, alkenylene, and alkynylene, along with possible substituents are defined in Section II, infra . Section II, infra, also provides definitions for other chemical groups described in the present application.
Preferred calcilytic compounds have an IC50 <. 50 μM, more preferably an IC50 < 10 μM, and even more preferably an IC50 < 1 μM, as measured using the "Calcium Receptor Inhibitor Assay" described in Example 1, infra.
Thus, a first aspect of the present invention features a method of treating a patient by administering to the patient a therapeutically effective amount of a Structure I α,α-disubstituted arylalkylamine derivative. Treatment can be carried out, for example, to retard the disease in a patient having a disease or to prophylactically retard or prevent the onset of a disease.
A therapeutically effective amount is the amount of compound which achieves a therapeutic effect by retarding a disease in a patient having a disease or prophylactically retarding or preventing the onset of a disease. Preferably, it is an amount which relieves to some extent one or more symptoms of a disease or disorder in a patient; returns to normal either partially or completely one or more physiological or biochemical parameters associated with or causative of the disease or disorder; and/or reduces the likelihood of the onset of the disease of disorder.
A "patient" refers to a mammal in which compounds characterized by their ability to inhibit calcium receptor activity, in vivo or in vitro, will have a beneficial effect. Preferably, the patient is a human being. Patients benefiting from the administration of a therapeutic amount of a calcilytic compound can be identified using standard techniques known to those in the medical profession. Diseases or disorders which can be treated by inhibiting one or more calcium receptor activities include one or more of the following types: (1) those characterized by an abnormal bone and mineral homeostasis; (2) those characterized by an abnormal amount of an extracellular or intracellular messenger whose production can be affected by one or more calcium receptor activities; (3) those characterized by an abnormal effect ( e. g. , a different effect in kind or magnitude) of an intracellular or extracellular messenger which can itself be ameliorated by one or more calcium receptor activities; and (4) other diseases or disorders where inhibition of one or more calcium receptor activities exerts a beneficial effect, for example, in diseases or disorders where the production of an intracellular or extracellular messenger stimulated by receptor activity compensates for an abnormal amount of a different messenger. Examples of extracellular messengers whose secretion and/or effect can be affected by inhibiting calcium receptor activity are believed to include inorganic ions, hormones, neurotransmitters, growth factors, and chemokines . Examples of intracellular messengers include cAMP, cGMP, IP3, calcium, magnesium, and diacylglycerol.
Preferably, a patient is a human having a disease or disorder characterized by one or more of the following: (1) an abnormal bone or mineral homeostasis; (2) an abnormal amount of an extracellular or intracellular messenger which is ameliorated by a compound able to effect one or more calcium receptor activities; and (3) an abnormal effect of an intracellular or extracellular messenger which is ameliorated by a compound able to effect one or more calcium receptor activities.
Preferably, the disease or disorder is characterized by an abnormal bone and mineral homeostasis, more preferably calcium homeostasis. Abnormal calcium homeostasis is characterized by one or more of the following activities: (1) an abnormal increase or decrease in serum calcium; (2) an abnormal increase or decrease in urinary excretion of calcium; (3) an abnormal increase or decrease in bone calcium levels, for example, as assessed by bone mineral density measurements; (4) an abnormal absorption of dietary calcium; (5) an abnormal increase or decrease in the production and/or release of messengers which affect serum calcium levels such as PTH and calcitonin; and (6) an abnormal change in the response elicited by messengers which affect serum calcium levels. The abnormal increase or decrease in these different aspects of calcium homeostasis is relative to that occurring in the general population and is generally associated with a disease or disorder. Preferably, the calcilytic compounds are used to treat diseases or disorders selected from the group consisting of: hypoparathyroidism, osteosarcoma, periodontal disease, fracture healing, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia malignancy, and osteoporosis.
Another aspect of the present invention describes a method of treating a patient comprising the step of administering to the patient an amount of a calcilytic compound sufficient to increase serum PTH level. Preferably, the method is carried out by administering an amount of the compound effective to cause an increase in duration and/or quantity of serum PTH level sufficient to have a therapeutic effect.
Increasing serum PTH may be used to achieve a therapeutic effect by retarding a disease in a patient having the disease or prophylactically retarding or preventing the onset of a disease. Prophylactic treatment can be performed, for example, on a person with an abnormally low serum PTH; or on a person without a low serum PTH, but were increasing PTH has a beneficial effect. An abnormally low serum PTH is a serum PTH level lower than that occurring in the general population, and is preferably an amount associated with a disease or the onset of a disease.
Increasing serum PTH levels can be used to treat different types of diseases including bone and mineral related diseases.
In different embodiments, the compound is administered to a patient to cause an increase in serum PTH having a duration up to one hour, about one to about twenty-four hours, about one to about twelve hours, about one to about six hours, about one to about five hours, about one to about four hours, about two to about five hours, about two to about four hours, or about three to about six hours.
In additional different embodiments, the compound is administered to a patient to cause an increase in serum PTH up to 0.5 fold, 0.5 to 5 fold, 5 fold to 10 ten fold, and at least 10 fold, greater than peak serum PTH in the patient. The peak serum level is measured with respect to the patient not undergoing treatment.
Another aspect of the present invention features Structure I calcilytic compounds.
Another aspect of the present invention features a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a calcilytic compound described herein. The pharmaceutical composition contains the calcilytic compound in a form suitable for administration into a mammal, preferably, a human being. Preferably, the pharmaceutical composition contains an amount of a calcilytic compound in a proper pharmaceutical dosage form sufficient to exert a therapeutic effect on a human being. However, multiple doses of pharmaceutical compositions may be used to treat a patient. Considerations and factors concerning dosage forms suitable for administration are known in the art and include potential toxic effects, solubility, route of administration, and maintaining activity. For example, pharmaceutical compositions injected into the bloodstream should be soluble. Another aspect of the present invention features a method of screening for Structure I α, -disubstituted arylalkylamine derivatives able to inhibit calcium receptor activity. The method involves the steps of contacting a cell having a calcium receptor with a Structure I α,α-di- substituted arylalkylamine derivative and measuring the ability of the compound to inhibit calcium receptor activity. The screening method can be carried out in vivo or in vitro and is particularly useful to identify those Structure I α, -disubstituted arylalkylamine derivatives most able to act as calcilytic compounds. In vivo assays include measuring a physiological parameter related to calcium receptor activity, such as serum hormone levels or serum calcium ion concentration. In vitro assays include measuring the ability of the calcilytic compound to affect intracellular calcium concentration, or cellular hormone secretion. Examples of hormones levels which can be affected by calcilytic compounds include PTH and calcitonin. The calcilytic compounds described herein can be used as part of in vivo or in vi tro methods. Preferably, the compounds are used in vivo to achieve a beneficial effect in a patient. Examples of in vitro uses, and other in vivo uses, include use in a method to identify other calcilytic compounds and use as a tool to investigate calcium receptor activity or the physiological effects of inhibiting calcium receptor activity in different organisms.
Other features and advantages of the invention will be apparent from the following detailed description of the invention, examples, and the claims.
DETAILED DESCRIPTION QF THE INVENTION The present application demonstrates the ability of calcilytic compounds to exert a physiologically relevant effect on a cell by illustrating the ability of such compounds to increase PTH secretion and also identifies a target site for calcilytic compounds. The present application is believed to be the first to demonstrate that calcilytic compounds can increase PTH secretion.
Calcium receptors are present on different cell types and can regulate different responses in different cell types. While the calcilytic compounds described herein are believed to act at a calcium receptor through a calcium receptor- activity modulating site, unless otherwise explicitly stated in the claims that a compound exerts an effect by acting at a calcium receptor through such a site, there is no intention to limit the claimed methods or compound to requiring inhibition of calcium receptor activity or any particular mode of action. Rather, the present application demonstrates that compounds able to inhibit calcium receptor activity, whose calcilytic activity can be measured in vivo or in vitro, exert significant physiological effects. For example, the present application demonstrates the ability of different calcilytic compounds to prevent Ca2* inhibition of PTH and, thereby, result in an increase in PTH release.
Compounds binding at the calcium receptor-activity modulating site can be identified using a labeled compound binding to the site in a competition-binding assay format.
Preferred calcilytic compounds described herein are Structure I α,α-disubstituted arylalkylamine derivatives able to inhibit calcium receptor activity. Other aspects of the present invention include assays which can be used to identify those Structure I α,α-disubstituted arylalkylamine derivatives expected to be effective in inhibiting calcium receptor activity, and/or exerting a therapeutic effect in a patient; preferred groups of Structure I a,α-disubstituted arylalkylamine derivatives; and the use of the compounds described herein to treat different diseases or disorders. i. Calcium Receptor Activity
Calcium receptors respond to changes in extracellular calcium levels. The exact changes resulting from calcium receptor activity depend on the particular receptor and the cell containing the receptor. For example, the in vi tro effect of calcium on the calcium receptor in a parathyroid cell includes the following:
1. An increase in internal calcium [Ca2*]^ The increase is due to the influx of external calcium and/or to the mobilization of internal calcium. Characteristics of the increase in internal calcium include the following:
(a) A rapid (time to peak < 5 seconds) and transient increase in [Ca2*] that is refractory to inhibition by 1 μM. La3* or 1 μM Gd3* and is abolished by pretreatment with ionomycin (in the absence of extracellular Ca2*) ;
(b) The increase is not inhibited by di- hydropyridines;
(c) The transient increase is abolished by pretreatment for 10 minutes with 10 mM sodium fluoride; (d) The transient increase is diminished by pretreatment with an activator of protein kinase C (PKC) , such as phorbol myristate acetate (PMA), mezerein or (-)- indolactam V. The overall effect of the protein kinase C activator is to shift the concentration-response curve of calcium to the right without affecting the maximal response; and
(e) Pretreatment with pertussis toxin (100 ng/ml for > 4 hours) does not affect the increase.
2. A rapid (< 30 seconds) increase in the formation of inositol-1, 4,5-triphosphate and/or diacylglycerol.
Pretreatment with pertussis toxin (100 ng/ml for > 4 hours) does not affect this increase; 3. The inhibition of dopamine- and isoproterenol- stimulated cyclic AMP formation. This effect is blocked by pretreatment with pertussis toxin (100 ng/ml for > 4 hours) ; and 4. The inhibition of PTH secretion. Pretreatment with pertussis toxin (100 ng/ml for > 4 hours) does not affect the inhibition of PTH secretion.
Calcilytic activity of a compound can be determined using techniques such as those described in the examples below and those described in publications such as Nemeth et al . , PCT/US92/07175, International Publication Number WO 93/04373, Nemeth et al . , PCT/US93/01642, International Publication Number WO 94/18959, and Nemeth et al . , PCT/US94/12117, International Publication Number WO 95/11211 (each of which are hereby incorporated by reference herein) . Calcilytic activity varies depending upon the cell type in which the activity is measured. For example, calcilytic compounds possess one or more, and preferably all, of the following characteristics when tested on parathyroid cells in vitro:
1. The compound blocks, either partially or completely, the ability of increased concentrations of extracellular Ca2* to:
(a) increase [Ca2*]if (b) mobilize intracellular Ca2*,
(c) increase the formation of inositol-1, 4, 5- triphosphate,
(d) decrease dopamine- or isoproterenol- stimulated cyclic AMP formation, and (e) inhibit PTH secretion;
2. The compound blocks increases in Cl" current in Xenopus oocytes injected with poly(A) '-mRNA from bovine or human parathyroid cells elicited by extracellular Ca2*, but not in Xenopus oocytes injected with water; and
3. Similarly, the compound blocks a response in Xenopus oocytes, injected with cloned nucleic acid expressing the calcium receptor, elicited by extracellular Ca2* or a calcimimetic compound (i.e., a compound able to mimic the effect of extracellular Ca2*, including compounds potentiating the effect of extracellular Ca2*) .
Calcium receptors are present in different cells. The pharmacological effects of the following cells, in response to extracellular Ca2*, is consistent with the presence of a calcium receptor: parathyroid cell, bone osteoclast, juxtaglomerular kidney cell, proximal tubule kidney cell, distal tubule kidney cell, central nervous system cell, peripheral nervous system cell, cell of the thick ascending limb of Henle's loop and/or collecting duct, keratinocyte in the epidermis, parafollicular cell in the thyroid (C-cell) , intestinal cell, trophoblast in the placenta, platelet, vascular smooth muscle cell, cardiac atrial cell, gastrin- secreting cell, glucagon-secreting cell, kidney mesangial cell, mammary cell, endocrine and exocrine cells in the pancreas, fat/adipose cell, immune cell, GI tract cell, skin cell, -adrenal cell, pituitary cell, hypothalamic cell and cell of the subfornical organ. The presence of a calcium receptor on the following cells have been confirmed using physical data, such as hybridization with nucleic acid encoding a calcium receptor: parathyroid cell, central nervous system cell, peripheral nervous system cell, cell of the thick ascending limb of Henle's loop and/or collecting duct in the kidney, parafollicular cell in the thyroid (C-cell), intestinal cell, GI tract cell, pituitary cell, hypothalamic cell, cell of the subfornical organ, and endocrine and exocrine cells in the pancreas.
II. α.α-Disubstituted Arylalkylamine Derivatives Structure I α, -disubstituted arylalkylamine derivatives have the following chemical formula:
STRUCTURE I
Figure imgf000016_0001
where Rj is selected from the group consisting of: aryl, longer-length alk, and cycloalk. Preferably, Rj is either optionally substituted phenyl, optionally substituted pyridyl, optionally substituted benzothiopyranyl, optionally substituted carbazole, optionally substituted naphthyl, optionally substituted tetrahydronaphthyl, optionally substituted longer-length alkyl, optionally substituted longer-length alkenyl or optionally substituted cycloalk.
More preferably, Rx is either an optionally substituted phenyl; an optionally substituted naphthyl; an optionally substituted pyridyl; an optionally substituted benzothiopyranyl; an optionally substituted carbazole; unsubstituted longer-length alkyl; unsubstituted longer- length alkenyl; or monosubstituted longer-length alkyl or alkenyl, where the monosubstituent is either an optionally substituted phenyl or an optionally substituted cycloalkyl provided that the optionally substituted phenyl or optionally substituted cycloalkyl can have one to four substituents each independently selected from the group consisting of: alkoxy, lower-haloalkyl, S-unsubstituted alkyl, lower-haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, N02, NH2 and OH; R2 is selected from the group consisting of: lower alk, cycloalk, alkoxy, H, OH, =0, C(0)0H, C(0)0-lower alk, C(0)NH- lower alk, C(0)N(lower alk)2, SH, S-lower alk, NH2, NH-lower alk, and N(lower alk)2. More preferably, R2 is OH or alkoxy, even more preferably, R2 is OH or methoxy; R3 and R„ is each independently lower alk or together cyclopropyl. Preferably, R3 and R4 are each independently a lower alkyl, more preferably, R3 and R4 are each independently methyl or ethyl;
R5 is aryl. Preferably, R5 is either optionally substituted naphthyl or optionally substituted phenyl. More preferably, R5 is substituted phenyl having a substituent in the meta or para position and optionally containing additional substituents;
R6 if present is either hydrogen, lower alkyl or lower alkenyl, wherein R6 is not present if R2 is =0. Preferably R6 is either hydrogen or lower alkyl, more preferably R6 is hydrogen.
Y1 is either covalent bond, alkylene, or alkenylene. Preferably, Yx is either covalent bond or lower alkylene. More preferably, Y is methylene;
Y2 is alkylene. Preferably, Y2 is lower alkylene. More preferably, Y2 is methylene;
Y3 is alkylene. Preferably, Y3 is lower alkylene. More preferably, Y3 is methylene; Z is selected from the group consisting of: covalent bond, 0, S, NH, N-lower alk, alkylene, alkenylene, and alkynylene, provided that if Z is either 0, S, NH, or N-lower alk, then Yτ is not a covalent bond, further provided that Yx and Z may together be a covalent bond. Preferably, Z is selected from the group consisting of: covalent bond, O, S, NH, N-lower alk, and alkylene. More preferably, Z is either O, S, lower alkylene, even more preferably, Z is O; and pharmaceutically acceptable salts and complexes thereof.
"Alk" refers to either alkyl, alkenyl, or alkynyl. "Lower alk" refers to either lower alkyl, lower alkenyl, or lower alkynyl, preferably, lower alkyl. "Alkenyl" refers to an optionally substituted hydrocarbon group containing at least one carbon-carbon double bond between the carbon atoms and containing 2-15 carbon atoms joined together. The alkenyl hydrocarbon group may be straight-chain or contain one or more branches. Branched- and straight-chain alkenyl preferably have 2 to 7 carbons, each of which may be optionally substituted. Alkenyl substituents are each independently selected from the group consisting of: lower alkyl, lower alkenyl, halogen, alkoxy, lower haloalkyl, lower haloalkoxy, methylene dioxy, unsubstituted aryl, unsubstituted cycloalkyl, OH, SH, CN, NO, N02, NH2, CH=NNHC(0)NH2, CH=NNHC(S)NH2, CH20-lower alkyl, C(O) lower alkyl, C(0)NH2, C(0)NH-lower alkyl, C(0) (lower alkyl}2, C(0)OH, C(0)0-lower alkyl, NH-lower alkyl, Ndower alkyl)2, NHC(O)unsubstituted aryl, NHC(O) lower alkyl, N=N- unsubstituted aryl, NHC(0)NH2, Ndower alkyl)C(O) lower alkyl, NHC(S) lower alkyl, Ndower alkyl)C(S) lower alkyl, NHS(O) lower alkyl, Ndower alkyl)S(0)lower alkyl, 0C(0) lower alkyl, 0CH2C(0)0H, OC(S)lower alkyl, S(0) lower alkyl, SC(0)lower alkyl, S-lower alkyl, S-lower haloalkyl, S02-lower alkyl, S02- lower haloalkyl, S(0)2NH2, S (0)2NH-lower alkyl, and
S(0)2N(lower alkyl)2. Preferably, no more than three substituents are present. Even more preferably, the alkenyl is a lower alkenyl, which is an unsubstituted branched- or straight-chain alkenyl having 2 to 4 carbons.
"Alkyl" refers to an optionally substituted hydrocarbon group joined by single carbon-carbon bonds and having 1-15 carbon atoms joined together. The alkyl hydrocarbon group may be straight-chain or contain one or more branches. Branched- and straight-chain alkyl preferably have 1 to 7 carbons, each of which may be optionally substituted. Alkyl substituents are each independently selected from the substituents described above for alkenyl. Preferably, no more than three substituents are present. More preferably, the alkyl is a lower alkyl, which is an unsubstituted branched- or straight-chain alkyl 1 to 4 carbons in length.
"Alkynyl" refers to an optionally substituted hydrocarbon group containing at least one carbon-carbon triple bond between the carbon atoms and containing 2-15 carbon atoms joined together. The alkynyl hydrocarbon group may be straight-chain or contain one or more branches. Branched- and straight-chain alkynyl preferably have 2 to 7 carbons, each of which may be optionally substituted.
Alkynyl substituents are each independently selected from the substituents described above for alkenyl. Preferably, no more than three substituents are present. More preferably, the alkynyl is a lower alkynyl, which is an unsubstituted branched- or straight-chain alkynyl having 2 to 4 carbons. "Alkenylene" refers to an optionally substituted hydrocarbon chain containing at least one carbon-carbon double bond between the carbon atoms. The alkenylene chain has 2 to 6 carbons and is attached at two locations to other functional groups or structural moieties. The alkenylene substituents are each independently selected from the substituents described above for alkenyl. Preferably, no 18 more than three substituents are present. More preferably, the alkenylene is a "lower alkenylene," which is an unsubstituted branched- or straight-chain alkenylene having 2 to 3 carbons. "Alkoxy" refers to oxygen joined to an unsubstituted alkyl 1 to 12 carbon atoms in length, preferably 1 to 2 carbons in length. More preferably, the alkoxy is methoxy.
"Alkylene" refers to an optionally substituted hydrocarbon chain containing only carbon-carbon single bonds between the carbon atoms. The alkylene chain has 1 to 6 carbons and is attached at two locations to other functional groups or structural moieties. The alkylene substituents are each independently selected from the substituents described above for alkenyl. Preferably, no more than three substituents are present.- More preferably, the alkylene is a "lower alkylene," which is an unsubstituted branched- or straight-chain alkylene having 1 to 3 carbons.
"Alkynylene" refers to an optionally substituted hydrocarbon chain containing at least one carbon-carbon triple bond between the carbon atoms. The alkynylene chain has 2 to 6 carbons and is attached at two locations to other functional groups or structural moieties. The alkynylene substituents are each independently selected from the substituents described above for alkenyl. More preferably, the alkynylene is a "lower alkynylene," which is an unsubstituted branched- or straight-chain alkynylene having 2 to 3 carbons.
"Aryl" refers to an optionally substituted aromatic group with at least one ring having a conjugated pi- electron system, containing up to two conjugated or fused ring systems. Aryl includes carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally substituted. Preferably, the aryl is either optionally substituted phenyl, optionally substituted pyridyl, optionally substituted benzothiopyranyl, optionally substituted carbazole, optionally substituted naphthyl, optionally substituted tetrahydronaphthyl.
Different substituents are preferred for the Structure I left hand Rx aryl and the Structure I R5 right hand aryl. Preferably, the aryl has no more than five independently selected substituents. Preferably, when R is an aryl, the aryl is either optionally substituted phenyl, optionally substituted pyridyl, optionally substituted benzothiopyranyl, optionally substituted carbazole, optionally substituted naphthyl, or optionally substituted tetrahydronaphthyl. Preferred,
Figure imgf000021_0001
substituents are each independently selected from the group consisting of: unsubstituted alkyl, unsubstituted alkenyl, halogen, alkoxy, lower haloalkyl, lower haloalkoxy, methylene dioxy, unsubstituted aryl, unsubstituted cycloalkyl, OH, SH, CN, NO, N02, NH2, methylene dioxy, CH=NNHC(0)NH2, CH=NNHC(S)NH2, CH20-unsubstituted alkyl, C(O)unsubstituted alkyl, C(0)NH2, C(O)NH-unsubstituted alkyl, C(0)N(unsubstituted alkyl)2, C(0)0H, C(O)O-unsubstituted alkyl,- NH-unsubstituted alkyl, N(unsubstituted alkyl)2, NHC(O)unsubstituted aryl, NHC(0)unsubstituted alkyl, N=N- unsubstituted aryl, NHC(0)NH2, N(unsubstituted alkyl)C(O)unsubstituted alkyl, NHC(S)unsubstituted alkyl,
N(unsubstituted alkyl)C(S)unsubstituted alkyl,
NHS(0)unsubstituted alkyl, N(unsubstituted alkyl)S (0)unsubstituted alkyl, NS(0)2aryl, OC(0)unsubstituted alkyl, 0CH2C(0)0H, 0C(S)unsubstituted alkyl, S(0)unsubstituted alkyl, SC(O)unsubstituted alkyl, S-unsubstituted alkyl, S-unsubstituted haloalkyl, S02-unsubstituted alkyl, S02-unsubstituted haloalkyl, S(0)2NH2, S (0) 2NH-unsubstituted alkyl, and S (O)2N(unsubstituted alkyl)2.
Preferred R aryl substituents are each independently selected from the group consisting of: alkoxy, methylene dioxy, N(CH3)2/ C(0)OCH3, phenyl, lower-haloalkyl,
S-unsubstituted alkyl, lower-haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, N02, NH2, and OH. More preferably, each RL aryl substituent is independently selected from the group consisting of: unsubstituted Cj.-C7 alkyl, Ci-C7 alkoxy, lower haloalkoxy, CF3, F, Cl, Br, CN, and N02.
In another preferred embodiment, R is either 2-CN- phenyl, 2,3-dichloro phenyl, 2-nitro-phenyl, or 2-cyano-3- chloro-phenyl. R5 right hand aryl substituents are each independently selected from the substituents described above for alkenyl . In a preferred embodiment, the R5 aryl substituents are each independently selected from the group consisting of: methoxy, lower alkyl, lower haloalkoxy, CFH2, CHF2, CF3, OCH2CF3, F, Cl, Br, I, OH, SH, CN, N02, NH2, methylene dioxy, NH-lower alkyl, Ndower alkyl) 2, C(O) lower alkyl, S-lower alkyl, S(0) lower alkyl, S(0)2lower alkyl, 0C(0) lower alkyl, SC(O) lower alkyl, 0C(S) lower alkyl, NHC(O) lower alkyl, Ndower alkyl) C(O) lower alkyl, NHC(S) lower alkyl, Ndower alkyl) C(S) lower alkyl, NHS(0)lower alkyl, Ndower alkyl) S (O) lower alkyl, C(0)OH,
C(0)0-lower alkyl, C(0)NH2, C(0)NH-lower alkyl, C(0)N(lower alkyl)2, S(0)2NH2, S(0)2NH-lower alkyl, and S(0)2N(lower alkyl)2.
In another preferred embodiment, R5 aryl substituents are each independently selected from the group consisting of: methylene dioxy, methoxy, lower-haloalkyl, S-lower alkyl, lower-haloalkoxy, lower alkyl, halogen, SH, CN, OH, Cl, F, and Br. Preferred halogens are Cl, F, and Br. "Carbocyclic aryl" refers to an aromatic ring or ring system having all carbon atoms. The carbon atoms are optionally substituted.
"Cycloalk" refers to an optionally substituted cyclic alkyl or an optionally substituted non-aromatic cyclic alkenyl and includes monocyclic and multiple ring structures such as bicyclic and tricyclic. The cycloalk has 3 to 15 carbon atoms, preferably, 5 to 12 carbon atoms. Optional substituents for the cycloalk are each independently selected from the group described above for alkenyl. Preferably, no more than three substituents are present. More preferably, the cycloalk is unsubstituted, even more preferably it is an unsubstituted cyclic alkyl. Preferred cycloalkyl groups include cyclohexyl and adamantyl. "Haloalk" refers to substituted alkyl or substituted alkenyl, having no more than 4 carbons, where the substituents are halogens and at least one halogen is present. Preferably, the haloalk is an alkyl 1 to 3 carbons in length and the halogens are each independently either Cl or F, more preferably the alkyl has 2 carbons, more preferably the haloalkyl is a lower haloalkyl which has 1 carbon.
"Heterocyclic aryl" refers to an aryl having 1 to 3 heteroatoms as ring atoms in the aromatic ring and the remainder of the ring atoms are carbon atoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen. Examples of heterocyclic aryl include indolyl, pyridyl, quinolinyl, and isoquinolinyl.
"Longer-length alk" refers to either longer-length alkyl, longer-length alkenyl, or longer-length alkynyl; preferably, longer-length alkyl or longer-length alkenyl. More preferably a longer-length alk is 4 to 20 carbon atoms. "Longer-length alkenyl" refers to an optionally substituted hydrocarbon group containing at least one carbon-carbon double bond between the carbon atoms, and which contains 2-20 carbon atoms joined together. Preferably, the longer-length alkenyl is 4 to 20 carbon atoms. The longer- length alkenyl hydrocarbon group may be straight-chain or contain one or more branches. Longer-length alkenyl substituents are each independently selected from the alkenyl substituent list described above. Preferably, the longer- length alkenyl is either unsubstituted or has one cycloalk or phenyl substituent. More preferably, the cycloalk substituent, if present, is unsubstituted, and more preferably the cycloalk substituent, if present, is either cyclohexyl or adamantyl. "Longer-length alkyl" refers to an optionally substituted hydrocarbon group joined by single carbon-carbon bonds and which contains 1-20 carbon atoms joined together. Preferably, the longer-length alkyl is 4 to 20 carbon atoms. The longer-length alkyl hydrocarbon group may be straight-chain or contain one or more branches. Longer- length alkyl substituents are each independently selected from the alkenyl substituent list described above. Preferably, the longer-length alkyl is either unsubstituted or has one cycloalk or phenyl substituent. More preferably, the cycloalk substituent, if present, is unsubstituted, and more preferably the cycloalk substituent, if present, is either cyclohexyl or adamantyl.
"Longer-length alkynyl" refers to an optionally substituted hydrocarbon group containing at least one carbon-carbon triple bond between the carbon atoms, and which contains 2-20 carbon atoms joined together. Preferably, the longer-length alkynyl is 4 to 20 carbon atoms. The longer- length alkynyl hydrocarbon group may be straight-chain or contain one or more branches. Longer-length alkynyl substituents are each independently selected from the alkenyl substituent list described above. Preferably, the longer- length alkynyl is either unsubstituted or has one cycloalk or phenyl substituent substituent. More preferably, the cycloalk substituent, if present, is unsubstituted, and more preferably the cycloalk substituent, if present, is either cyclohexyl or adamantyl. "Haloalkoxy" refers to oxygen joined to a "haloalk."
Preferably, the haloalkoxy is a "lower-haloalkoxy," which is an oxygen joined to a lower-haloalkyl.
. α.α-Disubstituted β-Phenethylamine Derivatives More preferred calcilytic compounds are Structure I derivatives where R3, R2, R3, R4, R6, Z, Yx and Y2 are as described above for Structure I α,α-disubstituted arylalkylamine derivatives, including preferred groups (see, Section II, supra) ; and
R5 is either phenyl substituted with one to four independently selected substituents or an optionally substituted naphthyl having up to four independently selected substituents. R5 substituents are provided in Section II, supra . , including preferred embodiments. More preferably R5 is either a substituted phenyl comprising a substituent in a meta or para position, more preferably, the substituent present in a meta or para position is either methyl, ethyl, isopropyl, methoxy, Cl, F, Br, or lower haloalkoxy.
The activity of different calcilytic compounds was measured using the Calcium Receptor Assay described below. Examples of compounds having an IC50 < 50 μ include compounds 1, 9, 17, 25, 29, 42, 56, 79, 90, 101 and 164; examples of preferred compounds having an IC50 < 10 μM include compounds 2, 3, 7, 8, 26, 27, 32, 33, 35, 37, 39, 41, 45, 48, 49, 59, 61, 66, 68, 71, 75, 93, 98, 103, 104, 110, 111, 114, 123, 124, 125, 128, 132, 144, 147, 152, 155, 158, 161, 162, 169 and 170; and examples of more preferred compounds having an IC50 < than 1 μM include compounds 5, 6, 19, 20, 21, 28, 38, 40, 43, 44, 46, 47, 50, 51, 63, 64, 65, 67, 69, 72, 74, 96, 105, 106, 109, 112, 113, 115, 116, 117, 118, 119, 120, 121, 122, 126, 127, 129, 130, 131, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 145, 146, 148, 149, 150, 151, 153, 154, 156, 157, 159, 160, 163, 166, 167, and 168.
£_. Structure II Compounds
Structure II compounds have the following structure:
Structure II
Figure imgf000026_0001
In one embodiment R1( R2, R3, and R4 are as described above for Structure I α,α-disubstituted arylalkylamine derivatives, including preferred groups (see, Section II, supra) ; and R5 is either an optionally substituted naphthyl having one to four substituents independently selected from the group consisting of methyl, ethyl, isopropyl, methoxy, Cl, F, Br, or lower haloalkoxy, preferably the naphthyl is unsubstituted; or a substituted phenyl having one to four substituent with at least one substituent in a meta or para position selected from the group consisting of: lower alkyl, methoxy, Cl, F, Br, and lower haloalkoxy, more preferably a methoxy is present in the para or meta position; even more preferably, the remaining R5 substituents are independently selected from the group consisting of: methoxy, lower-haloalkyl, S-lower alkyl, lower-haloalkoxy, lower alkyl, halogen, SH, CN, OH, Cl, F, and Br. provided that Rx is not 6-CN-2-pyridyl; and further provided that if R5 is 3,4 dimethoxy-phenyl, then Rα is not CH3 (CH2)50-phenyl; 2-cyciopentyl-phenyl; 2-Cl-phenyl; 2-CN-phenyl; 2- (3-furanyl)phenyl; or 4- (1, 2, -benzisothiazol) ; preferably, R5 is not 3,4 dimethoxy phenyl; further provided that if R5 is 4-methoxy-phenyl, then R is not 2-cyciopentyl-phenyl; 2-CH3-phenyl; 2-benzyl-phenyl; 3- CH3, 4-CH3S02-phenyl; or 4- (1,2, -benzisothiazol) ; further provided that if R5 is 4-C1-phenyl, then Rx is not 2-CH3-phenyl , 5-iso-propyl-phenyl; 2-CH3-phenyl; 4-CH3- phenyl; phenyl; 2-Cl-phenyl; 4-Cl-phenyl; 2-methoxy, 4-CHjCHCH-phenyl; 3,4 CH3-phenyl; 2,4 CH3-phenyl; 2,3 CH3- phenyl; 2-iso-propyl, 5-CH3-phenyl; pridyl; or 1-imidazole; 4- (1,2, -benzisothiazol) ; preferably, R4 is either not 4-C1, or R4 is 3,4 dichlorophenyl; and further provided that if Rs is 3,5, dimethyl, 4-methoxy- phenyl, then R is not 4-CH3, 6-CN-2-pyridyl; or thiophenecarboxa ide; preferably, R5 is not 3,5, dimethyl, 4- methoxy-phenyl.
In another embodiment, R2, R3, and R4 are as described above for Structure I α,α-disubstituted arylalkylamine derivatives, including preferred groups ( see, Section II, supra) , -
R5 is either an optionally substituted naphthyl having one to four substituents independently selected from the group consisting of methyl, ethyl, isopropyl, methoxy, Cl, F, Br, and lower haloalkoxy, preferably the naphthyl is unsubstituted; or a substituted phenyl having one to four substituent with at least one substituent in a meta or para position selected from the group consisting of: methyl, ethyl, isopropyl, methoxy, Cl, F, Br, and lower haloalkoxy, more preferably a methoxy is present in the para or meta position; even more preferably, the remaining R5 substituents are independently selected from the group consisting of: methoxy, lower-haloalkyl, S-lower alkyl, lower-haloalkoxy, lower alkyl, halogen, SH, CN, OH, Cl, F, and Br; and
Rx is either 2-CN-phenyl, 2,3-dichloro phenyl, 2-nitro- phenyl, 2-cyano-3-chloro-phenyl, an optionally substituted pyridyl, an optionally substituted benzothiopyranyl, or an optionally substituted carbazole, where the optionally present substituents for the pyridyl, benzothiopyranyl, and carbazole as described in Section II supra, for aryl Rx substituents, including preferred substituents, and are even more preferably independently selected from the group consisting of: methoxy, lower-haloalkyl, S-lower alkyl, lower-haloalkoxy, lower alkyl, halogen, SH, CN, OH, Cl, F, and Br.
£__. R7-σroup Stereochemistry The different calcilytic compounds described herein can have different stereochemistry around different groups. In an embodiment of the present invention the Structure I compounds have the following absolute configuration structure with respect to R2:
Figure imgf000029_0001
III. Pharmaceutical Composition
The calcilytic compounds described herein can be formulated as a pharmaceutical composition to facilitate the administration of the compound to a patient. Preferred formulations contain a pharmaceutically acceptable carrier and a calcilytic compound as described in Section II, supra . , including the different embodiments.
Examples of suitable carriers are provided below, in Section V, "Administration," and include calcium carbonate, calcium phosphate, lactose, glucose, sucrose, gelatin, vegetable oils, polyethylene glycols and physiologically compatible solvents.
EL TREATMENT OF DISEASES OR DISORDERS
Compounds inhibiting calcium receptor activity can be used to confer beneficial effects to patients suffering from a variety of diseases or disorders. Diseases or disorders which can be treated using a calcilytic compound are known in the art and can be identified using the present application as a guide. For example, diseases or disorders can be identified based on the functional responses of cells regulated by calcium receptor activity.
Diseases and disorders which can be treated using the calcilytic compounds described herein include those due to different cellular defects related to calcium receptor activity in different cells, such as a defective calcium receptor or an abnormal number of calcium receptors, a defective intracellular protein acted on by a calcium receptor, or a defective protein or an abnormal number of proteins acting on a calcium receptor. Functional responses of cells regulated by the calcium receptor are known in the art, including PTH secretion by parathyroid cells, calcitonin secretion by C-cells, bone resorption by osteoclasts, and Ca2* secretion by kidney cells. Such functional responses are associated with different diseases or disorders.
For example, isolated osteoclasts respond to increases in the concentration of extracellular Ca2* with corresponding increases in [Ca2*]i arising partly from the mobilization of intracellular Ca2*. Increases in [Ca2*] x in osteoclasts are associated with the inhibition of bone resorption.
Renin secretion from juxtaglomerular cells in the kidney is depressed by increased concentrations of extracellular Ca2*. Extracellular Ca2* causes the mobilization of intracellular Ca2* in these cells. Other kidney cells respond to extracellular Ca2* as follows: elevated Ca2* inhibits formation of 1,25(OH)2-vitamin D by proximal tubule cells, stimulates production of calcium-binding protein in distal tubule cells, and inhibits tubular reabsorption of Ca2* and Mg2* in the thick ascending limb of Henle's loop (MTAL) , and reduces vasopressin action in the cortical collecting duct. Other examples of functional responses affected by extracellular Ca2* include promoting differentiation of intestinal goblet cells, mammary cells, and skin cells; inhibiting atrial natriuretic peptide secretion from cardiac atria; reducing cAMP accumulation in platelets; altering gastrin and glucagon secretion; acting on perivascular nerves to modify cell secretion of vasoactive factors; and affecting cells of the central nervous and peripheral nervous systems. Diseases and disorders which might be treated or prevented, based upon the affected cells, include bone and mineral-related diseases or disorders; hypoparathyroidism; those of the central nervous system such as seizures, stroke, head trauma, spinal cord injury, hypoxia-induced nerve cell damage, such as occurs in cardiac arrest or neonatal distress, epilepsy, neurodegenerative diseases such as Alzheimer's disease, Huntington's disease and Parkinson's disease, dementia, muscle tension, depression, anxiety, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, schizophrenia, neuroleptic malignant syndrome, and Tourette's syndrome; diseases involving excess water reabsorption by the kidney, such as syndrome of inappropriate ADH secretion (SIADH) , cirrhosis, congestive heart failure, and nephrosis; hypertension; preventing and/or decreasing renal toxicity from cationic antibiotics ( e. g. , aminoglycoside antibiotics) ; gut motility disorders such as diarrhea and spastic colon,- GI ulcer diseases; GI diseases with excessive calcium absorption such as sarcoidosis; autoimmune diseases and organ transplant rejection; squamous cell carcinoma; and pancreatitis.
While calcilytic compounds of the present invention will typically be used to treat human patients, they may also be used to treat similar or identical diseases or disorders in other warm-blooded animal species, such as other primates, farm animals such as swine, cattle, and poultry; and sports animals and pets such as horses, dogs and cats.
Preferably, calcilytic compounds are used in the treatment of bone and mineral-related diseases or disorders. Bone and mineral-related diseases or disorders comprise a diverse class of disorders affecting nearly every major organ system in the body. Examples of bone and mineral-related diseases or disorders include osteosarcoma, periodontal disease, fracture healing, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia malignancy, and osteoporosis. More preferably, calcilytic compounds are used to treat osteoporosis, a disease characterized by reduced bone density and an increased susceptibility to fractures. Osteoporosis is associated with aging, especially in women.
One way of treating osteoporosis is by altering PTH secretion. PTH can have a catabolic or an anabolic effect on bone. Whether PTH causes a catabolic effect or an anabolic effect seems to depend on how plasma levels of PTH are altered. When plasma levels of PTH are chronically elevated, as in hyperparathyroid states, there is a net loss of bone. In contrast, intermittent increases in plasma PTH levels, as achieved by administration of exogenous hormone, result in new bone formation. Anabolic action of PTH on bone is described, for example, by Dempster et al . , Endocrin . Rev. 14:690-709, 1993.
As demonstrated by the Examples provided below, calcilytic compounds stimulate secretion of PTH. Such calcilytic compounds can be used to increase bone formation in a patient, for example, by intermittent dosing, thus achieving intermittent increases in the circulating levels of PTH.
I ADMINISTRATION
The calcilytic compounds described by the present invention can be formulated for a variety of modes of administration, including systemic and topical or localized administration. Techniques and formulations generally may be found in Remington's Pharmaceutical Sciences. 18th ed. , Mack Publishing Co., Easton, PA, 1990 (hereby incorporated by reference herein) . Suitable dosage forms, in part, depend upon the use or the route of entry, for example, oral, transdermal, trans¬ mucosal, or by injection (parenteral). Such dosage forms should allow the compound to reach a target cell whether the target cell is present in a multicellular host or in culture. For example, pharmacological compounds or compositions injected into the blood stream should be soluble. Other factors are known in the art, and include considerations such as toxicity and dosage forms which retard the compound or composition from exerting its effect.
Compounds can also be formulated as pharmaceutically acceptable salts and complexes thereof. Pharmaceutically acceptable salts are non-toxic salts in the amounts and concentrations at which they are administered. The preparation of such salts can facilitate the pharmacological use by altering the physical characteristics of the compound without preventing it from exerting its physiological effect. Useful alterations in physical properties include lowering the melting point to facilitate transmucosal administration and increasing the solubility to facilitate administering higher concentrations of the drug.
The pharmaceutically acceptable salt of the different compounds may be present as a complex. Examples of complexes include an 8-chlorotheophylline complex (analogous to, e.g., dimenhydrinate:diphenhydramine 8-chlorotheophylline (1:1) complex; Dramamine) and various cyclodextrin inclusion complexes.
Pharmaceutically acceptable salts include acid addition salts such as those containing sulfate, hydrochloride, fumarate, maleate, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate. Pharmaceutically acceptable salts can be obtained from acids such as hydrochloric acid, maleic acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, fumaric acid, and quinic acid.
Pharmaceutically acceptable salts also include basic addition salts such as those containing benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium, ammonium, alkylamine, and zinc, when acidic functional groups, such as carboxylic acid or phenol are present. For example, see Remington's Pharmaceutical Sciences. 18th ed. , Mack Publishing Co., Easton, PA, p. 1445, 1990. Such salts can be prepared using the appropriate corresponding bases.
Pharmaceutically acceptable salts can be prepared by standard techniques. For example, the free-base form of a compound is dissolved in a suitable solvent, such as an aqueous or aqueous-alcohol in solution containing the appropriate acid and then isolated by evaporating the solution. In another example, a salt is prepared by reacting the free base and acid in an organic solvent. (See, e . g. , PCT/US92/03736, hereby incorporated by reference herein.) Carriers or excipients can also be used to facilitate administration of the compound. Examples of carriers include calcium carbonate, calcium phosphate, various sugars such as lactose, glucose, or sucrose, or types of starch, cellulose derivatives, gelatin, vegetable oils, polyethylene glycols and physiologically compatible solvents. Examples of physiologically compatible solvents include sterile solutions of water for injection (WFI) , saline solution and dextrose. The calcilytic compounds can be administered by different routes including intravenous, intraperitoneal, subcutaneous, intramuscular, oral, topical (transdermal), or transmucosal administration. For systemic administration, oral administration is preferred. For oral administration, for example, the compounds can be formulated into conventional oral dosage forms such as capsules, tablets, and liquid preparations such as syrups, elixirs, and concentrated drops. Alternatively, injection (parenteral administration) may be used, e.g., intramuscular, intravenous, intraperitoneal, and subcutaneous. For injection, the compounds of the invention are formulated in liquid solutions, preferably, in physiologically compatible buffers or solutions, such as saline solution, Hank's solution, or Ringer's solution. In addition, the compounds may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms can also be produced.
Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, bile salts and fusidic acid derivatives. In addition, detergents may be used to facilitate permeation. Transmucosal administration, for example, may be through nasal sprays, rectal suppositories, or vaginal suppositories.
For topical administration, the compounds of the invention can be formulated into ointments, salves, gels, or creams, as is generally known in the art.
The amounts of various calcilytic compounds to be administered can be determined by standard procedures taking into account factors such as the compound IC50, EC50, the biological half-life of the compound, the age, size and weight of the patient, and the disease or disorder associated with the patient. The importance of these and other factors to be considered are known to those of ordinary skill in the art. Generally, it is an amount between about 0.1 and 50 mg/kg, preferably 0.01 and 20 mg/kg of the animal to be treated.
VI . Examples The examples provided below, like the other examples provided herein, are not intended to limit the claimed invention, but rather illustrate different aspects and embodiments of the present invention.
EXAMPLE 1: Calcium Receptor Inhibitor Assay This example illustrates the use of the Calcium Receptor Inhibitor Assay. Calcilytic activity was measured by determining the IC50 of the test compound for blocking increases of intracellular Ca2* elicited by extracellular Ca2* in HEK 293 4.0-7 cells stably expressing the human calcium receptor. HEK 293 4.0-7 cells were constructed as described by Rogers et al . , J. Bone Miner. Res . 10 Suppl. 1:S483, 1995 (hereby incorporated by reference herein) . Intracellular Ca2* increases were elicited by increasing extracellular Ca2* from 1 to 1.75 mM. Intracellular Ca2* was measured using fluo-3, a fluorescent calcium indicator.
The procedure was as follows:
1. Cells were maintained in T-150 flasks in selection media (DMEM supplemented with 10% fetal bovine serum and 200 μg/mL hygromycin B) , under 5% C02:95% air at 37 °C and were grown up to 90% confluency. 2. The medium was decanted and the cell monolayer was washed twice with phosphate-buffered saline (PBS) kept at 37 °C. After the second wash, 6 mL of 0.02% EDTA in PBS was added and incubated for 4 minutes at 37 °C. Following the incubation, cells were dispersed by gentle agitation.
3. Cells from 2 or 3 flasks were pooled and pelleted (100 x g) . The cellular pellet was resuspended in 10-15 mL of SPF-PCB+ and pelleted again by centrifugation. This washing was done twice. Sulfate- and phosphate-free parathyroid cell buffer
(SPF-PCB) contains 20 mM Na-Hepes, pH 7.4, 126 mM NaCl, 5 mM KCI, and 1 mM MgCl2. SPF-PCB was made up and stored at 4 °C. On the day of use, SPF-PCB was supplemented with 1 mg/mL of D-glucose and 1 mM CaCl2 and then split into two fractions. To one fraction, bovine serum albumin (BSA; fraction V, ICN) was added at 5 mg/mL (SPF-PCB+) . This buffer was used for washing, loading and maintaining the cells. The BSA-free fraction was used for diluting the cells in the cuvette for measurements of fluorescence. 4. The pellet was resuspended in 10 mL of SPF-PCB+ containing 2.2 μM fluo-3 (Molecular Probes) and incubated at room temperature for 35 minutes.
5. Following the incubation period, the cells were pelleted by centrifugation. The resulting pellet was washed with SPF-PCB+. After this washing, cells were resuspended in SPF-PCB+ at a density of 1-2 x 106 cells/mL.
6. For recording fluorescent signals, 300 μL of cell suspension were diluted in 1.2 mL of SPF buffer containing 1 mM CaCl2 and 1 mg/mL of D-glucose. Measurements of fluorescence were performed at 37 °C with constant stirring using a spectrofluorimeter. Excitation and emission wavelengths were measured at 485 and 535 nm, respectively. To calibrate fluorescence signals, digitonin (5 mg/mL in ethanol) was added to obtain Fmax, and the apparent Fmin was determined by adding Tris-EGTA (2.5 M Tris-Base, 0.3 M EGTA) . The concentration of intracellular calcium was calculated using the following equation:
Intracellular calcium = (F-F-ύn/F-u x Kd; where Kd = 400 nM.
7. To determine the potential calcilytic activity of test compounds, cells were incubated with test compound (or vehicle as a control) for 90 seconds before increasing the concentration of extracellular Ca2* from 1 to 2 mM. Cal¬ cilytic compounds were detected by their ability to block, in a concentration-dependent manner, increases in the concentration of intracellular Ca2* elicited by extracellular Ca2*. In general, those compounds having lower IC50 values in the Calcium Receptor Inhibitor Assay are more preferred compounds. Compounds having an IC50 greater than 50 μM were considered to be inactive. Preferred compounds are those having an ICS0 10-50 μM, more preferred compounds have an IC50 1-10 μM, and most preferred compounds have an IC50 less than 1 μM.
Examples of compounds having an IC50 greater than 50 μM include compounds 22, 24, 34, 36, 52, 53, 54, 55, 58, 60, 62, 70, 84, 92, 99, and 102.
EXAMPLE 2: Adrenerαic Receptor Activity
Structure I α,α-disubstituted arylalkylamine derivatives include compounds which have both calcilytic activity and β-adrenergic receptor activity. If desired, β- adrenergic activity can be reduced using appropriate functional groups and structural modifications.
Modifications which can be carried out to reduce β-adrenergic receptor activity include using alternative R2 groups and using absolute stereochemistry opposite to that which occurs in active β-adrenergic receptor antagonists, which provides compounds corresponding to the R enantiomer when R2 is OH. β- adrenergic receptor activity and binding to the β-adrenergic receptor can be measured using standard techniques. For example, see Riva et al . , Mol . Pharmacol . 35:201-210, 1989.
In one embodiment of the present invention the calcilytic compounds have an IC50 .> 1.0 nM, at the β- adrenergic receptor as measured using the "β-Adrenergic Receptor Binding Assay" described below. In other embodiments, using the β-Adrenergic Receptor Assay calcilytic compounds have an IC50 >. 1.0 μM, and IC50 >. 10.0 μM.
The "β-Adrenergic Receptor Binding Assay" is carried out as follows: Incubations are performed in polypropylene reaction tubes in a 37 °C water bath. To each tube 50 μL of test sample is added, followed by 300 μL of assay buffer (50 mM Tris-HCI, pH 7.5), and 50 μL of 20 nM [3H] - dihydroalprenolol. The binding reaction is initiated by the addition of 100 μL of 3.75 mg/mL well-washed rat cortex membranes in assay buffer, and allowed to incubate at 37 °C for 30 minutes. Non-specific binding is determined in the presence of 10 μM alprenolol. The final concentration of reactants is : 2 nM [3H] -dihydroalprenolol , and 75 mg/mL rat cortex membrane in a reaction volume of 0.5 mL. The binding reaction is terminated by rapid filtration with ice-cold assay buffer onto GF/C filters (Brandel, Gaithersburg, MD) which have been soaked for 15 minutes in assay buffer. The reaction is first diluted with 3 mL of cold assay buffer (4 °C) , then aspirated onto the filter followed by 3 x 3 mL washes. Filter disks are placed in 7-mL polypropylene scintillation vials with 5 mL of ScintiSafe 50% (Fisher Scientific, Pittsburgh, PA), and counted overnight. EXAMPLE 3: Stimulation of PTH Secretion
This example illustrates the ability of different cal¬ cilytic compounds to exert a biological effect on PTH secretion. PTH secretion was determined using dissociated bovine parathyroid cells as described below for Compounds 32, 33, and 38. Compounds 32, 33, and 38 all stimulated PTH secretion with an EC50 of less than 10 μM.
Stimulation of PTH secretion was assayed as follows:
Preparation of Dissociated Bovine Parathyroid Cells Parathyroid cell buffer (PCB) contains (mM) : NaCl, 126; KCI, 4; MgS04, 1; K2HP04/KH2P04, 0.7; Na-Hepes, pH 7.45, and variable amounts of CaCl2 as specified (reagent grade) . PCB was typically supplemented with bovine serum albumin (BSA fraction V; ICN Biomedicals, Inc., Costa Mesa, CA; catalog #81-003) and 1 mg/mL of D-glucose (reagent grade) as indicated. Percoll purification buffer was prepared immediately before use by mixing 8 mL of Percoll (Pharmacia LKB, Alameda, CA; catalog #17-0891-01) and 7 mL of a twice- concentrated PCB solution without phosphate and containing 2 mM CaCl2.
Parathyroid glands were obtained from calves within minutes of slaughter at an abattoir and shipped via overnight express on ice in PCB containing 1.25 mM CaCl2. The glands were trimmed and minced in ice-cold PCB containing 1.25 mM CaCl2, 1 mg/mL of D-glucose, and 2% BSA. Dissociated cells were obtained by collagenase digestion by vigorously shaking the minced tissue at 37 °C in PCB containing 0.5 to 1.0% Collagenase P (Boehringer Mannheim, Indianapolis, IN; catalog #1249 002), 2 to 5 units of deoxyribonuclease (Sigma, St. Louis, MO; catalog #D-0876) , 1 mg/mL of D-glucose, and 1.25 mM CaCl2 (reagent grade) . The cell suspension was triturated at 30 minute intervals using 25- and 10-mL pipettes as the minced tissue was digested and the cells were dispersed.
Cells were pooled at 1-hour intervals by filtering the cell suspension through a 250-μm Nitex screen into 15-mL polystyrene centrifuge tubes and spinning at 100 x g for 5 minutes at 22 °C. The pooled cell pellet was resuspended in Percoll purification buffer and purified by centrifugation at 14,500 x g for 20 minutes at 4 °C. Dissociated parathyroid cells equilibrated within a buoyant density of 1.048-1.062 above a dense band of red blood cells and below a diffuse band that contains adipocytes, strands of collagen, and damaged cells.
The dissociated parathyroid cells were removed with a sterile pipette and washed 3 to 4 times under sterile conditions in a 1:1 mixture of Ham's F-12 and Dulbecco's modified Eagle's medium (F-12/DMEM, Sigma, St. Louis, MO; catalog #D 8900) supplemented with 0.5% BSA, 100 U/mL of penicillin, 100 μg/mL of streptomycin (Gibco BRL, Grand Island, NY; catalog #15140-031) , and 20 μg/mL of gentamicin (Sigma, St. Louis, MO; catalog #G 1397) .
The cells were finally resuspended in F-12/DMEM supplemented with lower antibiotic concentrations (10 U/mL of penicillin, 10 μg/mL of streptomycin, and 4 μg/mL of gentamicin) . This latter medium lacks serum and contained ITS* (insulin, transferrin, selenous acid, BSA, and linoleic acid; Collaborative Biomedical Products, Bedford, MA; catalog #40352) .
Cells were incubated in T-75 flasks at 37 °C in a humid atmosphere of 5% C02 in air. Parathyroid cells were collected for use by decanting the flasks after 18 to 24 hours in primary culture. The concentrations of gentamicin and streptomycin used here are considerably below the ECS0 for mobilization of intracellular calcium (150 and 600 μM, respectively) .
Measurement of Parathyroid Hormone (PTH) Secretion Sulfate, phosphate-free parathyroid cell buffer (SPF- PCB) contains (mM) : NaCl, 126; KCI, 5; MgCl2, 1; Na-Hepes, pH 7.45, and variable amounts of CaCl2 as specified (reagent grade) . SPF-PCB was typically supplemented with bovine serum albumin (BSA fraction V; ICN Biomedicals, Inc., Costa Mesa, CA; catalog #81-003) and 1 mg/mL of D-glucose (reagent grade) as indicated.
Incubations were performed in triplicate in 12 x 75 mm polypropylene or polystyrene tubes to which were added 2.5 μL of test compound. The tubes were kept on ice until the drug additions were completed, then were transferred to a water bath at 37 °C, and the reactions were initiated by the addition of 0.2 mL of a suspension of dissociated cells at a density of 1 to 2 million cells/mL in SPF-PCB containing 0.5 mM Ca2*, 1 mg/mL of D-glucose, and 0.1% BSA. Incubation was for 30 minutes and the reaction was terminated by placing the tubes on ice. Cells were pelleted by gentle centrifugation (500 x g for 10 minutes at 4 °C) and 0.1 mL of supernatant was removed and stored at -20 °C.
Amino-terminal bovine PTH was measured by radioimmunoassay (RIA) using goat anti-hPTH antiserum H2, HPLC-purified 125I-hPTH (1-34) and bovine PTH (1-84) standards. Serial dilutions of bPTH standards (1,000 pg/25 μL to 3.8 pg/25 μL) were done in 50 mM Tris, pH 7.4, containing 0.5 mM Na azide and 2% bovine serum albumin (diluent) . Standards and samples were incubated for 2-3 days at 4 °C in the presence of antiserum after which 1,500-2,000 cpm label/tube was added. After an additional incubation for 1 to 2 days at 4 °C, dextran-coated charcoal was added to separate bound vs . free label. The contents of each tube were mixed and the charcoal was pelleted by centrifugation. The supematants were decanted into 12 x 75 mm polystyrene tubes and counted in a Packard Cobra gamma counter.
Example 4 : General Procedures for the Preparation of Calcilytic Compounds
The calcilytic compounds described by the present invention can be prepared using standard techniques. For example, an overall strategy for preparing preferred compounds described herein can be carried out as described in this section. The examples which follow illustrate the synthesis of specific compounds. Using the protocols described herein as a model, one of ordinary skill in the art can readily produce other Structure I compounds. All reagents and solvents were obtained from commercial vendors. Starting materials ( e . g. , amines and epoxides) were synthesized using standard techniques and procedures. GC/EI- MS (Gas Chromatographic/Electron-Impact Mass Spectrometric) analyses were performed on HP-5890 Series II gas chromato- graphs equipped with HP-Ultra-2 or HP-5MS columns (30 mm x 0.25 mm ID) and HP-5971 or HP-5972 Mass Selective Spectrometric Detectors (MSD's) were used. MPLC (Medium- Pressure Liquid Chromatography) separations were carried out on silica gel (400 mesh) using an FMI pump, ISCO UV-6 detector (254 nm) and FOXY 200 fraction collector. HPLC
(High Performance Liquid Chromatography) was performed using RAININ HP-XL pumps and Dynamix UV-1 detectors (254 mm) .
Examples of specific separation conditions and details are given in the individual experimental descriptions provided in the examples below. Chiral HPLC separations were carried out using a Beckman System Gold HPLC and UV detector (254 nm) on Diacel® ChiralCel OD columns (Chiral Technologies, Inc., Exton, PA 19341).
NMR (Nuclear Magnetic Resonance) spectroscopy was performed on a Varian Gemini 300 spectrometer. Proton and carbon spectra were taken at 300 MHz and 75 MHz, respectively. NMR resonances are reported in ppm relative to tetramethylsilane (TMS) with the following descriptors for the observed multiplicities: s (singlet), d (doublet), t (triplet) , q (quartet) , dd (doublet of doublets) and m (multiplet) . Jω coupling constants are reported in Hz. Elemental analyses were performed and FT-IR data were acquired by Oneida Research Services, Inc., Whitesboro, NY 13492.
A general procedure used to synthesize many of the compounds was carried out as follows: A solution of glycidyl ether (i.e., 1, 2-epoxy-3-phenoxypropane, 1 mmol) and excess amine (typically 1, l-dimethyl-2- (4-methoxyphenyl)ethylamine, 1.5 mmol) in absolute ethanol (2 mL) is stirred overnight at 50-60 °C. The product is purified by one of three general methods: (1) conversion to the hydrochloride salt, followed by Reversed-Phase High-Performance Liquid Chromatography (RP- HPLC, 0.1% HCl/acetonitrile) ; (2) conversion to the hydrochloride salt, followed by recrystallization from water- methanol or acetonitrile; and (3) purification by normal- phase chromatography (column chromatography or preparative, thin-layer chromatography (TLC)) . Hydrochloride salts were also prepared by treatment of the corresponding free base in diethyl ether with IM HCl (in diethyl ether) .
EXAMPLE 5: Preparation of N- r2-Hvdroxv-3- (1- naphthoxv)propvll -1. l-dimethyl-2- (4-fluorophenyl) ethylamine Hydrochloride. Compound 2
Figure imgf000045_0001
A stirred suspension of sodium hydride (4.0 g of 60% NaH in mineral oil, 100 mmol) in dimethylformamide (DMF, 100 ml) was treated with 1-naphthol (14.42 g, 100 mmol) . After stirring for 1 hour at ambient temperature (room temperature) , the reaction was treated with epichlorohydrin (10.18 g, 110 mmol) and stirred for 1 hour at 100 °C. The reaction was diluted with water and transferred to a separatory funnel using diethyl ether (500 ml) . The organic phase was washed with 10% aqueous NaHC03 (3 x 200 ml) , dried over anhydrous sodium sulfate, filtered, and concentrated. Kugelrohr distillation (-100 microns) yielded 1-naphthyl glycidyl ether as a clear, colorless oil: GC/EI-MS, m/z (rel. int.) 200 (M*, 61), 184 (1), 169 (5), 157 (12) , 144 (79), 129 (16), 115 (100), 101 (3), 89 (16) .
A stirred solution of 1-naphthyl glycidyl ether (400 mg, 2 mmol) and 1, l-dimethyl-2- (4-fluorophenyl) ethylamine (334 mg, 2 mmol) in absolute ethanol (2 mL) was heated at 50-60 °C for 16 hours. Chromatography of the resulting reaction mixture through silica (5 x 30 cm) using a gradient of chloroform to 5% methanol in chloroform afforded the free base of the title compound: GC/EI-MS, m/z (rel. int.) 368 (M*l, 1), 352 (2), 258 (100), 183 (5), 157 (4) , 127 (5), 115 (18) , 109 (23) , 71 (30) .
The free base in diethyl ether was treated with excess IM HCl (diethyl ether) . The resulting solid was recrystallized from hot acetonitrile to afford 300 mg of the title compound as a crystalline solid: lH-NMR (DMF-D7) δ 9.9 (IH, br s) , 9.5 (IH, br s) , 8.33 (IH, d, J=9) , 7.91 (IH, d, J=9), 7.57-7.50 (3H, m) , 7.48-7.41 (3H, m) , 7.19 (2H, t, J=10) , 7.03 (IH, d, J=7), 6.37 (IH, br d, J=5) , 4.67 (IH, br s), 4.31 (2H, br t, J=6) , 3.61 (IH, br t) , 3.42 (IH, br t) , 3.31 (2H, s) , 1.47 (3H, s), 1.46 (3H, s) ; "C-NMR (DMF-D,) δ 161.5, 158.2, 152.2, 132.5, 130.8, 130.7, 129.7, 125.4, 124.4, 124.1, 124.5, 120.0, 118.3, 113.1, 112.8, 103.1, 68.1, 64.2, 57.9, 43.5, 40.3, 20.2.
EXAMPLE 6: Preparation of N- (2-Hvdroxv-3- phenoxypropyl)-!.!-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride. Compound 3
Figure imgf000046_0001
A cooled (-78 °C) solution of diisopropylamine (65 g, 642 mmol) in tetrahydrofuran (THF, 800 mL) was treated with 244 mL of 2.5 M n-butyl lithium (610 mmol) in hexane. The reaction was stirred for 30 minutes at room temperature, cooled to -78 °C and treated dropwise with isobutyric acid (26.8 g, 305 mmol) and hexamethylphosphoramide (HMPA, 54.7 g, 305 mmol) . The reaction was stirred for 30 minutes at room temperature and treated with 4-methoxybenzyl chloride (43.4 g, 277 mmol) . The reaction was stirred for 48 hours at room temperature and treated with 10% HCl (200 mL) . The reaction was concentrated to 300 mL and diluted to 600 mL with water. The resulting solution was extracted with diethyl ether (2 x 300 mL) and the combined ether extracts were washed with 10% HCl (2 x 200 mL) . The ether extract was then extracted with IN NaOH (3 x 200 mL) . The combined IN NaOH washes were made acidic (pH 1) by the addition of concentrated HCl, and the resulting solution was extracted with diethyl ether (3 x 300 mL) . The combined ether extracts were dried over anhydrous magnesium sulfate, filtered, and concentrated to afford 32.6 g of 2,2-dimethyl-3- (4-methoxyphenyl)propionic acid as an oil: GC/EI-MS, m/z (rel. int.) 208 (M*, 7), 121 (100), 91 (5), 77 (6) .
Triethylamine (16.8 g, 166 mmol) and 2, 2-dimethyl-3- (4- methoxyphenyl)propionic acid (32.6 g, 157 mmol) were dissolved in 30 mL of water and enough acetone to maintain solubility at 0 °C. A solution of ethyl chloroformate (20.1 g, 185 mmol) in acetone (100 mL) was then added dropwise. An aqueous solution (95 mL) of sodium azide (12.9 g, 198 mmol) was then added dropwise and the resulting reaction mixture stirred 45 minutes at room temperature. The intermediate acyl azide was then extracted into toluene (200 mL) . The organic extract was washed with water, dried over anhydrous magnesium sulfate, and heated at 100 °C until the evolution of nitrogen ceased (-45 min) . The toluene was removed under vacuum and replaced with benzyl alcohol . The solution was then heated at 100 °C for 16 hours. The excess benzyl alcohol was removed under vacuum. The resulting benzyl carbamate was dissolved in absolute ethanol (200 mL) and reduced in the presence of palladium hydroxide (2 g) under 90 p.s.i. hydrogen for 4 hours at room temperature. The reaction was filtered and concentrated to a yellow oil. Vacuum distillation afforded 13.0 g of 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine as a clear, colorless oil: GC/EI- MS, /z (rel. int.) 180 (M+l, 1), 164 (5), 121 (25), 91 (5), 78 (19) , 58 (100) .
1, 2-Epoxy-3-phenoxypropane (150 mg, 1 mmol) and 1,1- dimethyl-2- (4-methoxyphenyl)ethylamine (269 mg, 1.5 mmol) were used to prepare the free base of the title compound using the method of Example 5, supra . The hydrochloride salt was prepared by dilution of the reaction mixture with HCl (3 mmol) and water. Reversed-phase high-performance liquid chromatography (RP-HPLC, 0.1%/HCl to acetonitrile) of the resulting solution yielded 35 mg of the title compound as a white solid: GC/EI-MS, m/z (rel. int.) 314 (M-15, 1), 209 5 (19), 208 (100), 163 (6), 120 (19), 114 (7), 106 (6), 77 (12) , 70 (9) , 69 (15) , 58 (6) .
EXAMPLE 7; Resolution of the Enantiomers (R) or
I S) -N- (2-Hydroxγ-3-phenoxvpropy]) -1. -dimethyl-2- (4- methoxyphenyl)ethylamine Hydrochloride. Compounds 32 and 33
° 0 X OMβ • "Cl 0 NX T°Me . HCl
* . H
OH OH
Compound 32 Compound 33
The enantiomers of (R) and ( S) -N- (2-hydroxy-3- phenoxypropyl) -1, l-dimethyl-2- (4-methoxyphenyl)ethylamine hydrochloride (compounds 32 and 33) were obtained by chiral 5 HPLC of the free base through ChiralCel OD (20 x 2.5 cm) using a combination of hexane-isopropanol containing 0.1% diethylamine (10 mL/min) measuring optical density at 260 nm. GC/EI-MS of each enantiomer gave m/z (rel. int.) 330 (M+l, 1), 314 (2), 208 (100), 183 (4) , 163 (5), 121 (16), 77 (10) , 0 70 (11) . The hydrochloride of each enantiomer was prepared by treatment of the free base in diethyl ether with excess IM HCl (diethyl ether) . Evaporation of the solvent yielded the hydrochloride product as a solid.
EXAMPLE 8: Preparation of N- r2-Hvdroxv-3- (4- 5 chlorophenoxv propvll -1.1-dimethyl-2- (4-me hoxvphenvlethvl- amine Hydrochloride. Compound 5
Figure imgf000049_0001
Using the method of Example 6, supra, 4-chlorophenyl glycidyl ether (185 mg, 1 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine (269 mg, 1.5 mmol) were used to prepare 272 mg of the title compound as a white solid: GC/EI- MS, m/z (rel. int.) 348 (M-15, 1), 244 (35) , 243 (15), 242 (100), 163 (9), 121 (24), 114 (7), 71 (24), 70 (26), 58 (15), 42 (7) .
EXAMPLE 9: Preparation of N- r2-Hvdroxv-3- (4-t- butylphenoxy)propyll -1. l-dimethyl-2- (4-methoxyphenyl) ethyl¬ amine Hydrochloride. Compound 6
Figure imgf000049_0002
Using the method of Example 5, supra, 4- -butylphenyl glycidyl ether (206 mg, l mmol) and 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine (269 mg, 1.5 mmol) were used to prepare the free base of the title compound. The hydrochloride was prepared by dilution of the reaction mixture with HCl (3 mmol) and water, which caused the product to precipitate. The mixture was heated to effect solution and allowed to cool slowly to crystallize the product. The crystals were collected by filtration, washed with water/MeOH, and dried under vacuum to give 106 mg of the title compound as a white solid: GC/EI-MS, m/z (rel. int.) 370 (M-15, 0.1), 265 (19), 264 (100), 163 (8), 121 (20), 114 (9), 91 (7), 71 (20), 70 (21), 58 (10) , 57 (12) . Example 10: Resolution of the Enantiomers IR) and (S)
N- r2-Hvdroxv-3- (4-t-butvlphenoxv) ropyll -1. l-dimethyl-2- (4- methoxyphenyl)ethylamine Hydrochloride. Compounds 20 and 21
Figure imgf000050_0001
The enantiomers of (i?) and ( S) -N- [2-hydroxy-3-
(4-t-butylphenoxy)propyl] -1, l-dimethyl-2- (4-methoxyphenyl) ethylamine hydrochloride were prepared using the method of Example 7, supra . GC/EI-MS of each enantiomer gave m/z (rel. int.) 386 (M*, 1), 370 (2), 264 (100), 163 (10), 135 (4), 121 (36) , 91 (8), 70 (11) . The hydrochloride salt of each enantiomer was prepared by treatment of the corresponding free base in diethyl ether with excess IM HCl (diethyl ether) . Evaporation of the solvent yielded the corresponding hydrochloride product as a solid.
EXAMPLE 11: Preparation of N- r2-Hγdroxv-3-
( -methoxyphenoxy)propyll -1. l-dimethyl-2- (4-methoxyphenyl) - ethylamine Hydrochloride. Compound 7
Figure imgf000050_0002
Using the method of Example 8, supra , 4-methoxyphenyl glycidyl ether (180 mg, 1 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine (269 mg, 1.5 mmol) were used to prepare 231 mg of the title compound as a white solid: GC/EI- MS, m/z (rel. int.) 344 (M-15, 0.1), 239 (17) , 238 (100), 163 (9), 123 (7), 120 (17), 114 (6), 77 (5), 70 (13), 70 (11), 58 (6) . EXAMPLE 12: Preparation of N- r2-Hvdroxv-3- (2-methylphenoxy)propvπ -1.1-dimethyl-2- (4-methoxvphenvl) ethylamine Hydrochloride. Compound 8
Figure imgf000051_0001
Using the method of Example 9, supra , 2-methylphenyl glycidyl ether (164 mg, 1 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine (269 mg, 1.5 mmol) were used to prepare 257 mg of the title compound as a white solid: GC/EI- MS, m/z (rel. int.) 328 (M-15, 0.1), 223 (17), 222 (100) , 163 (8), 121 (23), 114 (11), 91 (13), 77 (6), 71 (19), 70 (21), 58 (11) .
EXAMPLE 13: Preparation of N- r2-Hvdroxv-3- (4- (2-carboxamido) indoloxy)propyll -1. l-dimethvl-2- (4-methoxy- phenvl)ethylamine Hydrochloride. Compound 9
Figure imgf000051_0002
Using the method of Example 6, supra, 4-glycidyloxy-2- indolecarboxamide (232 mg, 1 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine (269 mg, 1.5 mmol) were used to prepare 222 mg of the title compound as a white solid: GC/EI- MS, m/z (rel. int.) 396 (M-15, 0.1), 291 (17), 290 (100) , 207 (10), 158 (7), 130 (7), 121 (28), 114 (19), 71 (18), 70 (15) .
EXAMPLE 14: Preparation of N- ( -Phenoxypropyl) - 1. l-dimethyl-2- (4-methoxyphenyl)ethylamine Hydrochloride.
Compound 17
Figure imgf000052_0001
To a stirred suspension of 50% KF-Celite (0.35 g, 3 mmol) in anhydrous acetonitrile (10 mL) was added 1,1- dimethyl-2- (4-methoxyphenyl) ethylamine (0.27 g, 1.5 mmol) and 3-phenoxypropyl bromide (0.484 g, 2.25 mmol) . The reaction mixture was refluxed under nitrogen for 6 hours, followed by stirring at room temperature for 62 hours. The mixture was filtered and the filtrate, was evaporated. The hydrochloride was prepared by dissolving the residue in HCl/methanol. The resulting solution was concentrated and dried on a lyophilizer. The residue was redissolved in dry methanol and diluted with diethyl ether, which caused precipitation of 210 mg of the title compound as a white solid: GC/EI-MS, m/z
(rel. int.) 298 (M-15, 2) , 193 (15), 192 (100), 120 (13), 107 (5), 98 (9), 77 (8), 72 (7) , 71 (8), 70 (6), 41 (4) .
EXAMPLE 15 Preparation Qt N- r2-Hydro y-3- (i- naphthoxy) ropyll -1. l-dimethyl-2- (4-methoxyphenyl)ethylamine Hydrochloride. Compound 19
Figure imgf000052_0002
Using the method of Example 5, supra , 1-naphthyl glycidyl ether (1.0 g, 5 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine (1.0 mg, 5.6 mmol) were used to prepare the free base of the title compound. Silica gel chromatography of the reaction mixture using 5% methanol in chloroform afforded 1.66 g (88%) of the purified product: GC/EI-MS, m/z (rel. int.) 364 (M-15, 1), 258 (100), 183 (3), 163 (4), 144 (4), 121 (23), 115 (18), 71 (19) : *H-NMR (C6D6) δ 8.50 (IH, d, .7=8.0), 7.65 (IH, d, .7=7.2), 7.36-7.31 (3H, m) , 7.21 (IH, t, J=7.9) , 6.98 (2H, d, J=8.6), 6.71 (2H, d, .7=8.6), 6.62 (IH, d, J=7.7), 4.08 (2H, m) , 3.93 (IH, m) , 3.32
(3H, s) , 2.80 (IH, dd, J=ll .6 and 3.7), 2.71 (IH, dd, J=11.4 and 6.4), 2.47 (2H, dd, J=13.3 and 6.2), 0.94 (3H, s) , 0.92
(3H, s) ; 13C-NMR (CDC13) δ 158.0, 154.3, 134.4, 131.2 (2 carbons), 129.9, 127.4, 126.3, 125.8, 125.2, 121.8, 120.5, 113.3 (2 carbons), 104.8, 70.4, 68.5, 55.0, 53.2, 46.4, 44.5, 26.9, 26.8. A portion of the free base in diethyl ether was treated with excess IM HCl (diethyl ether) . The resulting solid was recrystallized from hot acetonitrile to afford the title compound as a white solid.
EXAMPLE 16: Preparation of N- (2-Hvdroxv-3- t- butoxypropyl) -1. l-dimethyl-2- (4-methoxyphenyl)ethylamine. Compound 25
Figure imgf000053_0001
Using the method of Example 15, supra, t-butylglycidyl ether (142 mg, 1.0 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine (197 mg, 1.1 mmol) were used to prepare 106 mg of the title compound as a clear, colorless oil: GC/EI-MS, m/z (rel. int.) 310 (M+l. 0.3) , 294 (0.5), 222 (1.8), 188 (67.9), 163 (14.6), 132 (100), 121 (19.1); XH-NMR (CDClj) δ 7.09 (2H, d, J=8.6), 6.82 (2H, d, .7=8.6), 3.78 (3H, s), 3.68 (IH, m) , 3.37 (2H, m) , 2.27 (IH, dd, J=11.5 and 4.2), 2.63 (3H, m) , 1.19 (9H, s), 1.05 (3H, s) , 1.03 (3H, s) ; 13C-NMR (CDCI3) δ 156.0, 131.3, 130.3, 113.3, 72.9, 69.7, 64.5, 55.1, 52.9, 46.6, 44.7, 27.4, 26.9, 26.8. EXAMPLE 17: Preparation of N- ( 2-Hydroxy-3- butoxypropyl) -1.1-dimethyl-2- (4-methoxyphenyl) ethylamine. Compound 26
Figure imgf000054_0001
Using the method of Example 15, supra, n-butyl glycidyl ether (143 μL, 1.0 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine (197 mg, 1.1 mmol) were used to prepare 81 mg of the title compound as a clear, colorless oil: GC/EI-MS, m/z (rel. int.) 310 (M+l, 0.01), 174 (100), 163 (19), 132(18), 121(31), 70(20) ; αH-NMR (CDC13) δ 7.03 (2H, d, J=8.6), 6.87 (2H, d, J=8.6), 3.74 (IH, m) , 3.72 (3H, s) , 3.40 (4H, ) , 2.73 (3H, m) , 2.59 (3H, m) , 1.50 (2H, m) , 1.30 (2H, m) , 1.01 (3H, s) , 0.99 (3H, s) , 0.87 (3H, t, J=7.4) ; 13C- NMR (CDC13) δ 157.9, 131.2, 129.9, 113.2, 73.5, 71.2, 69.0, 54.9, 53.1, 46.2, 44.5, 31.5, 26.6, 26.4, 19.1, 13.8.
EXAMPLE 18: Preparation of N- (2-Hvdroxv-3- isopropoxypropyl) -1. l-dimethyl-2- (4-methoxyphenyl)ethylamine. ompoun 27
Figure imgf000054_0002
Using the method of Example 15, supra , isopropylglycidyl ether (126 μL, 1.0 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine (197 mg, 1.1 mmol) were used to prepare 53 mg of the title compound as a clear, colorless oil; GC/EI-MS, m/z (rel. int.) 296 (M+l, 0.2), 280 (1.4) , 222 (1.5), 174 (100), 132 (12) , 121(24); XH-NMR (CDC13) δ 7.03 (2H, d, =8.4), 6.77 (2H, d, =8.4) , 3.72 (3H, s), 3.70 (IH, m) , 3.53 (IH, m) , 3.38 (2H, m) , 2.80 (IH, broad s) , 2.73 (2H, m) , 2.58 (4H, m) 1.09 (6H, m) , 1.01 (3H, s) , 0.99 (3H, s) ; 13C-NMR (CDC13) δ 157.9, 131.2, 129.9, 113.2, 73.4, 71.2, 69.0, 54.9, 53.1, 46.2, 44.5, 31.5, 26.6, 26.4, 19.1, 13.8.
EXAMPLE 19: Preparation of N- \ -Hydroxy- - (2-ethyl)hexanoxvpropyπ -1. l-dimethvl-2- (4-methoxyphenyl) - ethylamine. Compound 28
Figure imgf000055_0001
Using the method of Example 15, supra, 2-ethylhexyl glycidyl ether (209 μL, 1.0 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl) ethylamine (197 mg, 1.1 mmol) were used to prepare 55 mg of the title compound as a clear, colorless oil: GC/EI-MS, m/z (rel. int.) 366 (M+l. 0.2) , 350 (1.1), 244 (100), 222 (2.5), 163 (8.7), 121 (15) ; Η-NMR (CDC13) δ 7.06 (2H, d, .7=8.5), 6.80 (2H, d, .7=8.6), 3.75 (3H, s) , 3.4 (2H, d, J=5.3), 3.31 (2H, d, .7=6.0), 2.88 (IH, broad), 2.78 (IH dd, .7=11.6 and 4.0), 2.62 (2H, m) , 1.46 (IH, q, 47=5.7), 1.24 (6H, m) , 1.03 (4H, m) , 0.84 (4H, m) ; 13C-NMR (CDC13) δ 158.0, 131.3, 130.0, 113.3, 74.4, 73.7, 69.0, 55.1, 53.3, 46.3, 44.6, 39.5, 30.5, 29.0, 26.6, 26.4, 23.8, 23.0, 14.0, 11.0; Anal, calculated for C22H39N03: C, 72.3, H, 10.8, N, 3.8. Found: C, 72.2, H, 9.9, N, 3.6.
EXAMPLE 20: Resolution of the Enantiomers (R) and
(S) -N- r2-Hydroxy-3- (2-ethyl)hexanoxypropvll -1. l-dimethyl-2- (4-methoxyphenyl)ethylamine Hydrochloride. Compounds 63 and
Figure imgf000056_0001
The enantiomers (i?) and (S) -N- [2-hydroxy-3- (2- ethyl)hexanoxypropy1] -1, l-dimethyl-2- (4-methoxyphenyl) - ethylamine hydrochloride were prepared using the method of Example 7, supra . GC/EI-MS of each enantiomer gave m/z (rel. int.) 366 (M+l, 1), 350 (2), 244 (100), 222 (3), 163 (12) , 133 (9), 121 (21), 115 (11), 100 (4), 71 (21) . The hydrochloride salt of each enantiomer was prepared by treatment of the free amine in diethyl ether with excess IM HCl (diethyl ether) . Evaporation of the solvent yielded the hydrochloride product as a solid.
EXAMPLE 21: Preparation of N- (2-Hvdroxv-3- allyloxypropyl) -1. l-dimethyl-2- (4-methoxyphenyl) ethylamine. Compound 29
Figure imgf000056_0002
Using the method of Example 15, supra, allyl glycidyl ether (119 μL, 1.0 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine (197 mg, 1.1 mmol) were used to prepare 79 mg of the title compound as a clear, colorless oil: GC/EI-MS, m/z (rel. int.) 294 (M+l, 0.1), 278 (0.9), 222 (1.5), 172 (100), 163 (11) , 121 (20) ; *H-NMR (CDC13) δ 7.04 <2H, d, J=8.6), 6.79 (2H, d, J=8.6), 5.85 (IH, ddd, J=22.2, 10.5 and 5.7) , 5.23 (IH, dd, J=17.3 and 1.5), 5.14 (IH, dd,
J=10.3 and 1.5), 3.96 (2H, d, J=5 . 7 ) , 3.74 (4H, m) , 3.43 (2H, d, J=5.7) , 2.83 (IH, broad s) , 2.77 (IH, dd, .7=11.7 and 4.1) , 2.62 (5H, m) , 1.02 (3H, s) , 1.01 (3H, s) ; "C-NMR (CDC13) δ 158.0, 134.5, 131.3, 129.9, 117.0, 113.3, 72.8, 72.2, 69.0, 55.0, 53.3, 46.3, 44.5, 26.6, 26.4.
EXAMPLE 22: Preparation of N- r2-Hvdroxv-3- (2- naphthoxy)propyll -1. l-dimethvl-2- (4-methoxyphenyl)ethyl¬ amine Hydrochloride. Compound 35
Figure imgf000057_0001
Using the method of Example 4, supra, 2-naphthyl glycidyl ether (400 mg, 2 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine (358 mg, 2 mmol) were used to prepare the free base of the title compound: GC/EI-MS, m/z (rel. int.) 364 (M-15, 1), 258 (100), 183 (2), 163 (3), 144 (4), 127 (10), 121 (22), 115 (20), 71 (11) . The free base in diethyl ether was treated with excess IM HCl (diethyl ether) . The resulting solid was recrystallized from hot acetonitrile to afford 496 mg of the hydrochloride product as a white solid.
EXAMPLE 23; Prepa ation of N-l2-Hydroxy-3- Phenvlpropy1)-!.!-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride. Compound 37
Nx Qr • nd
U OHH
Using the method of Example 6, supra, 2, 3-epoxy- propylbenzene (1 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine (1.25 mmol) yielded 179 mg of the title compound as a white solid: GC/EI-MS, m/z (rel. int.) 298 (M-15, 1), 193 (16), 192 (100), 163 (7), 121 (18), 117 (12), 91 (32), 77 (5), 76 (5), 70 (16), 58 (9) .
Example 24; Preparation of N- \2-Hydroxy-3-
(3-methoxyphenoxy)propyll -1. l-dimethyl-2- (4-methoxyphenyl) - ethylamine Hydrochloride. Compound 38
Figure imgf000058_0001
Using the method of Example 6, supra, 3-methoxyphenyl glycidyl ether (1.5 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine (1.9 mmol) yielded 403 mg of the title compound as a white solid: GC/EI-MS, m/z (rel. int.) 344 (M-15, 1), 239 (21), 238 (100), 163 (10), 121 (16), 114 (9), 106 (3), 77 (5), 71 (7), 70 (10), 58 (4) .
EXAMPLE 25 Preparation of iV- r2-Hvdroxv-3- (3-fluorophenoxy) ropyll -1. l-dimethyl-2- (4-methoxyphenyl) - ethylamine Hydrochloride. Compound 39
Figure imgf000058_0002
A solution of 3-fluorophenol (1.8 g, 16.1 mmol) in acetone (100 L) was treated with potassium carbonate (6.65 g, 48.2 mmol) and refluxed under nitrogen for 15 minutes.
Epibromohydrin (4.4 g, 32.1 mmol) was then added by syringe, and the mixture was refluxed 3 hours. The mixture was cooled and filtered, and the filtrate evaporated to dryness. The residue was partitioned between ether/water, and the layers separated. The ether layer was washed with saturated NaCl, dried over sodium sulfate and evaporated. The resulting oil was distilled under vacuum to give 1.2 g of 3-fluorophenyl glycidyl ether.
Using the method of Example 6, supra , 3-fluorophenyl glycidyl ether (1.5 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine (1.9 mmol) yielded 398 mg of the title compound as a white solid: GC/EI-MS, /z (rel. int.) 332 (M-15, 1), 227 (22), 226 (100) , 163 (7), 151 (6), 120 (22), 114 (6), 94 (7), 71 (11), 70 (16), 57 (8) .
EXAMPLE 26: Preparation of N- r2-Hydroxy-3-
(2-chlorophenoxy)propyll -1. l-dimethyl-2- (4-methoxyphenyl) - ethylamine Hydrochloride. Compound 40
Figure imgf000059_0001
Using the method of Example 25, supra , 2-chlorophenyl glycidyl ether (1.0 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine (1.25 mmol) yielded 279 mg of the title compound as a white solid: GC/EI-MS, m/z (rel. int.) 348 (M-15, 5), 245 (21), 244 (100), 242 (100), 163 (29), 121 (82), 114 (24), 77 (21), 71 (44), 70 (56), 58 (24) .
EXAMPLE 27; Preparation of N- r2-Hvdroxy-3-
(2-fluorophenoxy) ropyll -1. l-dimethyl-2- (4-methoxyphenyl) - ethylamine,Hydrochloride, Compound 41
Figure imgf000059_0002
Using the method of Example 25, supra , 2-fluorophenyl glycidyl ether (1.5 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine (1.9 mmol) yielded 385 mg of the title compound as a white solid: GC/EI-MS, m/z (rel. int.; 332 (M-15, 2), 227 (20), 226 (100), 163 (4), 125 (3), 121 (15), 78 (4), 77 (4), 71 (7), 70 (9), 58 (3) .
EXAMPLE 28: Preparation of N- r2-Hydroxv-3- (3- chlorophenoxv) ropyll -1. l-dimethvl-2- (4-methoxyphenyl) ethylamine Hydrochloride. Compound 43
Figure imgf000060_0001
Using the method of Example 25, supra, 3-chlorophenyl glycidyl ether (1.0 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl) ethylamine (1.25 mmol) yielded 168 mg of the title compound as a white solid: GC/EI-MS, m/z (rel. int.) 348 (M-15, 0.9), 245 (7) , 244 (35), 243 (25) , 242 (100) , 163 (7), 121 (22), 71 (11) , 70 (16) .
EXAMPLE 29: Preparation of N- r2-Hvdroxv-3- (4-fluorophenoxy) ropyll -1. l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride. Compound 44
Figure imgf000060_0002
Using the method of Example 25, supra , 4-fluorophenyl glycidyl ether (1.5 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine (1.9 mmol) yielded 398 mg of the title compound as a white solid: GC/EI-MS, /z (rel. int.) 332 (M-15, 1), 227 (20), 226 (100), 163 (5) , 125 (4), 121 (15), 114 (3), 95 (4), 71 (8), 70 (10) , 58 (5) . EXAMPLE 30: Preparation of N- r2-Hvdroxv-3-
(3-methylphenoxy)propyll -l. l-dimethyl-2- (4-methoxyphenyl! ethylamine Hydrochloride. Compound 45
Figure imgf000061_0001
Using the method of Example 25, supra, 3-methylphenyl glycidyl ether (2.0 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine (2.5 mmol) yielded 400 mg of the title compound as a white solid: GC/EI-MS, /z (rel. int.) 328 (M-15,1), 223 (16), 222 (100), 163 (5), 147 (5), 121 (18), 114 (6), 91 (8), 76 (4), 71 (6) , 70 (11) .
EXAMPLE 31; Preparation of iV- r2-Hvdroxv-3- (3- trifluoromethylphenoxy) ropyll -1. l-dimethyl-2- (4-methoxy phenyl)ethylamine Hydrochloride. Compound 46
Figure imgf000061_0002
Using the method of Example 25, supra, 3-tri- fluoromethylphenyl glycidyl ether (2.0 mmol) and 1,1- dimethyl-2- (4-methoxyphenyl)ethylamine (2.5 mmol) yielded 600 mg of the title compound as a white solid: GC/EI-MS, /z (rel. int.) 382 (M-15, 1), 277 (16), 276 (100), 163 (7) , 126 (4), 121 (18), 114 (5), 96 (6), 71 (8) , 70 (15) , 57 (4) .
EXAMPLE 32: Preparation of N- \2-Hydroxy- -
(2-trifluoromethylphenoxy) ropyll -1. l-dimethyl-2- (4- methoxyphenyl ) ethylamine Hydrochloride . Compound 47
Figure imgf000062_0001
Using the method of Example 25, supra, 2-tri- fluoromethylphenyl glycidyl ether (2.0 mmol) and 1,1- dimethyl-2- (4-methoxyphenyl)ethylamine (2.5 mmol) yielded 690 mg of the title compound as a white solid: GC/EI-MS, m/z (rel. int.) 382 (M-15, 1), 277 (16), 276 (100), 163 (10), 121 (22) , 114 (8), 96 (11), 71 (17), 70 (33) , 58 (9), 42 (6) .
EXAMPLE 33 : Preparation of N- r2-Hvdroxy-3- (2-t-butylphenoxy)propyll -1. l-dimethyl-2- (4- methoxyphenyl)ethylamine Hydrochloride. Compound 48
Figure imgf000062_0002
Using the method of Example 25, supra , 2- -butylphenyl glycidyl ether (2.0 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine (2.5 mmol) yielded 540 mg of the title compound as a white solid: GC/EI-MS, m/z (rel. int.) 370 (M-15, 1), 265 (19), 264 (100), 163 (5), 121 (17), 114 (6), 91 (8), 77 (3), 71 (9), 70 (8), 58 (3) .
EXAMPLE 34: Preparation N- f2-Hvdroxv-3- (2-methoxyphenoxy)propyll-l.l-dimethvl-2- (4- methoxyphenyl) ethylamine Hydrochloride. Compound 49
Figure imgf000063_0001
Using the method of Example 25, supra , 2-methoxyphenyl glycidyl ether (2.0 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl) ethylamine (2.5 mmol) yielded 60 mg of the title compound as a white solid: GC/EI-MS, m/z (rel. int.) 344 (M-15, 0.1), 239 (15), 238 (100), 163 (9), 122 (7), 121 (20) , 114 (13) , 77 (10) , 71 (19), 70 (21), 58 (7) .
EXAMPLE 35: Preparation of N- f2-Hydroxy-3- (3- t-butylphenoxy)propyll -1. l-dimethyl-2- (4- methoxyphenyl) ethylamine Hydrochloride. Compound 50
Figure imgf000063_0002
Using the method of Example 25, supra , 3- -butylphenyl glycidyl ether (2.0 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl) ethylamine (2.5 mmol) yielded 400 mg of the title compound as a white solid: GC/EI-MS, m/z (rel. int.) 370 (M-15, 1), 265 (19), 264 (100), 163 (5), 121 (15) , 114 (5), 110 (3), 91 (4) , 71 (6), 70 (9), 57 (3) .
EXAMPLE 36: Preparation of N- r2-Hvdroxv-3- (4- trifluoro ethylphenoxy)propyll -1. l-dimethyl-2- (4- methoxyphenyl) ethylamine Hydrochloride. Compound 51
Figure imgf000063_0003
Using the method of Example 25, supra , 4-tri- fluoromethylphenyl glycidyl ether (1.43 mmol) and 1,1- dimethyl-2- (4-methoxyphenyl)ethylamine (1.8 mmol) yielded 270 mg of the title compound as a white solid: GC/EI-MS, m/z (rel. int.) 382 (M-15, 3) , 277 (35), 276 (100) , 175 (8), 163 (8), 145 (16), 121 (34) , 78 (9), 71 (15) , 70 (19), 58 (8) .
EXAMPLE 37; Preparation of N- (2-Hγdroxv-3- phenoxypropyl) -1.1-dimethyl-2-phenylethylamine Hydrochloride. Compound 56
O-o^^cO • "Cl
OH H
Using the method of Example 5, supra , 1,2-epoxy-3- phenoxypropane (600 mg, 4 mmol) and 1, l-dimethyl-2- phenylethylamine (596 mg, 4 mmol) yielded the title compound: GC/EI-MS, m/z (rel. int.) 284 (M+l, 1) , 208 (100), 162 (1) , 133 (7), 91 (27), 77 (15), 70 (22) . The free base in diethyl ether was treated with excess IM HCl (diethyl ether) . The resulting solid was recrystallized from hot acetonitrile to afford 596 mg of the hydrochloride product as a white solid.
EXAMPLE 38: Preparation of N- (2-Methoxy-3- phenoxypropyl) -1. l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride. Compound 59
Figure imgf000064_0001
Allyl phenyl ether (1.34 g, 10 mmol) and N- bromosuccinimide (1.78 g, 10 mmol) were dissolved in 50 mL of methanol and stirred at room temperature for two days. The product, a 1:1 mixture of 2-bromo-1-methoxy-3-phenoxypropane and l-bromo-2-methoxy-3-phenoxypropane, was isolated by evaporating the methanol and dissolving the residue in heptane/ether/water. The organic layer was washed first with water, then brine, dried over sodium sulfate, and evaporated to dryness. The crude mixture (1.47 g, 6 mmol) was dissolved in 6 mL of acetonitrile, to which was added 50% KF-Celite (0.7 g, 12 mmol) and 1, l-dimethyl-2- (4-methoxyphenyl) - ethylamine (0.54 g, 3 mmole) . The mixture was refluxed under nitrogen for 48 hours, and then cooled and filtered. The filtrate was evaporated to dryness, and the residue was taken up in water and ether. The ether layer was dried over sodium sulfate and concentrated to dryness. The residue was dissolved in 10 mL of diethyl ether and precipitated as the HCl salt by the addition of 10 mL of IM HCl (diethyl ether) . The collected solid was purified by RP-HPLC to yield 330 mg of the title compound as a white solid: GC/EI-MS, m/z (rel. int.) 328 (M-15, 5), 223 (43) , 222 (100) , 163 (9) , 133 (13), 121 (42), 107 (13), 78 (11), 77 (23) , 71 (12), 70 (32) .
EXAMPLE 39; Preparation of N- ( -Hydroxy- - octanoxypropyl) -1. l-dimethyl-2- (4-methoxyphenyl) ethylamine. Compound 65
Figure imgf000065_0001
Using the method of Example 5, supra , 1-octyl glycidyl ether (187 mg, 1.0 mmol) and 1, l-dimethyl-2- (4-methoxy- phenyl) ethylamine (197 mg, 1.1 mmol) were used to prepare 105 mg of the title compound as a clear, colorless oil: GC/EI-MS, m/z (rel. int.) 366 (M+l, 0.08), 350 (0.08) , 244 (100), 222 (5.8), 163 (12), 121 (18) : Η-NMR (CDC1,) δ 7.08 (2H, d, J=8.6), 6.82 (2H, d, =8.6) , 3.79 (IH, m) , 3.77 (3H, s), 3.45 (4H, m) , 2.92 (IH, broad s) , 2.79 (IH, dd, J=11.6 and 4.1) ,
2.65 (2H, m) , 2.55 (2H, m) , 1.27 (8H, m) , 1.06 (3H, s) , 1.04 (3H, s), 0.88 (3H, t, J=6.7) ; "C-NMR (CDC13) δ 158.0, 131.2, 129.9, 113.2, 73.4, 71.6, 68.9, 55.0, 53.3, 46.2, 44.6, 31.7,
29.5, 29.3, 29.1, 26.5, 26.4, 26.0, 22.5, 14.0; FT-IR (film) cm"1 3409 (broad), 1611, 1512, 1245, 1120.
EXAMPLE 40: Preparation of N- (2-Hvdroxγ-3- hexanoxypropyl) -1. l-dimethyl-2- (4-methoxyphenyl) ethylamine . Compound 66
Figure imgf000066_0001
Using the method of Example 5, supra , 1-hexyl glycidyl ether (175 mg, 1.0 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl) ethylamine (197 mg, 1.1 mmol) were used to prepare 95 mg of the title compound as a clear, colorless oil: GC/EI-MS, m/z (rel. int.) 216 (M-121) , 163 (11) , 121 (22) , 114 (14) ; H-NMR (CDC13) δ 7.05 (2H, d, =8.7), 6.79 (2H, d, =8.7), 3.77 (IH, m) , 3.75 (3H, s) , 3.41 (4H, ) , 2.97 (2H, broad) , 2.79 (IH, dd, .7=11.7 and 4.1), 2.64 (3H, m) , 1.52 (2H, m) , 1.26 (6H, m) , 1.04 (3H, s) , 1.03 (3H, s) , 0.85 (3H, t, J=6.7); "C-NMR (CDC13) δ 158.1, 131.3, 129.9, 113.4, 73.4, 71.7, 68.9, 55.1, 53.6, 46.3, 44.6, 31.6, 29.5, 26.5, 26.4, 25.7, 22.6, 14.0; FT-IR, cm1 3405 (broad) , 1611, 1512, 1245, 1116, 824.
EXAMPLE 41: Preparation of N- (2-Hvdroxv-3- decanoxypropyl) -1. l-dimethyl-2- (4-methoxyphenyl)ethylamin . Compound 67
Using the method of Example 5, supra , 1-decyl glycidyl ether (235 mg, 1.0 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine (197 mg, 1.1 mmol) were used to prepare 175 mg of the title compound as a clear, colorless oil: GC/EI-MS, m/z (rel. int.) 394 (M+l, 1), 378 (6), 273 (97) , 272 (100), 222 (9) , 163 (37), 121 (61) ; Η-NMR (CDCl3) δ 7.49 (2H, d, .7=8.5), 6.82 (2H, d, J=8.5 Hz) , 3.78 (3H, s), 3.75 (IH, m) , 3.45 (4H, m) , 2.80 (IH, dd, =11.7 and 4.0) , 2.77 (IH, broad s) , 2.64 (4H, m) , 1.56 (2H, m) , 1.26 (16 H, m) , 1.06 (3H, s) , 1.05 (3H, s), 0.88 (3H, t, -7=6.1) ; "C-NMR (CDC13) δ 158.1, 131.3, 130.0, 113.4, 73.5, 71.7, 69.1, 55.1, 53.3, 46.4, 44.6, 31.8, 29.6, 29.5, 29.4, 29.3, 26.7, 26.6, 26.1, 22.6, 14.1; FT-IR (film) cm"1 3115 (broad s) , 1612, 1512, 1245, 1121, 824.
EXAMPLE 42: Preparation of N- (2-Hydroxy-3- thiophenylpropyl) -1. l-dimethyl-2- (4-methoxyphenyl) ethylamine. Compound 68
Figure imgf000067_0002
Using the method of Example 25, supra, phenyl glycidyl sulfide (3.9 mmol) and 1, l-dimethyl-2- (4-methoxyphenyl) - ethylamine (4.9 mmol) yielded 194 mg of the title compound as a white solid: GC/EI-MS, m/z (rel. int.) 330 (M-15, 4), 226 (21) , 225 (58), 224 (100) , 163 (25), 149 (25) , 123 (100) , 121 (75) , 77 (18), 71 (22), 70 (26) . EXAMPLE 43: Preparation of N- (2-Hvdroxvdecanyl) -1.1 ■ dimethyl-2- (4-methoxyphenyl) ethylamine. Compound 69
Figure imgf000068_0001
Using the method of Example 5, supra , 1, 2-epoxydecane (204 mg, 1.0 mmol) and 1, l-dimethyl-2- (4-methoxyphenyl) - ethylamine (197 mg, 1.1 mmol) were used to prepare 73 mg of the title compound as a clear, colorless oil: GC/EI-MS, /z (rel. int.) 214 (M-121, 100) , 196 (27.8) , 163 (10) , 121 (2.2) ; Η-NMR (CDC13) δ 7.08 (2H, d, .7=8.6) , 6.83 (2H, d, J=8.6), 3.79 (3H, s) , 3.53 (IH, m) , 2.79 (IH, dd, 7=11.7 and 2.9) , 2.67 (2H, s), 2.42 (IH, dd, .7=12.6 and 9.6) , 1.26 (18 H, m) , 1.08 (3H, s) , 0.88 (3H, t, =6.6); 13C-NMR (CDC13) δ 158.2, 131.4, 129.8, 113.5, 77.2, 69.8, 55.2, 53.8, 47.8, 46.5, 35.1, 31.9, 29.8, 29.7, 29.6, 29.3, 26.6, 26.4, 25.7, 22.7, 14.1; FT-IR (film) cm"1 3399 (broad s) , 1612, 1512, 1246, 1039, 823.
EXAMPLE 44: Preparation of N- (2-Hγdroxydodecanyl) -1.1- dimethyl-2- (4-methoxyphenyl) ethylamine. Compound 70
Figure imgf000068_0002
Using the method of Example 5, supra, 1, 2-epoxydodecane (240 μL, 1.0 mmol) and 1, l-dimethyl-2- (4-methoxyphenyl) - ethylamine (197 mg, 1.1 mmol) were used to prepare 68 mg of the title compound as a clear, colorless oil: GC/EI-MS, m/z (rel. int.) 363 (M+l, 0.2) , 348 (2) , 242 (100) , 224 (8) , 163 (7) , 121 (20) ; *H-NMR (CDC13) δ 7.08 (2H, d, .7=8.4), 6.83 (2H, d, J=8.4), 3.79 (3H, s) , 3.50 (IH, m) , 2.78 (IH, dd, J=11.8 and 3.1) , 2.66 (2H, s) , 2.41 (IH, dd, .7=11.5 and 9.3), 1.26 (18 H, m) , 1.07 (6H, s) , 0.88 (3H, t, ,7=6.5) ; "C-NMR (CDC13) δ 158.2, 131.4, 129.9, 113.4, 76.9, 70.0, 55.2, 53.6, 47.8, 46.6, 35.1, 31.9, 29.7, 29.6, 29.3, 26.7, 26.5, 25.7, 22.7, 14.1; FT-IR (film) cm1 3386, 1612, 1512, 1246, 1039, 824.
EXAMPLE 45: Preparation of N- (2-Hydroxydec-9-enyl ) -
1. l-dimethyl-2- (4 -methoxyphenyl) ethylamine, Compound 71
Figure imgf000069_0001
Using the method of Example 5, supra, 1, 2-epoxy-9-decene (202 mg, 1.0 mmol) and 1, l-dimethyl-2- (4-methoxyphenyl) - ethylamine (197 mg, 1.1 mmol) were used to prepare 80 mg of the title compound as a clear, colorless oil: GC/EI-MS, m/z (rel. int.) 334 (M+l, 0.02), 318 (0.7), 212 (100), 194 (13), 163 (11) , 121 (23) ; JH-NMR (CDC13) δ 7.06 (2H, d, .7=8.6) , 6.80 (2H, d, 7=8.6), 5.79 (IH, dddd, 7=23.1, 10.2, 6.6 and 6.6) , 4.95 (2H, m) , 3.77 (3H, s) , 3.52 (IH, m) , 2.76 (IH, dd,
7=11.7 and 3.0), 2.64 (IH, s) , 2.39 (IH, dd, .7=11.6 and 9.4) , 2.03 (2H, m) , 1.33 (10H, ) , 1.05 (6H, s) : "C-NMR (CDCl3) δ 158.1, 139.1, 131.4, 129.8, 114.1, 113.4, 69.8, 55.2, 53.7, 47.8, 46.5, 35.1, 33.8, 29.6, 29.0, 28.8, 26.6, 26.4, 25.7; FT-IR (film) cm"1 3387 (broad, s) , 1612, 1512, 1246, 1038, 910, 760.
EXAMPLE 46: Preparation of N- (3-Dodecanoxy-2- hvdroxypropyl) -1.1-dimethyl-2- (4-methoxyphenyl) ethylamine. Compound 72
Figure imgf000069_0002
Using the method of Example 5, supra, dodecyl glycidyl ether (242 mg, 1.0 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine (197 mg, 1.1 mmol) were used to prepare 121 mg of the title compound as a clear, colorless oil: GC/EI-MS, m/z (rel. int.) 422 (M+l, 1), 406 (4) , 300 (100), 222 (11), 163 (23) , 121 (34); *H-NMR (CDC13) δ 7.09 (2H, d, 7=8.6), 6.83 (2H, d, .7=8.6), 3.79 <3H, s), 3.76 (IH, m) , 3.45 (4H, m) , 2.81 (IH, dd, 7=7.6 and 4.0), 2.65 (4H, m) , 1.53 (2H, m) , 1.26 (20H, m) , 1.06 (3H, s) , 1.05 (3H, s) , 0.88 (3H, t, 7=6.4); "C-NMR (CDCl3) δ 158.1, 131.3, 130.0, 113.4, 73.5, 71.7, 69.0, 55.1, 53.4, 46.4, 44.6, 31.9, 29.6, 29.4, 29.3, 26.7, 26.6, 26.1, 22.7, 14.1; FT-IR (film) cm"1 3415 (broad, s) , 1612, 1512, 1246, 1121, 825.
EXAMPLE 47; Preparation of N- r2-Hvdroxv-3- (l- adamantylmethoxy) ropyll -1. l-dimethyl-2- ( -methoxyphenyl) ethylamine Hydrochloride. Compound 74
Figure imgf000070_0001
Using the method of Example 9, supra , 1 ,2-epoxy-3- (l- adamantylmethoxy)propane (410 mg, 1.8 mmol) and 1, 1-dimethyl- 2- (4-methoxyphenyl) ethylamine (403 mg, 2.25 mmol) were used to prepare 625 mg of the title compound as a white solid: GC/EI-MS, m/z (rel. int.) 386 (M-15, 5) , 281 (97), 280 (100) , 163 (26), 149 (77), 135 (23) , 121 (63), 107 (18) , 93 (29) , 79 (20) , 71 (26) .
EXAMPLE 48: Preparation of iV- ( 2-Hvdroxv-3- cyclohexylmethoxypropyl) -1. l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride. Compound 75
Figure imgf000071_0001
Using the method of Example 6, supra , 1, 2-epoxy-3-cyclo- hexylmethoxypropane (212 mg, 1.2 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine (279 mg, 1.6 mmol) were used to prepare 200 mg of the title compound as a white solid: GC/EI- MS, m/z (rel. int.) 334 (M-15, .l), 229 (15) , 228 (100), 163 (9) , 132 (5), 121 (16) , 114 (9), 97 (7), 71 (8) , 70 (9), 55 (16) .
EXAMPLE 49: Preparation of N- (2-Hvdroxv-4-phenvlbutvl) - 1. l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride. Compound 79
Figure imgf000071_0002
A solution of m-chloroperbenzoic acid (43.5 g, 151 mmol) in chloroform (250 ml) was treated with 4-phenyl-1-butene (20 g, 151 mmol) . The reaction was stirred for 1 hour at room temperature and washed with sodium bicarbonate, sodium sulfite, and saturated sodium chloride. The solution was dried over sodium sulfate and evaporated to dryness to afford 3, 4-epoxybutylbenzene (100%) . Using the method of Example 6, supra , 3,4- epoxybutylbenzene (1.4 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl) ethylamine (1.7 mmol) were used to prepare 235 mg of the title compound as a white solid: GC/EI-MS, m/z (rel. int.) 312 (M-15, 0.1) , 207 (16), 206 (100) , 163 (7) , 131 (28), 121 (19), 91 (28) , 77 (7), 71 (7), 70 (10) , 58 (10) . EXAMPLE 50: Preparation of N- (2-Hvdroxy-3- phenoxypropyl) -1. l-dimethyl-3- (4-methoxyphenyl) ropylamine Hydrochloride. Compound 90
Figure imgf000072_0001
4-Methoxycinnamonitrile was hydrogenated in ethanol with palladium hydroxide on carbon to give 3- (4-methoxyphenyl) - propionitrile. A mixture of anhydrous cerium (III) chloride (1.99 g, 8.1 mmol) in dry THF (12 L) was stirred for 3 hours at room temperature, cooled to -78 °C, and treated with MeLi (5.8 mL, 8.1 mmol). After stirring for 1 hour at -78 °C the reaction mixture was treated with 3- (4-methoxy¬ phenyl)propionitrile (0.45 g, 2.8 mmol) . The reaction mixture was stirred for 5 hours at -78 °C and then quenched with ammonium hydroxide. After warming to room temperature, the mixture was filtered, and the filtrate diluted with water and extracted with diethyl ether. The diethyl ether layer was dried over sodium sulfate and evaporated. The crude oil was purified by normal-phase chromatography to give 150 mg of 1, l-dimethyl-2- (4-methoxyphenyl)ethylamine as a light yellow oil.
Using the method of Example 6, supra , l,2-epoxy-3- phenoxypropane (0.62 mmol) and 1, l-dimethyl-2- (4- ethoxyphenyl) ethylamine (0.78 mmol) were used to prepare 105 mg of the title compound as a white solid: GC/EI-MS, m/z (rel. int.) 343 (M\ 4), 209 (14), 208 (99), 161 (13), 122
(9) , 121 (100) , 77 (17) , 72 (25) , 71 (12), 70 (18), 58 (13) . EXAMPLE 51: Preparation of N- f2-Hvdroxy-3- (1- adamantanoxy)propyll -1. l-dimethyl-2- (4-methoxyphenyl)ethyl amine. Compound 96
Figure imgf000073_0001
Using the method of Example 16, supra, 1-adamantyl glycidyl ether (350 mg, 1.0 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl)ethylamine (197 mg, 1.1 mmol) were used to prepare 207 mg of the title compound as a clear, colorless oil: GC/EI-MS, /z (rel. int.) 338 (M+l, 0.1) , 372 (0.3) , 266 (65) , 163 (1), 135 (100), 121 (16) ; αH-NMR (CDC13) δ 7.02 (2H, d, 7=8.3), 6.74 (2H, d, 7=8.6), 3.70 (3H, s), 3.64 (IH, m) , 3.38 (4H, m) , 2.71 (IH, dd, 7=11.5 and 4.0) , 2.57 (3H, ) , 2.06 (3H, broad s) , 1.64 (6H, broad s) , 1.53 (6H, m) , 1.13 (4H, apparent t, 7=6.9), 0.98 (3H, s) , 0.97 (3H, s) ; "C-NMR (CDC13) δ 157.8, 131.2, 130.0, 113.1, 77.8, 70.5, 69.4, 54.9, 52.8, 46.3, 44.6, 32.0, 26.7, 26.6, 25.6, 23.9.
EXAMPLE 52: Preparation of N- (2-Hvdroxv-3- phenoxypropyl) -1. l-dimethyl-2- (4-methylphenyl) ethylamine Hydrochloride. Compound 98
Figure imgf000073_0002
A solution of 2, 4, 6-triphenylpyrylium tetrafluoroborate (2.97 g, 7.5 mmol) in ethanol (15 mL) was treated with 4- methylbenzylamine (1 g, 8.25 mmol) . The reaction was stirred overnight at room temperature and diluted with diethyl ether to precipitate the product. The product was recrystallized from ethanol/diethyl ether to give 3.15 g of N- (4- methylbenzyl) -2, 4, 6-triphenylpyridinium tetrafluoroborate as a tan solid.
Sodium hydride (0.92 g, 60% oil dispersion, 22.9 mmol) was added to methanol (10 mL) at 0 °C, followed by the addition of 2-nitropropane (2.04 g, 22.9 mmol) . The reaction mixture was stirred for 30 minutes at room temperature and the methanol was evaporated at reduced pressure. A solution of the N- (4-methylbenzyl) -2,4, 6-triphenylpyridinium tetrafluoroborate (3.15 g, 7.6 mmol) in DMSO (25 mL) was then added to the dry sodium salt of 2-nitropropane. The mixture was stirred at 60 °C overnight under nitrogen. The reaction was diluted with water, and the product extracted into diethyl ether. The ether layer was washed with saturated NaCl and dried over sodium sulfate. The ether solution was treated with Amberlyst 15 ion-exchange resin to absorb the 2, 4, 6-triphenylpyridine. The resin was filtered and the filtrate evaporated to yield 1.3 g of pure 1- (4- methylphenyl) -2-methyl-2-nitropropane.
The 1- (4-methylphenyl) -2-methyl-2-nitropropane (1.3 g) was hydrogenated for 5 hours at 65 p.s.i. hydrogen in ethanol (30 mL) using 1.4 g of Raney nickel as catalyst. Removal of the catalyst by filtration and evaporation of the solvent yielded 1.15 g of 1, l-dimethyl-2- (4-me hoxyphenyl) ethylamine as a clear oil. Using the method of Example 6, supra , 1,2-epoxy-3- phenoxypropane (1.3 mmol) and 1, l-dimethyl-2- (4-methoxy- phenyl) ethylamine (0.6 mmol) were used to prepare 85 mg of the title compound as a white solid: GC/EI-MS, m/z (rel. int.) 298 (M-15, 7) , 209 (47) , 208 (100) , 114 (14), 107 (13), 105 (46), 79 (12) , 77 (28) , 71 (18) , 70 (31), 58 (13) . EXAMPLE 53: Preparation of N- ( 2-Hydroxy-3- phenoxypropyl) -1. l-dimethyl-2- (3-methoxyphenyl) ethylamine Hydrochloride, Compound 99
Figure imgf000075_0001
Using the method of Example 6, supra , l,2-epoxy-3- phenoxypropane (200 mg, 1.3 mmol) and 1, l-dimethyl-2- (3- methoxyphenyl)ethylamine (263 mg, 1.5 mmol) were used to prepare 340 mg of the title compound as a white solid: GC/EI- MS, m/z (rel. int.) 209 (14) , 208 (100), 206 (6) , 121 (11) , 114 (5), 107 (5), 91 (6), 77 (12) , 71 (8) , 70 (16) .
EXAMPLE 54 preparation of N- (2-Hγdrpxy-2-methyl-3- phenoxypropyl) -1. l-dimethyl-2- (4-methoxyphenyl)ethylamine Hydrochloride. Compound 101
Figure imgf000075_0002
To a solution of 3-chloroperoxybenzoic acid (70% pure, 4.2 g, 17 mmol) in 40 mL of chloroform was added methallyl phenyl ether (2.5 g, 16.87 mmol) . The mixture was stirred at room temperature for 5 hours then worked up by pouring into ether and sodium bicarbonate. The organic phase was washed with sodium bisulfite, sodium bicarbonate, and sodium chloride, dried over anhydrous sodium sulfate and evaporated to give 2.3 g of 1, 2-epoxy-2-methyl-3-phenoxypropane .
Using the method of Example 6, supra , l,2-epoxy-2- methyl-3-phenoxypropane (0.092 g, 0.56 mmol) and 1,1- dimethyl-2- (4-methoxyphenyl) ethylamine (0.10 g, 0.56 mmol) were used to prepare 120 mg of the title compound as a white solid: GC/EI-MS, /z, (rel. int.) 328 (M-15,1) , 223 (15) , 222 (100), 163 (13), 147 (13), 121 (21), 107 (11) , 91 (9) , 77 (13) 71 (12) , 70 (49) .
EXAMPLE 55: Preparation of N- (2-Hvdroxv-3- henoxypropyl) -1. l-dimethyl-2- (4-chlorophenyl) ethylamine Hydrochloride. Compound 103
Using the method of Example 6, supra , l,2-epoxy-3- phenoxypropane (950 mg, 6.3 mmol) and 1, l-dimethyl-2- (4- chlorophenyl) ethylamine (1.45 g, 7.9 mmol) were used to prepare 150 mg of the title compound as a white solid: GC/EI- MS, m/z (rel. int.) 318 (M-15, 7), 209 (47) , 208 (100) , 127 (11), 125 (33), 114 (13) , 107 (12), 77 (23) , 71 (16) , 70 (29) , 58 (13) .
EXAMPLE 56: Preparation of N- (2-Hvdroxy-3- phenoxypropyl) -1. l-dimethyl-2- (3-chlorophenyl)ethylamine Hydrochloride. Compound 104
Figure imgf000076_0002
Using the method of Example 6, supra , l,2-epoxy-3- phenoxypropane (1.3 g, 8.8 mmol) and 1, l-dimethyl-2- (4- chlorophenyl) ethylamine (2.0 g, 11 mmol) were used to prepare 338 mg of the title compound as a white solid: GC/EI-MS, m/z (rel. int.) 318 (M-15, 1), 209 (14), 208 (100) , 133 (4) , 125 (12) , 114 (6), 107 (6), 77 (10) , 71 (8) , 70 (15), 58 (5) . EXAMPLE 57: Resolution of the Enantiomers of IR) - and ( S) - N- r2-Hydroxγ-3- ( 1-naphthoxy)propvll -1. l-dimethvl-2- (4- methoxyphenyl) ethylamine Hydrochloride. Compounds 105 and 106
Figure imgf000077_0001
Compound 105 Compound 106
The free base (1.5 g) of compound 19 was chromatographed through ChiralCel OD (20 x 2.5 cm) using ethanol-hexane (1:4, plus 0.1% diethylamine) at 10 mL/min (270 nm) . Chromatography of each enantiomer through Vydac C-18 (5 x 25 cm) using a gradient of 0.1% HCl to acetonitrile (50 mL/min., 264 nm) afforded the hydrochloride salt of compound 105 (464 mg) [ ]D 26 = 15.3° (c = 0.928, CHC13) , m.p. 113-115°C and compound 106 (463 mg) [α] D 26 = -13.8° (c = 0.926, CHC13) .
EXAMPLE 58: Preparation of N- r2-Hydroxy-3- (4-methoxy- (1- naphthoxy) ) ropyll -1. l-dimethyl-2- (4-methoxyphenyl)ethylamine Hydrochloride, Compound 107
Figure imgf000077_0002
Using the method of Example 5, supra , 1, 2-epoxy-3- [4- methoxy- (l-naphthoxy) ]propane (462 mg, 2 mmol) and 1,1- dimethyl-2- (4-methoxyphenyl)ethylamine (120 mg, 0.67 mmol) yielded, after preparative TLC and RP-HPLC, 116 mg of the title compound as a white solid: GC/EI-MS, m/z (rel. int.) 394 (M-15,2) , 288 (100), 731 (11) , 121 (15) , 71 (22) . EXAMPLE 59 : Preparat i on of N- r2 -Hvdroxy- 3 - ( 4 - chloro- f 1 - naphthoxy) ) propyl l - 1 . l - dimethyl - 2 - ( 4 -methoxyphenyl ) ethylamine Hydrochloride . Compound 108
Figure imgf000078_0001
Using the method of Example 5, supra, 1 ,2-epoxy-3- [4- chloro- (1-naphthoxy) ]propane (469 mg, 2 mmol) and 1,1- dimethyl-2- (4-methoxyphenyl)ethylamine (120 mg, 0.67 mmol) yielded, after preparative TLC and RP-HPLC, 131 mg of the title compound as a white solid: GC/EI-MS, m/z (rel. int.) 414 (M\0.5), 398 (1), 292 (100), 121 (33), 71 (43) .
EXAMPLE 60: Preparation of (R) -N- r2-Hvdroxv-3- (3- chloro-2-cyanophenoxy)propyll -1.1-dimethyl-2- (4- methoxyphenyl) -ethylamine Hydrochloride, Compound 109
Figure imgf000078_0002
To a solution of 18-crown-6 (3.96 g, 15 mmol) in 30 mL of acetonitrile were added dry potassium acetate (1.47 g, 15 mmol) and 2-chloro-6-fluorobenzonitrile (1.56 g, 10 mmol) . The reaction was refluxed under nitrogen for 25 hours, then cooled to room temperature. Sodium hydroxide (2 L of a 10 M solution, 20 mmol) and water (5 mL) were added, and the reaction stirred at room temperature for two hours. The acetonitrile was removed on a rotary evaporator, and the residue was taken up in ether and water. The basic aqueous layer was washed three times with ether. The aqueous layer was then made acidic with HCl, and the product extracted into ether. The ether layer was dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting solid was crystallized from water/methanol to yield 1.11 g of 3-chloro-2-cyanophenol .
3-Chloro-2-cyanophenol (0.55 g, 3.58 mmol) was dissolved in 10 mL of dimethylformamide, and the solution cooled to 0 °C. Sodium hydride (0.158 g, 3.94 mmol 60% in oil) , washed with hexane and dimethylformamide, was added to cooled solution over a period of one minute. After stirring for 10 minutes at room temperature, (2R) -{-) -glycidyl 3-nitrobenzenesulfonate was added and stirred 16 hours. The reaction was poured into ether and dilute sodium hydroxide. The ether layer was separated and the aqueous layer extracted once more with ether. The combined ether extracts were washed with water and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give 0.7 g of (R) -3-chloro-2-cyanophenyl glycidyl ether.
Using the method of Example 6, supra , (R) -3- chloro-2- cyanophenyl glycidyl ether (0.7 g, 3.34 mmol) and 1, 1-dimethyl- (4-methoxyphenyl) ethylamine (0.72 g, 4.0 mmol) were used to prepare 570 mg of the title compound as a white solid: Η-NMR (CDC13) 9.65 (IH, br s) , 8.2 (IH, br s) , 7.4 (IH, t) , 7.15 (2H, d) , 7.03 (IH, d) , 6.95 (IH, d) , 6.8 (2H, d) , 4.8 (IH, m) , 4.3 (2H, d) , 3.75 (3H, s), 3.4 (2H, m) , 3.13 (2H, dd) , 1.44 (3H, s) , 1.40 (3H, s) ; "C-NMR 161.9, 159.4, 138.2, 135.1, 132.4, 126.8, 122.8, 114.4, 114.2, 111.6, 104.0, 71.8, 66.0, 61.9, 55.8, 45.4, 43.9, 23.5, 23.3.
EXAMPLE 61: Preparation of iV- (2-Hvdroxv-
3-phenoxypropyl) -1, l-dimethyl-2- (4-ethvlphenyl)ethylamine Hydrochloride. Compound 110
Figure imgf000079_0001
Using the method of Example 52, supra , 4- ethylbenzylamine (4.0 g, 29.6 mmol) was used to prepare 3.6 g of 1, l-dimethyl-2- (4-ethylphenyl)ethylamine. Using the method of Example 6, supra , 1, 2-epoxy-3-phenoxypropane (0.43 g, 2.9 mmol) and 1, l-dimethyl-2- (4-ethylphenyl)ethylamine (0.5 g, 2.8 mmol) were used to prepare 600 mg of the title compound as a white solid: GC/EI-MS, /z , (rel. int.) 313 (M-15,.l) , 209 (23), 208 (100) , 133 (5) , 119 (12) , 114 (6), 107 (5), 104 (7), 91 (6), 77 (10) , 71 (8) , 70 (12) .
EXAMPLE 62: Preparation of JV- (2-Hvdroxy-
3-Phenoxypropyl) -1 , l-dimethyl-2- (4-trifluoromethoxyphenyl) ethylamine Hydrochloride. C mpound HI
Figure imgf000080_0001
Using the method of Example 52, supra , 4-trifluoro- methoxybenzylamine (2.0 g, 10.5 mmol) was used to prepare 2.2 g of 1, l-dimethyl-2- (4-trifluoromethoxyphenyl) ethylamine .
Using the method of Example 6, supra , l,2-epoxy-3- phenoxypropane (0.12 g, 0.8 mmol) and 1, l-dimethyl-2- (4- trifluoromethoxyphenyl) ethylamine (0.175 g, 0.8 mmol) were used to prepare 15 mg of the title compound as a white solid: GC/EI-MS, m/z, (rel. int.) 368 (M-15,2) , 209 (39) , 208 (100) , 175 (20) , 133 (5), 114 (5) , 107 (6) , 77 (11), 71 (7), 70 (12) , 58 (5) .
EXAMPLE 63: Preparation of N- (2-Hvdroxv-3- phenoxypropyl) -1. l-dimethyl-2- (4-isopropylphenvl)ethylamine Hydrochloride. Compound 112
Figure imgf000081_0001
Using the method of Example 52, supra, 4-isopropylbenzylamine (4.89 g, 32.8 mmol) was used to prepare 4.1 g of 1, l-dimethyl-2- (4-isopropylphenyl) - ethylamine. Using the method of Example 6, supra, 1, 2-epoxy-3-phenoxypropane (0.173 g, 1.15 mmol) and 1, l-dimethyl-2- (4-isopropylphenyl) ethylamine (0.275 g, 1.44 mmol) were used to prepare 89 mg of the title compound as a white solid: GC/EI-MS, m/z , (rel. int.) 326 (M-15,1) , 209 (14), 208 (100), 133 (9), 117 (5), 114 (5), 105 (5), 91 (6), 77 (8) , 71 (8) , 70 (13) , 58 (5) .
EXAMPLE 64: Preparation of N- (2-Hvdroxv-3- phenoxypropyl) -1-ethyl-1-methyl-2- (4-methoxyphenyl) ethylamine Hydrochloride. Compound 113
Figure imgf000081_0002
4-Hydroxybenzyl alcohol (0.35 g, 2.82 mmol) and tetrabutylammonium fluoride (0.147 g, 0.56 mmol) were dissolved in 3 mL of 2-nitrobutane and heated to 130-145 °C under nitrogen for 20 hours. The reaction mixture was cooled and partitioned between water and ether. The ether layer was separated, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The crude material was purified by preparative TLC using ethyl acetate/hexane as the elutant. The yield of l-ethyl-l-methyl-2- (4-hydroxyphenyl) - nitroethane was 0.21 grams. To a suspension of 40% (wt/wt) potassium fluoride on alumina (0.73 g, 5 mmol) in 3 mL of acetonitrile were added 1-ethyl-l-methyl-2- (4-hydroxyphenyl)nitroethane (0.21 g, 1.0 mmol) and iodomethane (0.21 g, 1.5 mmol) . The reaction was stirred at room temperature for 4 days and then filtered and rinsed with acetonitrile. The acetonitrile was removed on a rotary evaporator, and the residue was partitioned between ether and water. The ether layer was separated, washed with sodium bisulfite, sodium carbonate, and saturated brine, then dried over anhydrous sodium sulfate and concentrated. The yield of 1-ethyl-1-methyl-2- (4-methoxyphenyl)nitroethane was 0.183 g.
Nickel chloride monohydrate (0.107 g, 0.404 mmol) was dissolved in 5 mL of methanol, followed by the addition of sodium borohydride (0.05 g, 1.2 mmol) . After stirring for 5 minutes, 1-ethyl-l-methyl-2- ( -methoxyphenyl)nitroethane (0.18 g, 0.807 mmol) in 3 mL of methanol was added, and stirred for 5 minutes. Sodium borohydride (0.11 g, 2.83 mmol) was then added in portions over 5 minutes. The reaction was then stirred overnight under a hydrogen balloon. The reaction mixture was filtered, and the methanol was removed on a rotary evaporator. The residue was taken up in ether and dilute sodium hydroxide. The ether layer was separated, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The yield of
1-ethyl-1-methyl-2- (4-methoxy-phenyl) ethylamine was 0.127 grams.
Using the method of Example 6, supra, l,2-epoxy-3- phenoxypropane (0.086 g, 0.57 mmol) and 1-ethyl-1-methyl-2- (4-methoxyphenyl) ethylamine (0.11 g, 0.57 mmol) were used to prepare 90 mg of the title compound as a white solid: GC/EI-MS, m/z , (rel. int.) 314 (M-29,2), 223 (15) , 222 (100) , 128 (6), 121 (20), 107 (5), 84 (10) , 78 (5) , 77 (12) , 72 (5) , 56 (7) .
EXAMPLE 65: Preparation of N- ( 2-Hydroxy-3- phenoxypropyl) -1. l-diethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride, Compound 114
Figure imgf000083_0001
Anhydrous cerium (III) chloride (13.6 g, 55.2 mmol) was suspended in 80 L of dry terahydrofuran, and stirred under nitrogen for 16 hours. This suspension was cooled in an ice bath, and ethylmagnesium chloride (27.6 mL, 55.18 mmol, 2 M solution in tetrahydrofuran) was added over 5 minutes. After stirring for 1 hour, methyl 4-methoxyphenylacetate (3.98 g, 22.07 mmol) was added to the suspension and stirred for another 2 hours. The reaction was then partitioned between ether and saturated ammonium chloride. The ether layer was separated, washed with dilute HCl, water, and saturated brine, dried over anhydrous sodium sulfate, and concentrated. The yield of 1, l-diethyl-2- ( -methoxyphenyl)ethanol was 4.65 g- Powdered sodium cyanide (1.18 g, 24 mmol) was placed in a flask and covered with 5.5 mL of acetic acid. A mixture of sulfuric acid (3 mL) and acetic acid (2.75 mL) was cooled to 0 °C and then added to the cyanide suspension over a period of 3 minutes. The mixture was stirred for 30 minutes at room temperature, followed by the addition of 1, l-diethyl-2- (4- methoxyphenyl)ethanol (4.6 g, 22 mmol) . The mixture was stirred overnight then poured into ice and sodium hydroxide. The product was extracted with ether, and the ether layer dried over anhydrous sodium sulfate, and concentrated. The residue was suspended in 20% sodium hydroxide and refluxed overnight under nitrogen. The reaction was cooled, diluted with water, and extracted with ether. The ether layer was separated, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by reversed-phase HPLC (C-18 using 0.1% HCl/acetonitrile as the elutant) to give 1.91 g of 1, l-diethyl-2- (4-methoxy- phenyl) ethylamine.
Using the method of Example 6, supra , 1,2-epoxy- 3-phenoxypropane (0.15 g, 1.0 mmol) and 1,1-diethyl-
2- (4-methoxyphenyl) ethylamine (0.249 g, 1.2 mmol) were used to prepare 244 mg of the title compound as a white solid: GC/EI-MS, m/z, (rel. int.) 328 (M-29,6), 237 (17), 236 (100), 121 (22), 106 (5), 98 (7), 78 (5), 77 (11), 70 (7) , 56 (5) .
EXAMPLE 66: Preparation of (R) -N- r2-Hvdroxv-3- ( 2 .3- dichlorophenoxy) ropyl1-1.1-dimethyl-2- (4-methoxyphenyl) ethyl amine Hydrochloride. Compound 115
Figure imgf000084_0001
2, 3-Dichlorophenol (0.69 g, 4.24 mmol) was dissolved in 15 mL of acetone, followed by the addition of powdered potassium carbonate (1.6 g, 11.57 mmol) . This mixture was stirred for 2 hours then (2R) -(-) -glycidyl 3-nitro- benzenesulfonate was added and stirred overnight. The reaction was worked up by pouring into water and ether. The ether layer was separated, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The yield of (R) -2, 3-dichlorophenyl glycidyl ether was 0.837 g.
Using the method of Example 6, supra , (R)-2,3- dichlorophenyl glycidyl ether (0.837 g, 3.82 mmol) and 1, l-dimethyl-2- (4-methoxyphenyl) ethylamine (0.75 g, 4.18 mmol) were used to prepare 860 mg of the title compound as a white solid: GC/EI-MS, m/z, (rel. int.) 382 (M-15, .1), 280 (11), 278 (64), 277 (16), 276 (100), 163 (10), 121 (35), 77 (10), 71 (24), 70 (27), 58 (12) .
EXAMPLE 67: Preparation of ( S) -N- r2-Hvdroxv-3- (2.3- dichlorophenoxy)propyll -1. l-dimethyl-2- (4-methoxyphenyl)ethyl amine Hydrochloride. om ound 116
Figure imgf000085_0001
2 , 3-Dichlorophenol (0.69 g, 4.24 mmol) was dissolved in 15 mL of acetone, followed by the addition of powdered potassium carbonate (1.6 g, 11.57 mmol) . This mixture was stirred for 2 hours then (2S) -(+) -glycidyl 3-nitro- benzenesulfonate was added and stirred overnight. The reaction was worked up by pouring into water and ether. The ether layer was separated, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The yield of (S) -2 , 3-dichlorophenyl glycidyl ether was 0.84 g.
Using the method of Example 6, supra , (S)-2,3-di- chlorophenyl glycidyl ether (0.84 g, 3.82 mmol) and
1, l-dimethyl-2- ( -methoxyphenyl)ethylamine (0.75 g, 4.18 mmol) were used to prepare 860 mg of the title compound as a white solid: GC/EI-MS, m/z, (rel. int.) 382 (M-15, .1), 280 (10), 279 (9), 278 (63), 276 (100) , 163 (11), 121 (28) , 77 (7), 71 (21), 70 (23), 58 (10) .
EXAMPLE 68: Preparation of N- (2-Hvdroxv-3- phenoxypropyl) -1. l-dimethyl-2- (4-methoxy-3-methylphenyl) ethylamine Hydrochloride, Compound 117 χiXMe
Figure imgf000086_0001
-I
OH H
Using the method of Example 64, supra, -hydroxy- 3-methylbenzyl alcohol (1.0 g, 7.25 mmol), 2-nitrσpropane (5 mL) , and tetrabutylammonium fluoride (0.38 g, 0.145 mmol) were used to prepare 0.8 g of 1, 1-dimethyl- 2- (4-methoxy-3- ethylphenyl)ethylamine.
Using the method of Example 6, supra , 1,2-epoxy- 3-phenoxypropane (0.151 g, 1.0 mmol) and 1, 1-dimethyl- 2- (4-methoxy-3-methylphenyl)ethylamine (0.2 g, 1.0 mmol) were used to prepare 130 mg of the title compound as a white solid: GC/EI-MS, m/z , (rel. int.) 328 (M-15, .l) , 209 (14) , 208 (100), 177 (5), 135 (14), 114 (5) , 91 (6), 76 (9), 71 (8) , 70 (13) , 58 (5) .
EXAMPLE 69: Preparation of N- f2-Hvdroxy- - (2-cyano-3- methoxyphenoxy)propyll -1. l-dimethyl-2- (4-methoxyphenyl) - ethylamine Hydrochloride. Compound 118
Figure imgf000086_0002
Powdered sodium cyanide (9.0 g, 184 mmol) and 2, 6-dimethoxybenzonitrile were added to 50 mL of dimethylsulfoxide and heated to 145 °C for 110 min under nitrogen. The reaction was cooled and poured into ether and dilute HCl. The ether layer was separated, washed twice with dilute acid, once with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The yield of 2-cyano- 3-methoxyphenol was 8.1 g. 2-Cyano-3-methoxyphenol (1 g, 6.7 mmol) and powdered potassium carbonate (2.78 g, 20.1 mmol) were stirred in 15 mL of acetone for 5 minutes, followed by addition of epibromohydrin (1.38 g, 10.1 mmol) . The mixture was stirred for 72 hours then poured into water/ether. The ether layer was separated, washed with sodium carbonate and saturated brine, dried over anhydrous sodium sulfate, and concentrated. The resulting crude solid was triturated with ether/hexane, filtered, and dried under vacuum to give 0.44 g of 2-cyano- -methoxyphenyl glcidyl ether.
Using the method of Example 6, supra, 2-cyano-3- methoxyphenyl glcidyl ether (0.205 g, 1.0 mmol) and 1, l-dimethyl-2- (4-methoxyphenyl)ethylamine (0.215 g, 1.2 mmol) were used to prepare 265 mg of the title compound as a white solid: Η-NMR (CDC13) d 9.6 (IH, br s) , 8.2 (IH, br s) , 7.4 (IH, t) , 7.15 (2H, d) , 6.8 (2H, d) , 6.6 (IH, d) , 6.53 (IH, d) , 4.75 (IH, m) , 4.25 (2H, m) , 3.87 (3H, s), 3.77 (3H, s) , 3.43 (2H, m) , 3.12 (2H, dd) , 1.45 (3H, s) , 1.41 (3H, s) . "C-NMR a 162.9, 162, 159.3, 135.5, 132.4, 127, 114.7, 114.4, 105.6, 104.6, 92.2, 71.4, 66.1, 61.9, 56.8, 55.8, 45.4, 43.8, 23.5, 23.3.
EXAMPLE 70: Preparation of N- f2-Hydroxy-3- (3-chloro-2- cyanophenoxy)propyll -1. l-dimethyl-2- (4-methoxyphenyl) - ethylamine Hydrochloride. Compound 119
Figure imgf000087_0001
Using the method of Example 69, supra, 3-chloro-2- cyanophenol (made using the method of Example 60, supra) (0.48 g, 3.13 mmol), potassium carbonate (1.3 g, 9.38 mmol) , and epibromohydrin (0.86 g, 6.25 mmol) were used to prepare 93 mg of 3-chloro-2-cyanophenyl glycidyl ether.
Using the method of Example 6, supra , 3-chloro- 2-cyanophenyl glycidyl ether (0.093 g, 0.44 mmol) and 1, 1-dimethyl- (4-methoxyphenyl)ethylamine (0.095 g, 0.53 mmol) were used to prepare 134 mg of the title compound as a white solid: Η-NMR (CDC13) d 9.68 (IH, br s) , 8.2 (IH, br s) , 7.4 (IH, t), 7.15 (2H, d) , 7.03 (IH, d) , 6.95 (IH, d) , 6.8 (2H, d) , 5.7 (IH, br s), 4.8 (IH, m) , 4.3 (2H, d) , 3.75 (3H, s) , 3.4 (2H, m) , 3.13 (2H, dd) , 1.44 (3H, s) , 1.40 (3H, s) .
E AMPLE 71; Preparation of N- (2-Hvdroxy- - henoxypropyl) -1. l-dimethyl-2- (2-naphthyl)ethylamine Hydrochloride, Compound 120
Figure imgf000088_0001
Using the method of Example 52, supra , 2-amino- methylnaphthalene (2.51 g, 16 mmol) was used to prepare 1.9 g of 1, l-dimethyl-2- (2-naphthyl)ethylamine.
Using the method of Example 6, supra , 1,2-epoxy-3- phenoxypropane (0.163 g, 1.1 mmol) and 1, 1-dimethyl- 2- (2-naphthyl)ethylamine (0.26 g, 1.3 mmol) were used to prepare 243 mg of the title compound as a white solid: GC/EI-MS, m/z, (rel. int.) 334 (M-15, .l), 209 (14) , 208 (100) , 141 (16), 115 (7), 76 (5) , 70 (7) .
EXAMPLE 72: Preparation of N- (2-Hvdroxv- 3- henoxv)propvl) -1.1-dimethyl-2- (3.4-di ethvlphenvl) ethylamine Hydrochloride. Compound 121 I. H CC • HCl
OH . H
Using the method of Example 52, supra , 3 , 4-dimethyl- benzylamine (5 g, 37 mmol) was used to prepare 2.29 g of 1, l-dimethyl-2- (3, 4-dimethylphenyl) ethylamine. Using the method of Example 6, supra , 1,2-epoxy-3- phenoxypropane (0.165 g, 1.1 mmol) and 1, l-dimethyl-2- (3 , -dimethylphenyl) ethylamine (0.22 g, 1.2 mmol) were used to prepare 268 mg of the title compound as a white solid: GC/EI-MS, m/z, (rel. int.) 312 (M-15,1) , 209 (14), 208 (100) , 133 (5), 119 (13), 114 (5) , 107 (5) , 91 (5), 76 (10), 71 (8) , 70 (14) , 58 (6) .
EXAMPLE 73: Preparation of (R) -N- \ 2-Hvdroxy-3- ( 2 - cyanophenoxy)propyll -1. l-dimethyl-2- (4-methoxyphenyl) - ethylamine Hydrochloride. Compound 122
Figure imgf000089_0001
Using the method of Example 60, supra, 2-cyanophenol (0.54 g, 4.5 mmol), sodium hydride (0.188 g, 4.7 mmol), and (2R) -(-) -glycidyl 3-nitrobenzenesulfonate (1.06 g, 4.1 mmol) were used to prepare 350 mg of (R) -2-cyanophenyl glycidyl ether.
Using the method of Example 6, supra , (R) -2-cyanopheny1 glycidyl ether (0.35 g, 2.0 mmol) and 1, 1-dimethyl- (4- methoxyphenyl) ethylamine (0.35 g, 1.96 mmol) were used to prepare 600 mg of the title compound as a white solid: H-NMR (CDC13) θ 9.7 (IH, br s) , 8.2 (IH, br s) , 7.5 (2H, m) , 7.15 (2H, d) , 7.0 (2H, m) , 6.8 (2H, d) , 4.8 (IH, br m) , 4.25 (2H, m) , 3.75 (3H, s) , 3.45 (2H, m) , 3.12 (2H, dd) , 1.45 (3H, s) , 1.41 (3H, s) .
EXAMPLE 74: Preparation of N- (2.10-Dihydroxydecyl) - 1, l-dimethyl-2- (4-methoxyphenyl)ethylamine Hydrochloride. Compound 123
Figure imgf000090_0001
Using the method of Example 9, supra, 1,2- epoxy-10-hydroxydecane (172 mg, 1 mmol) and 1, 1-dimethyl- 2- (4-methoxyphenyl) ethylamine (230 mg, 1.5 mmol) were used to prepare the hydrochloride salt of the title compound. MPLC of the free amine (silica gel, 1% MeOH/CHCl3) , followed by treatment with an excess of 1 M HCl/ether, yielded 130 mg of the title compound as a white powder: GC/EI-MS, m/z (rel. int.) 336 (M - 15, .1), 231 (14), 230 (100), 212 (9), 163 (10), 122 (5) , 121 (42), 91 (8) , 78 (6), 77 (5), 71 (13), 70 (11) , 58 (8) , 55 (8) , 41 (6) .
EXAMPLE 75: Preparation o£ N- 2-hydroχy-3- (3,4- methylene-dioxyphenyl) ropyll -1. l-dimethvl-2- (4- methoxyphenyl) -ethylamine Hydrochloride. Compound 124
Figure imgf000090_0002
Safrole oxide was prepared by stirring a solution of safrole (1.48 mL, 10 mmol) and m-chloroperoxybenzoic acid (2.70 g, 11 mmol) in methylene dichloride (25 L) overnight. The reaction was quenched by pouring into water (50 mL) . The aqueous was extracted with ether (3 x 25 mL) . The organic layers were combined and washed with 10% aqueous sodium sulfate (2 x 25 mL) , saturated aqueous sodium bicarbonate (3 x 25 mL) , and brine (25 mL) . The organic phase was dried over magnesium sulfate and the solvents were removed in vacuo. The resulting yellow oil was used without further purification.
To a solution of safrole oxide (196 mg, 1.1 mmol) in acetonitrile (1.0 mL) was added lithium perchlorate (107 mg) . The solution was stirred at ambient temperature to dissolve all of the solid lithium perchlorate. To this solution was added 1, l-dimethyl-2- (4-methoxyphenyl)ethylamine (180 mg, 1.0 mmol) and the reaction was stirred at 50 °C overnight. To the cooled reaction mixture was added water (5 mL) and was subsequently extracted with methylene dichloride (3 x 1 mL) . The combined organic phases were washed with water (l L) and brine (1 mL) and dried over magnesium sulfate. The crude orange oil was purified (MPLC, silica gel, 1% MeOH/CHCl3) and dissolved in methylene dichloride (5 mL) . The hydrochloride salt was prepared by adding an excess of 1 M HCl/ether. The solvents were removed in vacuo to yield 139 mg of thick oil: GC/EI-MS, /z (rel. int.) 342 (M+, .l) , 237 (15) , 236 (100) , 163 (5), 136 (6), 135 (61), 121 (23) , 78 (7), 77 (13), 70 (15) , 58 (7) .
EXAMPLE 76: Preparation of N- f2-hydroxy-3- (3.4- methylene-dioxyphenoxy)propyll -1. l-dimethyl-2- (4- methoxyphenyl) -ethylamine Hydrochloride. Compound 125
• HCl
Figure imgf000091_0001
Using the method of Example 9, supra , 1,2-epoxy-3- (3, 4- methylenedioxyphenoxy)propane (194 mg, 1 mmol) and 1, l-di¬ methyl-2- (4-methoxyphenyl) ethylamine (180 mg, 1 mmol) were used to prepare the hydrochloride salt of the title compound. MPLC of the free amine (silica gel, 1% MeOH/CHCl3) , followed by treatment with an excess of 1 M HCl/ether, yielded 88 mg of a white powder: GC/EI-MS, m/z (rel. int.) 374 (M\ .0) , 253 (15), 252 (100), 137 (8), 121 (16), 114 (8) , 71 (12) , 70 (8) .
EXAMPLE 77: Preparation of N- r2-hvdroxy-3- (6-phenyl- hexanoxy) ropyll -1, l-dimethyl-2- (4-methoxyphenyl) ethylamine. Compound 126
Figure imgf000092_0001
Using the method of Example 9, supra , 6-phenyl- hexylglycidyl ether (337 mg, 1.44 mmol) and l, l-dimethyl- 2- (4-methoxyphenyl)ethylamine (180 mg, 1 mmol) were used to prepare the title compound. Preparative TLC (20 cm x 20 cm x 2 mm silica, eluted with l%MeOH/CHCl3) was used to purify the material and yielded 275 mg of free base: GC/EI-MS, m/z (rel. int.)_398 (M* - 15,.1), 293 (21) , 292 (100) , 163 (10) , 121 (19), 114 (9), 91 (5), 90 (45) , 71 (13), 70 (14), 58 (9) .
EXAMPLE 78: Preparation of N- r2-hvdroxv-3- (4-phenvl- butanoxy)propyl1 -1.1-dimethyl-2- ( -methoxyphenyl)ethylamine. Compound 127
Figure imgf000092_0002
* HC1 Using the method of Example 9, supra , 4-phenylbutyl glycidyl ether (348 mg, 1.5 mmol) and 1, l-dimethyl-2- (4- methoxyphenyl) ethylamine (268 mg, 1.5 mmol) were used to prepare the title compound. Preparative TLC (20 cm x 20 cm x 2 mm silica, eluted with 5%MeOH/CHCl3) was used to purify the material and yielded 275 mg of free base: GC/EI-MS, m/z (rel. int.) 370 (M* - 15, .1), 265 (19), 264 (100), 163 (11), 121 (19), 114 (9), 90 (43), 71 (10) , 70 (12), 58 (7) .
EXAMPLE 79: Preparation of N- (2-hvdroxv-3- phenoxypropyl) -1. l-dimethyl-2- (3-fluoro-4-methoxyphenyl) ethylamine. Compound 128
Figure imgf000093_0001
Using the method of Example 6, supra , phenyl glycidyl ether (150 mg, 1.1 mmol) and 1, l-dimethyl-2- (3-fluoro- 4-methoxyphenyl) ethylamine (197 mg, 1 mmol) were used to prepare the title compound. The title compound crystallized on standing to yield 169 mg of small crystals: GC/EI-MS, m/z (rel. int.) 332 (M* - 15, .1) , 209 (16) , 208 (100), 139 (13) , 133 (5), 114 (7), 107 (6), 77 (11), 71 (12) , 70 (20) , 58 (9) .
EXAMPLE 80: Preparation of N- (2-hydroxy- 3-phenoxypropyl) -1. l-dimethyl-2- (2-fluoro-4- methoxyphenyl)ethylamine Hydrochloride. Compound 129
Figure imgf000093_0002
Using the method of Example 6, supra , phenyl glycidyl ether (150 mg, 1.1 mmol) and 1, l-dimethyl-2- (2-fluoro- 4-methoxyphenyl)ethylamine (197 mg, 1 mmol) were used to prepare the title compound. Preparative HPLC (CJ8 reversed-phase, eluted with 1% HC1/CH3CN gradient) was used to purify the compound, yielding 301 mg of a white powder: GC/EI-MS, m/z (rel. int.) 332 (M* - 15,1), 209 (15) , 208
(100), 139 (14), 114 (5), 107 (5), 77 (6), 71 (7), 70 (13), 58 (5) .
EXAMPLE 81: Preparation of N- f2-hvdroxv-3- (5-methoxy-
1-napthoxy)propyll -1. l-dimethvl-2- (4-methoxyphenyl) ethylamine Hydrochloride. Compound 130
Figure imgf000094_0001
Potassium carbonate (13 mmol) was added to a solution of 1, 5-dihydroxy napthalene (6.2 mmol) in acetone in a sealed vacuum tube. The tube was heated to 70 °C for 30 minutes. lodomethane (9.4 mmol) was added and the tube heated to 70 °C overnight .
The reaction mixture was partitioned between ether and 10% aqueous HCl. The ether layer was separated and extracted with 0.5 M KOH. The water layer was separated and acidified with 10% aqueous HCl and extracted into ether. The ether layer was separated and dried over magnesium sulfate and evaporated to a solid. The solid was purified using reverse phase HPLC using a acetonitrile/0.1% HCl gradient yielding 179 mg 1-hydroxy-5-methoxy napthalene. Sodium hydride (60% suspension in mineral oil, 1 mmol) was added to a solution of 1-hydroxy-5-methoxy napthalene (1 mmol) and stirred 10 minutes. Epichlorohydrin (l mmol) was added and the reaction stirred at 70 °C for 72 hours. The reaction mixture was diluted with 1 liter of saturated sodium chloride solution and extracted into ether. The ether layer was then washed with water, separated and dried over anhydrous sodium sulfate and evaporated to give 5-methoxy- napthalene glycidyl ether. Using the method of Example 6, supra , 5-methoxy- napthalene glycidyl ether (1 mmol) and 1, 1-dimethyl-2- (4-methoxyphenyl)ethylamine (1 mmol) yielded 161 mg of the title compound as a white solid: GC /EI-MS, m/z (rel. int.) 360 (M+, 1) , 289 (18), 288 (100), 173 (8), 121 (20) , 71 (18), 70 (12) .
EXAMPLE 82: Preparation of N- T2-hydroxy-3- (2-cyano- cyclohexyloxy)propyll -1. l-dimethyl-2- (4-methoxyphenyl) ethyl¬ amine Hydrochloride. Compound 131
Figure imgf000095_0001
Sodium hydride (60% suspension in mineral oil, 60 mg, 1.59 mmol) was added to a solution of trans-2-cyano- cyclohexanol in N,N-dimethylformamide (2.0 mL) and stirred for 10 minutes at room temperature. Epibromohydrin (0.22 g, 1.59 mmol) was then added and the reaction stirred for an additional 3 hours. The solution was partitioned between diethyl ether/water, and the layers separated. The ether layer was washed with water (3 X 100 mL) and dried over magnesium sulfate and evaporated to give 0.17 g of 2-cyanocyclohexyl glycidyl ether. Using the method of Example 6, supra, 2-cyanocyclohexyl glycidyl ether (0.94 mmol) and 1, l-dimethyl-2- (4-methoxy¬ phenyl)ethylamine (1.17 mmol) yielded 55 mg of the title compound as a white solid: GC /EI-MS, m/z (rel. int.) 360 (M+, 1), 239 (100), 121 (22), 240 (14), 70 (11), 163 (8) , 71 (8) , 81 (7) .
EXAMPLE 83: Synthesis of (R/S) -1- \ \2 , 2-d.imeth.yl- (4 'methoxy) phenethyll 1 amino-2-hydroxv-4 (1 ' -naphthyl) -butane. Compound 162
Figure imgf000096_0001
A solution of 1-chloromethylnaphthaline (750 uL, 5 mmol, Aldrich) in anhydrous ether (10 mL) was added dropwise to 25 mL of allyl magnesium bromide (1 M in ether) over 30 minutes. The resulting mixture was heated at reflux for 14 hours. After cooling the reaction to room temperature, it was quenched with 25 mL of saturated NH„C1 (aqueous) . The layers were separated and the organic layer was washed with brine, dried over Na2S04, filtered and evaporated to give 1 g of 1- but-3-enyl-naphthalane that was carried without further purification.
1-But-3-enyl-naphthaline (1 g) from above was added to a solution of 50% mCPBA (2.1 g) in CH2C12 (50 mL) and the reaction stirred at room temperature for 48 hours. The material was diluted with CH2C12 and was extracted with sodium sulfite (aqueous) and NaHC03 (aqueous) , dried over MgSO„, filtered and evaporated to give 1- [ (2-oxoaryl) ethyl] - naphthaline (1 g) that was carried without further purification. A solution of 1- [ (2-oxoaryl) ethyl] -naphthaline (1 g) and 1, l-dimethyl-2 (4-methoxyphenyl) ethylamine (985 mg, 5.5 mmol) in ethanol (25 mL) was heated at reflux for 12 hours. The reaction was evaporated and the residue dissolved in 4 N HCl/dioxane. Upon addition of ether, crystals formed and were subsequently collected and dried in a vacuum oven to give 1.4 g of (R/S) -1-] ] 2, 2-dimethyl- (4 'methoxy) - phenethyl] ]amino-2-hydroxy-4 (1' -naphthyl) -butane. ESMS [(M+H]*= 378, *H NMR (CDC13, 360MHz) @300°K δ 8.06 (IH, d of d) , 7.83 (IH, d of d) , 7.78-7.61 (2H, m) , 7.49-7.35 (3H, m) , 7.09-7.02 (2H, m) , 6.84-6.79 (2H, m) , 3.76 (3H, s) , 3.61 (lH,m), 3.33-3.09 (2H, m) , 2.77-2.72 (IH, d of d) , 2.62 (2H, s) , 2.47-2.42 (IH, m) , 1.85-1.82 (2H, m) , 1.04 (6H, s) .
Exampl 8 Synthesis of (R/S) -1- r \2 ■ 2-dimethyl- (4'methoxy)phenethyl11 amino-2-hydroxv-4 fl' -2, 3- dichlorophenyl) 1 -butane. Compound 163
Figure imgf000097_0001
Starting from 2, 3-dichlorobenzylchloride (lg, 5 mmol) and following the three step procedure described in Example 83, 660 mg of (R/S) -1- [ [2 , 2-dimethyl- (4 'methoxy) - phenethyl] ] amino-2-hydroxy-4 [1 ' - (2, 3-dichlorophenyl) ] -butane was synthesized and isolated as white crystals. ESMS [M+H]*=396 αH NMR (CDC13, 360 MHz) @ 300°K δ 7.3 (IH, d of d) , 7.18 (IH, d of d) , 7.10-7.03 (3H, m) , 6.82-6.80 (2H, m) , 3.78 (3H, s) , 3.47 (IH, m) , 2.97-2.83 (2H, m) , 2.74 (IH, ) 2.60 (2H, s) , 2.43-2.37 (IH, m) , 1.71 (2H, m) , 1.04 (6H, s) .
Example 85: Synthesis of (R/S) -l-nitro-5-hydroxy-6- Tl .1- dimethyl-2- (4-methoxyphenyl) 1 hexane , Compound 164
Figure imgf000098_0001
Starting from 6-nitro-l-hexene (1 g, 7.75 mmol) and following the two last steps described in Example 83, 1 g of (R/S) -1-nitro-5-hydroxy-6- [1, l-dimethyl-2 (4- methoxyphenyl) ] hexane was synthesized and isolated as tan crystals. ESMS [M+H]-=325 XH NMR (CDC13, 360 MHz) @ 300°K δ 7.00 (4H, d of d) , 4.37 (2H, t) , 3.77 (3H, s) , 3.49 (IH, m) , 2.74 (IH, d of d) , 2.61 (2H, s) , 2.35 (IH, m) 2.03 (2H, m) , 1.60-1.43 (4H, m) 1.08 (6H, s) .
EXAMPLE 86: Additional compounds Additional compounds were synthesized using techniques along lines as those described above. Examples of such compounds include the following:
Compound 1: iV- [2-hydroxy-3- (2-hydroxybenzimidazol-4- oxyl)propyl] -1, l-dimethyl-2-4-methoxyphenyl) ethylamine. Compound 14: (R) -N- [2-hydroxy-3- (1-naphthoxy)propyl] -1- methyl-3-methoxybenzylamine .
Compound 22: N- (3-phenylpropyl) -1, l-dimethyl-2 (4- methoxyphenyl)ethylamine. Compound 24: iV- (4-phenylbutyl) -1, l-dimethyl-2- (4- methoxyphenyl)ethylamine.
Compound 34: N- (Benzyl) -1, l-dimethyl-2- (4- methoxyphenyl) ethylamine. Compound 36: N- (4-phenoxybutyl) -1, l-dimethyl-2- (4- methoxyphenyl)ethylamine.
Compound 42: N- (3- (1-napthoxy)propyl) -1, l-dimethyl-2- (4- methoxyphenyl) .
Compound 52: N- [2-hydroxy-3- (2-acetamidophenoxy)propyl] - 1, l-dimethyl-2 (4-methoxyphenyl) ethylamine.
Compound 53: N- (2-phenoxyethyl) -1, l-dimethyl-2- (4- methoxyphenyl)ethylamine.
Compound 54: iV-2-hydroxy-3- (4- tert-butylphenoxy)propyl] - 1, 1-dimethyl-2-phenylethylamine. Compound 55: N- [2-hydroxy-3- (1-naphthoxy)propyl] -1, 1- dimethyl-2-phenylethylamine.
Compound 58: N- [2-hydroxy-3- (4-acetamidophenoxy)propyl] - 1, l-dimethyl-2 (4-methoxyphenyl) ethylamine.
Compound 60: 2V- [2-hydroxy-3- (2-phenylphenoxy)propyl] - 1, l-dimethyl-2- ( -methoxyphenyl) ethylamine.
Compound 61: N- [2-hydroxy-3- (3-phenylphenoxy)propyl] - 1, l-dimethyl-2- (4-methoxyphenyl)ethylamine.
Compound 62: N- [2-Hydroxy-3- (4-phenylphenoxy)propyl] - 1, l-dimethyl-2- (4-methoxyphenyl) ethylamine. Compound 84: N- (2-Phenylethyl) -1, l-dimethyl-2- (4- methoxyphenyl) ethylamine.
Compound 92: N- (2-hydroxy-3-phenoxypropyl) -1, 1-dimethyl- 2- (1-naphthyl)ethylamine.
Compound 93: N- (2-hydroxy-3-cyclohexoxypropyl) -1, 1- dimethyl-2- (4-methoxyphenyl) ethylamine.
Compound 102 : N- (2-hydroxy-3-phenoxypropyl) -1, 1- dimethyl-2- (4-ethoxyphenyl)ethylamine. Compound 132: N- [2-hydroxy-3- (3, 4-dimethoxy- phenoxy)propyl] -1, l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 390 (M+,.0) , 269 (17), 268 (100), 163 (6), 153 (5), 121 (21) , 114 (17) , 77 (5) , 71 (19) , 70 (17) , 58 (7) .
Compound 133: N- [2-hydroxy-3- (3 , 5-dimethoxy- phenoxy)propyl] -1, l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 390 (M+, .0) , 269 (16), 268 (100), 193 (9), 163 (8), 154 (7), 121 (24), 114 (46), 76 (6), 71 (11), 70 (18) .
Compound 134: N- [2-hydroxy-3- (2-carbomethoxy- phenoxy)propyl] -1, l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride; XH NMR (CDCl3) d 1.42 (s, 3H) , 1.44 (s, 3H) , 3.2 (dd, 2H) , 3.3-3.6 (bm, 2H) , 3.7 (s, 3H) , 3.8 (ε, 3H) , 4.1-4.4 (m, 3H) , 4.7 (m, IH) , 6.8 (d, 2H) , 7.0 (m, 2H) , 7.2 (d, 2H) , 7.5 (t, IH) , 7.8 (d, IH) , 8.8 (m, IH) , 9.3 (m, IH) . Compound 135: N- [2-hydroxy-3- (4-methylphenoxy)propyl] - 1, l-dimethyl-2- (4-methoxyphenyl)ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 328 (M-15, .1), 223 (15), 222 (100) , 163 (6), 147 (6) , 121 (23), 114 (9) .
Compound 136: N- [2-hydroxy-3- (2, 3-dichlorophenoxy) - propyl] -1, l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 382 (M-15, .l) , 280 (10), 279 (9), 278 (62), 276 (100) , 163 (11), 121 (28) . Compound 137: N- [2-hydroxy-3- (3, 5-dichlorophenoxy) - propyl] -1, l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 382 (M-15,1), 280 (11), 279 (9) , 278 (65), 277 (16), 276 (100) , 163 (8), 146 (5) , 144 (5) . Compound 138: N- [2-hydroxy-3- (2, 4-dichloro- phenoxy)propyl] -1, l-dimethyl-2- (4-methoxyphenyl)ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 382 (M-15,1) , 280 (11), 279 (9), 278 (65), 277 (5) , 276 (100) , 163 (10) , 161 (6), 132 (5) .
Compound 139: N- [2-hydroxy-3- (3 , 4-dichloro- phenoxy)propyl] -1, l-dimethyl-2- (4-methoxyphenyl)ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 382 (M-15, .l), 279 (10) , 279 (9), 278 (63), 276 (100) , 163 (9), 146 (5) , 121 (29) .
Compound 140: N- [2-hydroxy-3- (2, 5-dichloro- phenoxy)propyl] -1, l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 382 (M-15, .l), 280 (11) , 279 (9), 278 (64), 276 (100) , 163 (9), 161 (5) , 121 (29) , 113 (8) .
Compound 141: N- [2-hydroxy-3- (4-ethylphenoxy)propyl] - 1, l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 342 (M-15, .1) , 237 (15) , 236 (100), 163 (5) , 121 (19) , 114 (7) .
Compound 142: N- [2-hydroxy-3- (2-cyanophenoxy)propyl] - 1, l-dimethyl-2- (4-methoxyphenyl)ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 339 (M-15,1) , 234 (15) , 233 (100) , 163 (5) , 121 (14) .
Compound 143 : N- [2-hydroxy-3- (3-nitrophenoxy)propyl] - 1, l-dimethyl-2- (4-methoxyphenyl)ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 359 (M-15, .1) , 254 (15), 253 (100), 163 (5) , 121 (15) . Compound 144: N- [2-hydroxy-3- (4-ethoxyphenoxy)propyl] - 1, l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 358 (M-15, .l) , 253 (17), 252 (100), 163 (6), 121 (21), 114 (8), 108 (8) .
Compound 145: N- [2-hydroxy-3- (4-iso-propyl- phenoxy)propyl] -1, l-dimethyl-2- (4-methoxyphenyl) ethylamine
Hydrochloride; GC/EI-MS, m/z (rel. int.) 356 (M-15, .l), 251 (18), 250 (100) , 163 (7), 121 (23) , 117 (7) , 114 (8) . Compound 146: N- [2-hydroxy-3- (3-iso-propyl- phenoxy)propyl] -1, l-dimethyl-2- (4-methoxyphenyl)ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 356 (M-15, .l) , 251 (18), 250 (100), 163 (6), 121 (21), 117 (5) , 114 (10) , 91 (9) .
Compound 147: N- [2-hydroxy-3- (3-ethoxyphenoxy)propyl] - 1, l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 358 (M-15,1) , 253(16) , 252 (100) , 163 (5) , 121 (20), 114 (12) , 77 (5) . Compound 148: N- [2-hydroxy-3- (2-n-propylphenoxy)propyl] 1, l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 356 (M-15,1) , 251(17), 250 (100) , 163 (6) , 121 (34), 114 (9) , 107 (6), 90 (17), 78 (9) , 77 (10) , 71 (17) . Compound 149: N- [2-hydroxy-3- (4-n-propylphenoxy)propyl] 1, l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 356 (M-15, .8) , 251(18) , 250 (100) , 163 (5) , 121 (19), 114 (7) , 110 (5), 107 (7) , 91 (6) .
Compound 150: N- [2-Hydroxy-3- (3-ethylphenoxy)propyl] - 1, l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride,-
GC/EI-MS, m/z (rel. int.) 342 (M-15,.6), 237(16), 236 (100), 163 (5) , 121 (21), 114 (6) , 105 (5), 90 (6) .
Compound 151: N- [2-hydroxy-3- (2-ethylphenoxy)propyl] - 1, l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 342 (M-15,1) , 237 (16) , 236 (100), 163 (5) , 121 (17), 114 (7) , 91 (6) , 77 (7) .
Compound 152: N- [2-hydroxy-3- (4-trifluoro- methoxyphenoxy)propyl] -1, l-dimethyl-2- (4-methoxy- phenyl) ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 398 (M-15,2) , 293(15), 292 (100) , 121 (20) , 77 (5) . Compound 153: N- [2-hydroxy-3- (2 -iso-propyl- phenoxy)propyl] -1, l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 356 (M-15,1) , 251 (19) , 250 (100) , 163 (5) , 122 (5) , 121 (53) , 114 (8) , 104 (6) ,103 (6) , 91 (24) , 77 (14) .
Compound 154: N- [2-hydroxy-3- (3-trifluoro- methoxyphenoxy)propyl] -1, l-dimethyl-2- (4-methoxy- phenyl) ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 398 (M-15, .1) , 293 (15) , 292 (100) , 163 (7) , 121 (18) .
Compound 155: N- [2-hydroxy-3- (2 , 6-dichloro- phenoxy)propyl] -1, 1-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 382 (M-15,1) , 279 (11) , 279 (9) , 277 (64) , 275 (100) , 163 (11) , 163 (5) , 161 (6) , 121 (33) , 114 (12) .
Compound 156: N- [2-hydroxy-3- (3 , 5-bistrifluoro- methylphenoxy)propyl] -1, l-dimethyl-2- (4-methoxy- phenyl)ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 450 (M-15, .l) , 345 (16) , 344 (100) , 213 (5) , 163 (8) , 121 (20) .
Compound 157: N- [2-hydroxy-3- (3-chloro-5-methoxy- phenoxy)propyl] -1, l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 378 (M-15, .1) , 275 (5) , 274 (34) , 273 (16) , 272 (100) , 163 (5) , 121 (17) , 114 (8) .
Compound 158: N- [2-hydroxy-3- (4-nitrophenoxy)propyl] - 1, l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 359 (M-15,1) , 254 (14) , 253 (100) , 121 (12) .
Compound 159: N- [2-hydroxy-3 - (2-nitrophenoxy) propyl] - 1, l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 359 (M-15, .1) , 254 (15) , 253 (100) , 163 (6) , 121 (17) , 114 (10) , 96 (5) , 78 (5) . Compound 160: N- [2-hydroxy-3- (3-cyanophenoxy)propyl] - 1, l-dimethyl-2- (4-methoxyphenyl) ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 339 (M-15, .l) , 234 (15) , 233 (100) , 121 (21) , 102 (7) , 90 (6) . Compound 161: N- [2-hydroxy-3- (4-cyanophenoxy)propyl] - 1, l-dimethyl-2- (4-methoxyphenyl)ethylamine Hydrochloride; GC/EI-MS, m/z (rel. int.) 339 (M-15,1), 234 (16), 233 (100) , 163 (5) , 121 (15) , 102 (5) . Compound 166: N- [2R-Hydroxy-3- [ (2-cyanobenzthien-3- yloxy)propyl] -1, l-dimethyl-2- (3 , 4,dichlorophenyl) ethylamine . Prepared as a hydrochloride salt, MS (ES) m/e 449 [M+H] ♦
Compound 167: R-l-[l,l Dimethyl-2- (4-methoxyphenyl) ethylaminol-3- (2 ' -carbazoloxy)pran-2-ol . Prepared as a trifluoroacetate salt, MS (ES) m/e 419.2 [M+H]*.
Compound 168: N- [2R-Hydroxy-3- [ (2-bromopyridinyloxy) - propyl] -1, l-dimethyl-2- (4-methoxy) ethylamine. Prepared as a hydrochloride salt, MS (ES) m/e 411,409 [M+H]*.
Compound 169: N- (2-hydroxy-3- (3-N,N-dimethylphenoxy) propyl) -1, l-dimethyl-2- (-4-methoxyphenyl)ethylamine, GC/MS 251(100), 176(9) , 163(5) , 138(11), 137(6) , (8), 125(10), 121(23), 114(46) , 108(6), 77(6), 76(7), (10), 70(14), 42(8) .
Compound 170: N- (2-hydroxy-3- (3-phenylphenoxy)propyl) - 1, l-dimethyl-2- (-4-methoxyphenyl) ethylamine. GC/MS (mt, 0.1) , 284(100), 121(28) , 285 (27) , 152(13) , 70(13), 71(11), 153 (10) .
Other embodiments are within the following claims. Thus, while several embodiments have been shown and described, various modifications may be made, without departing from the spirit and scope of the present invention.

Claims

CLAIMS 1. A compound having the chemical formula;
Figure imgf000105_0001
wherein Rj is selected from the group consisting of: aryl, longer-length alk, and cycloalk;
R2 is selected from the group consisting of: lower alk, cycloalk, alkoxy, H, OH, =0, C(0)OH, C(0)0-lower alk, C(0)NH- lower alk, C(0)N(lower alk)2, SH, S-lower alk, NH2, NH-lower alk, and Ndower alk)2; R3 and R4 is each independently lower alk or together cyclopropyl;
R5 is either an optionally substituted naphthyl having one to four substituents independently selected from the group consisting of methyl, ethyl, isopropyl, methoxy, Cl, F, Br, and lower haloalkoxy, or a substituted phenyl having one to four substituents with at least one substituent in a meta or para position selected from the group consisting of: lower alkyl, methoxy, Cl, F, Br, and lower haloalkoxy, provided that said substituted phenyl may also have 2 to 3 additional substituents;
R6 if present is either hydrogen, lower alkyl or lower alkenyl, wherein R6 is not present if R2 is =0;
Yx is either covalent bond, alkylene, or alkenylene; Y2 is alkylene; Y3 is alkylene;
Z is selected from the group consisting of: covalent bond, 0, S, NH, N-lower alk, alkylene, alkenylene, and alkynylene, provided that if Z is either O, S, NH, or N-lower alk, then Yx is not a covalent bond; further provided that Yx and Z may together be a covalent bond; provided that Rx is not 6-CN-2-pyridyl ; further provided that if R5 is 3,4 dimethoxy-phenyl, then Rj is not CH3 (CH2) 50-phenyl; 2-cyciopentyl-phenyl; 2-Cl-phenyl; 2-CN-phenyl; 2- (3-furanyl)phenyl ; or 4- (1, 2 , -benzisothiazol) ; further provided that if R6 is 4-methoxy-phenyl, then Rx is not 2-cyciopentyl-phenyl ; 2-CH3-phenyl ; 2-benzyl-phenyl; 3- CH3, 4-CH3S02-phenyl; 4- (1, 2 , -benzisothiazol) ; further provided that if R5 is 4-Cl-phenyl, then Rx is not 2-CH3-phenyl, 5-iso-propyl-phenyl; 2-CH3-phenyl ; 4-CH3- phenyl; phenyl; 2-Cl-phenyl ; 4-Cl-phenyl; 2-methoxy, 4-CH3CHCH-phenyl; 3,4 CH3-phenyl; 2,4 CH3-phenyl; 2,3 CH3- phenyl; 2-iso-propyl, 5-CH3-phenyl; pridyl; 1-imidazole; or 4- (1, 2, -benzisothiazol) ; and further provided that if R5 is 3,5 dimethyl, 4-methoxy¬ phenyl, then Rx is not 4-CH3, 6-CN-2-pyridyl; or thiophenecarboxamide; and pharmaceutically acceptable salts and complexes thereof; wherein said compound has an IC50 <. 10 μM using the Calcium Receptor Inhibitor Assay.
2. A compound having the chemical formula:
Figure imgf000106_0001
wherein Rx is either 2-CN-phenyl, 2,3-dichloro phenyl, 2- nitro-phenyl, 2-cyano-3-chloro-phenyl, an optionally substituted pyridyl, an optionally substituted benzothiopyranyl, an optionally carbazole, or a longer-length alk;
R2 is selected from the group consisting of: lower alk, cycloalk, alkoxy, H, OH, =0, C(0)0H, C(0)0-lower alk, C{0)NH- lower alk, C(0)N(lower alk)2, SH, S-lower alk, NH2, NH-lower alk, and N(lower alk)2;
R3 and R4 is each independently lower alk or together cyclopropyl; R5 is either an optionally substituted naphthyl having one to four substituents independently selected from the group consisting of methyl, ethyl, isopropyl, methoxy, Cl, F, Br, and lower haloalkoxy, or a substituted phenyl having one to four substituents with at least one substituent in a meta or para position selected from the group consisting of: lower alkyl, methoxy, Cl, F, Br, and lower haloalkoxy, provided that said substituted phenyl may also have 2 to 3 additional subs ituents;
Rs if present is either hydrogen, lower alkyl or lower alkenyl, wherein R6 is not present if R2 is =0;
Yj is either covalent bond, alkylene, or alkenylene;
Y2 is alkylene;
Y3 is alkylene;
Z is selected from the group consisting of: covalent bond, 0, S, NH, N-lower alk, alkylene, alkenylene, and alkynylene, provided that if Z is either O, S, NH, or N-lower alk, then Yx is not a covalent bond; further provided that Yx and Z may together be a covalent bond; and pharmaceutically acceptable salts and complexes thereof.
3. The compound of claim 2, wherein Y: is methylene; Y2 is methylene; and Y3 is methylene.
4. The compound of claim 3, wherein Rx is either 2- CN-phenyl, 2,3-dichloro phenyl, 2-nitro-phenyl, or 2-cyano-3- chloro-phenyl .
5. The compound of claim 3, wherein Rx is either said optionally substituted pyridyl, said optionally substituted benzothiopyranyl, or said optionally carbazole wherein said optionally substituted pyridyl, said optionally substituted benzothiopyranyl, or said optionally carbazole is optionally substituted with 1 to 4 substituents independently selected from the group consisting of: unsubstituted C:-C, alkyl, C],-C7 alkoxy, lower haloalkoxy, CF3, F, Cl, Br, CN, and N02.
6. The compound of claim 3, wherein R2 is either unsubstituted longer-length alkyl; unsubstituted longer- length alkenyl; monosubstituted longer-length alkyl with an optionally substituted cycloalkyl having up to four substituents each independently selected from the group consisting of: alkoxy, lower-haloalkyl, S-unsubstituted alkyl, lower-haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, N02, NH2 and OH; monosubstituted longer-length alkenyl with an optionally substituted cycloalkyl having up to four substituents each independently selected from the group consisting of: alkoxy, lower- haloalkyl, S-unsubstituted alkyl, lower-haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, N02, NH2 and OH; monosubstituted longer-length alkyl with an optionally substituted phenyl having up to four substituents each independently selected from the group consisting of: alkoxy, lower-haloalkyl, S-unsubstituted alkyl, lower- haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, N02, NH2 and OH; monosubstituted longer- length alkenyl with an optionally substituted phenyl having up to four substituents each independently selected from the group consisting of: alkoxy, lower-haloalkyl, S-unsubstituted alkyl, lower-haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, N02, NH2 and OH; or an optionally substituted cycloalkyl having up to four substituents each independently selected from the group consisting of: alkoxy, lower-haloalkyl, S-unsubstituted alkyl, lower-haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, N02, NH2 and OH.
7. The compound of claim 6, wherein Rx is either unsubstituted longer-length alkyl; unsubstituted longer- length alkenyl; or said optionally substituted cycloalkyl.
8. The compound of any of claims 2-7, wherein R2 is OH or methoxy, R6 is hydrogen,
R3 and R„ is independently methyl or ethyl; and Z is O, S, or unsubstituted alkylene.
9. The compound of claim 8, wherein Rx is OH, and Z is O.
10. The compound of claim 8, wherein said compound is -V- [2-hydroxy-3- (3-chloro-2-cyanophenoxy)propyl] -
1, l-dimethyl-2- (4-methoxyphenyl) -ethylamine or a pharmaceutically acceptable salt or complex thereof
11. The compound of claims 2-7, wherein R2 is hydrogen,
R6 is hydrogen, R3 and R is independently methyl or ethyl; and Z is O or methylene.
12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of any of claims 1-11.
13. A method of treating a patient comprising the step of administering to said patient a therapeutically effective amount of a compound having the formula:
Figure imgf000110_0001
wherein Rx is selected from the group consisting of: aryl, longer-length alk, and cycloalk,-
R2 is selected from the group consisting of: lower alk, cycloalk, alkoxy, H, OH, =0, C(0)0H, C(0)0-lower alk, C(O)NH- lower alk, C(0)N(lower alk)2, SH, S-lower alk, NH2, NH-lower alk, and Ndower alk)2;
R3 and R4 is each independently lower alk or together cyclopropyl;
R5 is aryl;
R6 if present is either hydrogen, lower alkyl or lower alkenyl, wherein R6 is not present if R2 is =0;
Y is either covalent bond, alkylene, or alkenylene; Y2 is alkylene; Y3 is alkylene; Z is selected from the group consisting of .- covalent bond, O, S, NH, N-lower alk, alkylene, alkenylene, and alkynylene, provided that if Z is either O, S, NH, or N-lower alk, then Yx is not a covalent bond; further provided that Yx and Z may together be a covalent bond; and pharmaceutically acceptable salts and complexes thereof; wherein said patient has a disease or disorder characterized by one or more of the following: (1) an abnormal bone or mineral homeostasis; (2) an abnormal amount of an extracellular or intracellular messenger which is ameliorated by a compound able to effect one or more calcium receptor activities; or (3) an abnormal effect of an intracellular or extracellular messenger which is ameliorated by a compound able to affect one or more calcium receptor activities.
14. The method of claim 13, wherein said disease or disorder is characterized by said abnormal bone or mineral homeostasis .
15. The method of claim 14, wherein said bone or mineral disease or disorder is selected from the group consisting of: osteosarcoma, periodontal disease, fracture healing, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia malignancy, and osteoporosis.
16. The method of claim 15, wherein said bone or mineral disease or disorder is osteoporosis.
17. A method of treating a patient comprising the step of administering to said patient an amount of a compound sufficient to increase serum PTH level, said compound having the formula:
Figure imgf000112_0001
wherein Rx is selected from the group consisting of: aryl, longer-length alk, and cycloalk;
R2 is selected from the group consisting of: lower alk, cycloalk, alkoxy, H, OH, =0, C(0)OH, C(0)0-lower alk, C(O)NH- lower alk, C(0)N(lower alk)2, SH, S-lower alk, NH2, NH-lower alk, and Ndower alk)2;
R3 and R4 is each independently lower alk or together cyclopropyl; R5 is aryl;
R6 if present is either hydrogen, lower alkyl or lower alkenyl, wherein R6 is not present if R2 is =0;
Yx is either covalent bond, alkylene, or alkenylene;
Y2 is alkylene; Y3 is alkylene
Z is selected from the group consisting of: covalent bond, O, S, NH, N-lower alk, alkylene, alkenylene, and alkynylene, provided that if Z is either 0, S, NH, or N-lower alk, then Yx is not a covalent bond; further provided that Yx and Z may together be a covalent bond; and pharmaceutically acceptable salts and complexes thereof.
18. The method of claim 17, wherein said method is carried out by administering an amount of said compound effective to cause an increase in either duration, quantity, or both duration and quantitiy, of serum PTH level sufficient to have a therapeutic effect.
19. The method of claims 17 or 18, wherein said compound is administered to said patient to cause an increase in serum PTH having a duration of one to twelve hours.
20. The method of claim 19, wherein said duration is about two to about four hours .
21. The method of claims 17 or 18, wherein said compound is administered to said patient to cause an increase in serum PTH up to 0.5 fold greater than peak serum PTH in said patient.
22. The method of claims 17 or 18, wherein said compound is administered to said patient to cause an increase in serum PTH 0.5 fold to 5 fold greater than peak serum PTH in said patient.
23. The method of claims 17 or 18, wherein said compound is administered to said patient to cause an increase in serum PTH 5 fold to 10 fold greater than peak serum PTH in said patient.
24. The method of claims 17 or 18, wherein said compound is administered to said patient to cause an increase in serum PTH at least 10 fold greater than peak serum PTH in said patient.
25. The method of any of claims 13-24, wherein R5 is a substituted phenyl having one to four substituents each independently selected from the group consisting of: methoxy, lower alkyl, OCF3, CFH2, CHF2, CF3, 0CH2CF3, F, Cl, Br, I, OH, SH, CN, N02, NH2, methylene dioxy, NH-lower alkyl, Ndower alkyl) 2, C(0) lower alkyl, S-lower alkyl, S (O) lower alkyl, S(0)2lower alkyl, OC(0) lower alkyl, SC(O) lower alkyl, OC(S) lower alkyl, NHC (O) lower alkyl, Ndower alkyl) C (O) lower alkyl, NHC(S) lower alkyl, Ndower alkyl) C(S) lower alkyl, NHS(O) lower alkyl, Ndower alkyl)S (0) lower alkyl, C(0)OH, C(0)0-lower alkyl, C(0)NH2, C(0)NH-lower alkyl, C(0)N(lower alkyl) 2, S(0)2NH2, S (0) 2NH-lower alkyl, and S(0)2N(lower alkyl)2.
26. The method of claim 25, wherein each R5 substituent is independently selected from the group consisting of: alkoxy, lower-haloalkyl, S-unsubstituted alkyl, lower-haloalkoxy, -unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, N02, NH2 and OH.
27. The method of claim 26, wherein R5 is a substituted phenyl with at least one substituent in a meta or para position selected from the group consisting of : lower alkyl, methoxy, Cl, F, Br, and lower haloalkoxy, provided that said Rx substituted phenyl may also have 2 to 3 additional substituents.
28. The method of any of claims 13-24, wherein R5 is an optionally substituted naphthyl.
29. The method of claim 28, wherein R5 is a substituted naphthyl having one to four substituents each independently selected from the group consisting of: alkoxy, lower-haloalkyl, S-unsubstituted alkyl, lower-haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, N02, NH2 and OH.
30. The method of claim 28, wherein R5 is naphthyl.
31. The method of any of claims 13-30, wherein Rx is either unsubstituted longer-length alkyl; unsubstituted longer-length alkenyl; monosubstituted longer-length alkyl with an optionally substituted cycloalkyl having up to four substituents each independently selected from the group consisting of: alkoxy, lower-haloalkyl, S-unsubstituted alkyl, lower-haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, N02, NH2 and OH; monosubstituted longer-length alkenyl with an optionally substituted cycloalkyl having up to four substituents each independently selected from the group consisting of: alkoxy, lower- haloalkyl, S-unsubstituted alkyl, lower-haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, N02, NH2 and OH; monosubstituted longer-length alkyl with an optionally substituted phenyl having up to four substituents each independently selected from the group consisting of: alkoxy, lower-haloalkyl, S-unsubstituted alkyl, lower- haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, N02, NH2 and OH; monosubstituted longer- length alkenyl with an optionally substituted phenyl having up to four substituents each independently selected from the group consisting of: alkoxy, lower-haloalkyl, S-unsubstituted alkyl, lower-haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, N02, NH2 and OH; or an optionally substituted cycloalkyl having up to four substituents each independently selected from the group consisting of: alkoxy, lower-haloalkyl, S-unsubstituted alkyl, lower-haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, N02, NH2 and OH.
32. The method of claim 31, wherein Rx is either unsubstituted longer-length alkyl, unsubstituted longer- length alkenyl, or said optionally substituted cycloalkyl.
33. The method of any of claims 13-30, wherein Rx is either an optionally substituted phenyl, an optionally substituted pyridyl, an optionally substituted benzothiopyranyl, an optionally carbazole.
34. The method of claim 33, wherein Rx is a substituted phenyl having one to four substituents each independently selected from the group consisting of: alkoxy, lower-haloalkyl, S-unsubstituted alkyl, lower-haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, N02, NH2 and OH.
35. The method of claim 34, wherein Rx is either 2-CN- phenyl, 2,3-dichloro phenyl, 2-nitro-phenyl, or 2-cyano-3- chloro-phenyl .
36. The method of any of claims 13-35, wherein R2 is OH or alkoxy,
R6 is hydrogen, R3 and R4 is each independently a lower alkyl ; and Z is either 0, S, or unsubstituted alkylene.
37. The method of claim 36, wherein R2 is OH or methoxy;
Yj is methylene; Y2 is methylene; and Y3 is methylene.
38. The method of claim 37, wherein R3 is methyl or ethyl; and R4 is methyl or ethyl.
39. The method of claim 38, wherein Z is 0 or methylene and R2 is OH.
40. The method of any of claims 13-24, wherein said compound is N- [2-hydroxy-3- (3-chloro-2-cyanophenoxy)propyl] - 1, l-dimethyl-2- (4-methoxyphenyl) -ethylamine or a pharmaceutically acceptable salt or complex thereof.
41. A method of screening for a calcilytic compound comprising the step of measuring the ability of a compound to inhibit one or more calcium receptor activities, said compound having the formula:
Figure imgf000117_0001
wherein Rx is selected from the group consisting of: aryl, longer-length alk, and cycloalk;
R2 is selected from the group consisting of: lower alk, cycloalk, alkoxy, H, OH, =0, C(0)0H, C(0)0-lower alk, C (O)NH- lower alk, C(0)N(lower alk)2, SH, S-lower alk, NH2, NH-lower alk, and Ndower alk)2; R3 and R4 is each independently lower alk or together cyclopropyl,-
R5 is aryl;
R6 if present is either hydrogen, lower alkyl or lower alkenyl, wherein R6 is not present if R2 is =0; Y is either covalent bond, alkylene, or alkenylene;
Y2 is alkylene;
Y3 is alkylene;
Z is selected from the group consisting of: covalent bond, O, S, NH, N-lower alk, alkylene, alkenylene, and alkynylene, provided that if Z is either 0, S, NH, or N-lower alk, then Yx is not a covalent bond; further provided that Yx and Z may together be a covalent bond; and pharmaceutically acceptable salts and complexes thereof.
42. The method of claim 41, wherein said method is carried out under conditions wherein influx of extracellular Ca2+ is inhibited.
PCT/US1997/005558 1996-04-09 1997-04-04 Calcilytic compounds WO1997037967A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
NZ332068A NZ332068A (en) 1996-04-09 1997-04-04 Alpha, alpha-disubstituted arylalkylamine derivatives as calcilytic compounds
EP97917848A EP0901459B1 (en) 1996-04-09 1997-04-04 Calcilytic compounds
PL329314A PL191027B1 (en) 1996-04-09 1997-04-04 α,α-disubstituted arylalkylamine derivative, pharmaceutical composition and use of α,α-disubstituted arylalkylamine
EA199800913A EA002984B1 (en) 1996-04-09 1997-04-04 Calcilytic compounds, pharmaceutical compositions and method of screening for calcilytic compounds
CA002251331A CA2251331C (en) 1996-04-09 1997-04-04 Calcilytic compounds
JP09536327A JP2001501584A (en) 1996-04-09 1997-04-04 Calcilytic compound
AT97917848T ATE298739T1 (en) 1996-04-09 1997-04-04 CALCYLITIC COMPOUNDS
BR9708632-0A BR9708632A (en) 1996-04-09 1997-04-04 Calcilic compounds
AU26070/97A AU726659B2 (en) 1996-04-09 1997-04-04 Calcilytic compounds
IL12645897A IL126458A (en) 1996-04-09 1997-04-04 Calcium receptor inhibiting calcilytic compounds
DE69733649T DE69733649T2 (en) 1996-04-09 1997-04-04 CALCYLITIC COMPOUNDS
HK99103964A HK1018899A1 (en) 1996-04-09 1999-09-11 Calcilytic compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62960896A 1996-04-09 1996-04-09
US08/629,608 1996-04-09
US3226396P 1996-12-03 1996-12-03
US60/032,263 1996-12-03

Publications (1)

Publication Number Publication Date
WO1997037967A1 true WO1997037967A1 (en) 1997-10-16

Family

ID=26708193

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/005558 WO1997037967A1 (en) 1996-04-09 1997-04-04 Calcilytic compounds

Country Status (19)

Country Link
US (2) US6022894A (en)
EP (1) EP0901459B1 (en)
JP (1) JP2001501584A (en)
CN (1) CN1254465C (en)
AR (1) AR008586A1 (en)
AT (1) ATE298739T1 (en)
AU (1) AU726659B2 (en)
BR (1) BR9708632A (en)
CA (1) CA2251331C (en)
CO (1) CO4820431A1 (en)
DE (1) DE69733649T2 (en)
EA (1) EA002984B1 (en)
HK (1) HK1018899A1 (en)
IL (1) IL126458A (en)
NZ (1) NZ332068A (en)
PL (1) PL191027B1 (en)
SA (1) SA97180135B1 (en)
SG (1) SG99290A1 (en)
WO (1) WO1997037967A1 (en)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038500A2 (en) * 1998-01-30 1999-08-05 The Brigham And Women's Hospital, Inc. The human calcium-sensing receptor in the detection and treatment of cancer
EP0973730A1 (en) * 1997-04-08 2000-01-26 Smithkline Beecham Corporation Calcilytic compounds
EP1070048A1 (en) * 1998-04-08 2001-01-24 Smithkline Beecham Corporation Calcilytic compounds
WO2001053254A1 (en) * 2000-01-24 2001-07-26 Smithkline Beecham Corporation Calcilytic compounds
EP1148876A1 (en) * 1999-02-02 2001-10-31 SmithKline Beecham Corporation Calcilytic compounds
EP1308436A1 (en) * 2000-08-11 2003-05-07 Japan Tobacco Inc. Calcium receptor antagonists
EP1368318A2 (en) * 2000-07-21 2003-12-10 SmithKline Beecham Corporation Calcilytic compounds
EP1383511A2 (en) * 2000-10-25 2004-01-28 Smithkline Beecham Corporation Calcilytic compounds
EP1420008A1 (en) * 2002-11-15 2004-05-19 L'oreal Composition, in particular cosmetic, comprising a secondary or tertiary amine
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
WO2005115975A1 (en) 2004-05-28 2005-12-08 Tanabe Seiyaku Co., Ltd. Arylalkylamines and process for production thereof
US7105537B2 (en) 2003-01-28 2006-09-12 Bristol-Myers Squibb Company 2-substituted cyclic amines as calcium sensing receptor modulators
US7109238B2 (en) 2000-01-24 2006-09-19 Smith Kline Beecham Corporation Calcilytic compounds
EP1713767A1 (en) * 2004-02-06 2006-10-25 Smithkline Beecham Corporation Calcilytic compounds
US7157498B2 (en) 2000-08-08 2007-01-02 Centre National De La Recherche Scientifique (Cnrs) Diamines having a CaSR modulating activity
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
WO2007060026A1 (en) * 2005-11-25 2007-05-31 Galapagos Sas Urea derivatives useful as calcium receptor modulators
US7262280B1 (en) 1998-04-03 2007-08-28 Nps Pharmaceuticals, Inc. G-protein fusion receptors and constructs encoding same
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
US7285572B2 (en) 2003-05-28 2007-10-23 Japan Tobacco Inc. CaSR antagonist
US7304174B2 (en) 2003-04-23 2007-12-04 Japan Tobacco Inc. CaSR antagonist
US7338772B2 (en) 2002-04-12 2008-03-04 Schering Corporation G-protein coupled receptor ligands and methods
US7393837B2 (en) 1998-09-28 2008-07-01 Mcgill University Inhibition of PEX in the treatment of metabolic bone diseases
US7514473B2 (en) 2002-11-26 2009-04-07 Smithkline Beecham, Corp. Calcilytic compounds
US7582658B2 (en) 2003-12-25 2009-09-01 Asahi Kasei Pharma Corporation Bicyclic compound
WO2009148052A1 (en) 2008-06-05 2009-12-10 旭化成ファーマ株式会社 Sulfonamide compound and application thereof
EP2196461A1 (en) 2008-12-15 2010-06-16 Bayer CropScience AG 4-Amino-1,2,3-benzoxathiazine-derivatives as pesticides
WO2010103429A1 (en) 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists
US8247412B2 (en) 2005-04-29 2012-08-21 Galapagos Sasu Urea derivatives methods for their manufacture and uses thereof
US8486381B2 (en) 2005-09-02 2013-07-16 Amgen Inc. Methods of modulating intestinal fluid balance
US9861606B2 (en) 2012-09-28 2018-01-09 King's College London Therapeutic for treating inflammatory lung disorders

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (en) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-phenyl-3-dimethylamino-propane compounds with pharmacological activity
US7202261B2 (en) * 1996-12-03 2007-04-10 Nps Pharmaceuticals, Inc. Calcilytic compounds
CO5180628A1 (en) * 1999-07-31 2002-07-30 Smithkline Beecham Corp CALCIOLITIC COMPOUNDS
US7648965B2 (en) * 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US7531518B2 (en) 2004-05-14 2009-05-12 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20080069814A1 (en) * 2005-01-05 2008-03-20 Novacea, Inc. Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof
MX2007013029A (en) * 2005-04-22 2008-01-11 Novacea Inc Treatment, prevention and amelioration of pulmonary disorders associated with chemotherapy or radiotherapy with active vitamin d compounds or mimics thereof.
US20060293667A1 (en) * 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
WO2009055631A1 (en) * 2007-10-25 2009-04-30 Smithkline Beecham Corporation Calcilytic compounds
CN103601645B (en) * 2013-11-07 2016-05-25 上海适济生物科技有限公司 The preparation method of 1-(phenethyl amino) propane-2-alcohol compound or its salt
WO2019153216A1 (en) * 2018-02-09 2019-08-15 北京梅尔森医药技术开发有限公司 Substituted arylamino alcohol compound, preparation method therefor, and application thereof
EP4069669A1 (en) * 2019-12-05 2022-10-12 Syngenta Crop Protection AG One step process for the preparation of phenyl ethyl amine derivatives
CN116199605A (en) * 2023-02-27 2023-06-02 上海睿腾医药科技有限公司 Synthesis method of 5-chloro-2-hydroxy-dimethylbenzenesulfonamide

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2502993A1 (en) * 1974-02-14 1975-09-04 Haessle Ab AMINES, THE METHOD OF MANUFACTURING THEIR PRODUCTS AND THE MEDICINAL PRODUCTS CONTAINING THEY
EP0002792A1 (en) * 1978-01-03 1979-07-11 Sandoz Ag 3-Aminopropoxyaryl derivatives, their preparation and pharmaceutical compositions containing them
ES480066A1 (en) * 1979-04-28 1980-04-01 Especialid Latin Medicam Unive Procedure for obtaining 1- (4-chloro-alpha, alpha-dimethyl-benzene-etanalline) -2-oxy-3- (aricoxi) propanes. (Machine-translation by Google Translate, not legally binding)
EP0009075A1 (en) * 1978-06-27 1980-04-02 Merck & Co. Inc. Pyridyloxy-propanol amines and esters thereof, process for preparing the same and pharmaceutical compositions containing them
DE2943406A1 (en) * 1979-10-26 1981-05-07 Basf Ag, 6700 Ludwigshafen AMINO DERIVATIVES OF 2-METHYL-5- (2-HYDROXYSTYRYL) -1,3,4-THIADIAZOL
DE2944222A1 (en) * 1979-11-02 1981-05-14 Basf Ag, 6700 Ludwigshafen Amino derivs. of 1,2-benzisothiazole - beta:sympatholytics suitable for the treatment of coronary heart disease, hypertonia and cardiac arrhythmia
CH636856A5 (en) * 1978-07-17 1983-06-30 Sandoz Ag 4-(3-Aminopropoxy)indole derivatives, their preparation and medicines containing them
DE3301198A1 (en) * 1983-01-15 1984-07-19 Hoechst Ag, 6230 Frankfurt N-Arylalkylamine-3-propoxypyridine derivatives, process for their preparation, pharmaceutical preparations containing them and their use
EP0188361A1 (en) * 1985-01-15 1986-07-23 Glaxo Group Limited Amine derivatives
DE4040186A1 (en) * 1989-12-20 1991-06-27 Hoechst Ag Use of 3-amino-propan-1,2-di:ol derivs. - as racemate, enantiomeric mixt. or pure enantiomer in treatment of diabetes mellitus
WO1993004373A1 (en) * 1991-08-23 1993-03-04 Nps Pharmaceuticals, Inc. Calcium receptor active molecules
WO1994018959A1 (en) * 1993-02-23 1994-09-01 Brigham And Women's Hospital, Inc. Calcium receptor-active molecules

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE298506C (en) *
GB1129072A (en) * 1966-02-01 1968-10-02 Ici Ltd Benzofuran and indole derivatives
GB1058822A (en) * 1963-07-30 1967-02-15 Ici Ltd 3-amino-2-hydroxypropoxy heterocyclic derivatives
GB1199037A (en) * 1967-09-27 1970-07-15 Ici Ltd Alkanolamine Derivatives
ES410417A1 (en) * 1973-01-08 1976-01-01 Andreu Sa Dr Procedure for the obtaining of aminoalcohols derived from p-acetamidophenol. (Machine-translation by Google Translate, not legally binding)
DE2530613A1 (en) * 1974-11-01 1976-05-06 Haessle Ab AMINE DERIVATIVES, PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THEM
US4067904A (en) * 1975-12-19 1978-01-10 Mead Johnson & Company Alkylsulfonylphenoxypropanolamine derivatives
JPS5936617B2 (en) * 1976-03-05 1984-09-05 大塚製薬株式会社 carbostyril derivatives
CH619453A5 (en) * 1976-03-17 1980-09-30 Otsuka Pharma Co Ltd
US4235919A (en) * 1977-07-21 1980-11-25 Sandoz Ltd. 1-(Indol-4-yloxy)-3-(2-substituted amino)-2-propanols and pharmaceutical use thereof
DE2830211A1 (en) * 1977-07-21 1979-02-01 Sandoz Ag SUBSTITUTED INDOL DERIVATIVES, THEIR PRODUCTION AND USE
DE2914166A1 (en) * 1979-04-07 1980-10-23 Beiersdorf Ag ARYL-SUBSTITUTED FURANE AND METHOD FOR THEIR PRODUCTION
JPS568319A (en) * 1980-03-26 1981-01-28 Otsuka Pharmaceut Co Ltd Antihistamine
US4332787A (en) * 1980-06-23 1982-06-01 The Massachusetts General Hospital Assay for beta-adrenergic antagonists and antibody therefor
JPS5780321A (en) * 1980-11-05 1982-05-19 Otsuka Pharmaceut Co Ltd Cardiotonic agent
US4376125A (en) * 1980-11-05 1983-03-08 University Of Virginia Alumni Patents Foundation Aminobenzlpropranolol and pharmaceutical preparation thereof
EP0095454A3 (en) * 1982-05-13 1985-04-03 Gerot-Pharmazeutika Gesellschaft m.b.H. Nuclens-substituted pyrogallol derivatives
US4517188A (en) * 1983-05-09 1985-05-14 Mead Johnson & Company 1-Pyrimidinyloxy-3-hetaryl-alkylamino-2-propanols
GB2192394A (en) * 1986-07-11 1988-01-13 Glaxo Group Ltd Amine derivatives
US5053514A (en) * 1988-08-10 1991-10-01 Otsuka Pharmaceutical Company, Limited Cardiotonics
DE4017019A1 (en) * 1990-05-26 1991-11-28 Hoechst Ag USE OF SUBSTITUTED SS-HYDROXYETHYLAMINES AS POTENTIAL INGREDIENTS OF THE EXOENZYME OF MUSHROOMS
CA2102780C (en) * 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
CA2173747C (en) * 1991-08-23 2006-05-23 Edward F. Nemeth Calcium receptor-active arylalkyl amines
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
GB9312893D0 (en) * 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2502993A1 (en) * 1974-02-14 1975-09-04 Haessle Ab AMINES, THE METHOD OF MANUFACTURING THEIR PRODUCTS AND THE MEDICINAL PRODUCTS CONTAINING THEY
EP0002792A1 (en) * 1978-01-03 1979-07-11 Sandoz Ag 3-Aminopropoxyaryl derivatives, their preparation and pharmaceutical compositions containing them
EP0009075A1 (en) * 1978-06-27 1980-04-02 Merck & Co. Inc. Pyridyloxy-propanol amines and esters thereof, process for preparing the same and pharmaceutical compositions containing them
CH636856A5 (en) * 1978-07-17 1983-06-30 Sandoz Ag 4-(3-Aminopropoxy)indole derivatives, their preparation and medicines containing them
ES480066A1 (en) * 1979-04-28 1980-04-01 Especialid Latin Medicam Unive Procedure for obtaining 1- (4-chloro-alpha, alpha-dimethyl-benzene-etanalline) -2-oxy-3- (aricoxi) propanes. (Machine-translation by Google Translate, not legally binding)
DE2943406A1 (en) * 1979-10-26 1981-05-07 Basf Ag, 6700 Ludwigshafen AMINO DERIVATIVES OF 2-METHYL-5- (2-HYDROXYSTYRYL) -1,3,4-THIADIAZOL
DE2944222A1 (en) * 1979-11-02 1981-05-14 Basf Ag, 6700 Ludwigshafen Amino derivs. of 1,2-benzisothiazole - beta:sympatholytics suitable for the treatment of coronary heart disease, hypertonia and cardiac arrhythmia
DE3301198A1 (en) * 1983-01-15 1984-07-19 Hoechst Ag, 6230 Frankfurt N-Arylalkylamine-3-propoxypyridine derivatives, process for their preparation, pharmaceutical preparations containing them and their use
EP0188361A1 (en) * 1985-01-15 1986-07-23 Glaxo Group Limited Amine derivatives
DE4040186A1 (en) * 1989-12-20 1991-06-27 Hoechst Ag Use of 3-amino-propan-1,2-di:ol derivs. - as racemate, enantiomeric mixt. or pure enantiomer in treatment of diabetes mellitus
WO1993004373A1 (en) * 1991-08-23 1993-03-04 Nps Pharmaceuticals, Inc. Calcium receptor active molecules
WO1994018959A1 (en) * 1993-02-23 1994-09-01 Brigham And Women's Hospital, Inc. Calcium receptor-active molecules

Cited By (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0973730A1 (en) * 1997-04-08 2000-01-26 Smithkline Beecham Corporation Calcilytic compounds
EP0973730A4 (en) * 1997-04-08 2000-08-23 Smithkline Beecham Corp Calcilytic compounds
US6294531B1 (en) 1997-04-08 2001-09-25 Smithkline Beecham Corporation Calcilytic compounds
WO1999038500A3 (en) * 1998-01-30 2000-04-13 Brigham & Womens Hospital The human calcium-sensing receptor in the detection and treatment of cancer
WO1999038500A2 (en) * 1998-01-30 1999-08-05 The Brigham And Women's Hospital, Inc. The human calcium-sensing receptor in the detection and treatment of cancer
US6296833B1 (en) 1998-01-30 2001-10-02 The Brigham And Women's Hospital, Inc. Human calcium-sensing receptor in the detection and treatment of cancer
US7262280B1 (en) 1998-04-03 2007-08-28 Nps Pharmaceuticals, Inc. G-protein fusion receptors and constructs encoding same
EP1070048A1 (en) * 1998-04-08 2001-01-24 Smithkline Beecham Corporation Calcilytic compounds
EP1070048A4 (en) * 1998-04-08 2001-11-07 Smithkline Beecham Corp Calcilytic compounds
US6395919B1 (en) 1998-04-08 2002-05-28 Smithkline Beecham Corporation Calcilytic compounds
US7393837B2 (en) 1998-09-28 2008-07-01 Mcgill University Inhibition of PEX in the treatment of metabolic bone diseases
EP1148876A1 (en) * 1999-02-02 2001-10-31 SmithKline Beecham Corporation Calcilytic compounds
EP1148876A4 (en) * 1999-02-02 2003-07-23 Smithkline Beecham Corp Calcilytic compounds
AU764746B2 (en) * 2000-01-24 2003-08-28 Nps Pharmaceuticals, Inc. Calcilytic compounds
US7109238B2 (en) 2000-01-24 2006-09-19 Smith Kline Beecham Corporation Calcilytic compounds
EP2141146A1 (en) * 2000-01-24 2010-01-06 SmithKline Beecham Corporation Calcilytic compounds
WO2001053254A1 (en) * 2000-01-24 2001-07-26 Smithkline Beecham Corporation Calcilytic compounds
EP1368318A2 (en) * 2000-07-21 2003-12-10 SmithKline Beecham Corporation Calcilytic compounds
EP1368318A4 (en) * 2000-07-21 2006-08-23 Smithkline Beecham Corp Calcilytic compounds
US7157498B2 (en) 2000-08-08 2007-01-02 Centre National De La Recherche Scientifique (Cnrs) Diamines having a CaSR modulating activity
EP1308436A4 (en) * 2000-08-11 2005-10-05 Japan Tobacco Inc Calcium receptor antagonists
US6916956B2 (en) 2000-08-11 2005-07-12 Japan Tobacco, Inc. Calcium receptor antagonist
US7211685B2 (en) 2000-08-11 2007-05-01 Japan Tobacco Inc. Calcium receptor antagonists
EP1308436A1 (en) * 2000-08-11 2003-05-07 Japan Tobacco Inc. Calcium receptor antagonists
EP1383511A4 (en) * 2000-10-25 2005-05-18 Smithkline Beecham Corp Calcilytic compounds
EP1383511A2 (en) * 2000-10-25 2004-01-28 Smithkline Beecham Corporation Calcilytic compounds
US7807390B2 (en) 2002-04-12 2010-10-05 Schering Corporation G-protein coupled receptor ligands and methods
US7338772B2 (en) 2002-04-12 2008-03-04 Schering Corporation G-protein coupled receptor ligands and methods
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US7196102B2 (en) 2002-05-23 2007-03-27 Amgen Inc. Calcium receptor modulating agents
EP1420008A1 (en) * 2002-11-15 2004-05-19 L'oreal Composition, in particular cosmetic, comprising a secondary or tertiary amine
FR2847250A1 (en) * 2002-11-15 2004-05-21 Oreal COMPOSITION, IN PARTICULAR COSMETIC, COMPRISING SECONDARY OR TERTIARY AMINE
US7829594B2 (en) 2002-11-26 2010-11-09 GlaxoSmithKline, LLC Calcilytic compounds
US8399517B2 (en) 2002-11-26 2013-03-19 GlaxoSmithKline, LLC Calcilytic compounds
US9227914B2 (en) 2002-11-26 2016-01-05 GlaxoSmithKline, LLC Calcilytic compounds
US8586631B2 (en) 2002-11-26 2013-11-19 GlaxoSmithKline, LLC Calcilytic compounds
US8980950B2 (en) 2002-11-26 2015-03-17 GlaxoSmithKline, LLC Calcilytic compounds
US7514473B2 (en) 2002-11-26 2009-04-07 Smithkline Beecham, Corp. Calcilytic compounds
US7105537B2 (en) 2003-01-28 2006-09-12 Bristol-Myers Squibb Company 2-substituted cyclic amines as calcium sensing receptor modulators
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
EP2308828A2 (en) 2003-04-23 2011-04-13 Japan Tobacco Inc. CaSR antagonist
US7304174B2 (en) 2003-04-23 2007-12-04 Japan Tobacco Inc. CaSR antagonist
EP2189439A2 (en) 2003-04-23 2010-05-26 Japan Tobacco, Inc. CaSR antagonist
US7285572B2 (en) 2003-05-28 2007-10-23 Japan Tobacco Inc. CaSR antagonist
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
US7582658B2 (en) 2003-12-25 2009-09-01 Asahi Kasei Pharma Corporation Bicyclic compound
EP1713767A1 (en) * 2004-02-06 2006-10-25 Smithkline Beecham Corporation Calcilytic compounds
EP1713767A4 (en) * 2004-02-06 2008-01-16 Smithkline Beecham Corp Calcilytic compounds
US8492111B2 (en) 2004-05-28 2013-07-23 Mitsubishi Tanabe Pharma Corporation Arylalkylamine compound and process for preparing the same
WO2005115975A1 (en) 2004-05-28 2005-12-08 Tanabe Seiyaku Co., Ltd. Arylalkylamines and process for production thereof
US8778628B2 (en) 2004-05-28 2014-07-15 Mitsubishi Tanabe Pharma Corporation Arylalkylamine compound and process for preparing the same
US8703721B2 (en) 2004-05-28 2014-04-22 Mitsubishi Tanabe Pharma Corporation Arylalkylamine compound and process for preparing the same
US8362274B2 (en) 2004-05-28 2013-01-29 Mitsubishi Tanabe Pharma Corporation Arylalkylamine compound and process for preparing the same
US8759387B2 (en) 2004-05-28 2014-06-24 Mitsubishi Tanabe Pharma Corporation Arylalkylamine compound and process for preparing the same
US8247412B2 (en) 2005-04-29 2012-08-21 Galapagos Sasu Urea derivatives methods for their manufacture and uses thereof
US8486381B2 (en) 2005-09-02 2013-07-16 Amgen Inc. Methods of modulating intestinal fluid balance
US7875609B2 (en) 2005-11-25 2011-01-25 Galapagos Sasu Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them
WO2007060026A1 (en) * 2005-11-25 2007-05-31 Galapagos Sas Urea derivatives useful as calcium receptor modulators
WO2009148052A1 (en) 2008-06-05 2009-12-10 旭化成ファーマ株式会社 Sulfonamide compound and application thereof
US8039514B2 (en) 2008-06-05 2011-10-18 Asahi Kasei Pharma Corporation Sulfonamide compounds and use thereof
US8173641B2 (en) 2008-12-15 2012-05-08 Bayer Cropscience Ag 4-amino-1,2,3-benzoxathiazine-derivatives as pesticides
EP2196461A1 (en) 2008-12-15 2010-06-16 Bayer CropScience AG 4-Amino-1,2,3-benzoxathiazine-derivatives as pesticides
WO2010103429A1 (en) 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists
US9861606B2 (en) 2012-09-28 2018-01-09 King's College London Therapeutic for treating inflammatory lung disorders

Also Published As

Publication number Publication date
NZ332068A (en) 2001-03-30
IL126458A0 (en) 1999-08-17
HK1018899A1 (en) 2000-01-07
EP0901459B1 (en) 2005-06-29
IL126458A (en) 2004-06-20
CA2251331C (en) 2009-06-09
AR008586A1 (en) 2000-02-09
AU726659B2 (en) 2000-11-16
CN1221401A (en) 1999-06-30
US6521667B1 (en) 2003-02-18
PL191027B1 (en) 2006-03-31
EP0901459A1 (en) 1999-03-17
SG99290A1 (en) 2003-10-27
EA002984B1 (en) 2002-12-26
US6022894A (en) 2000-02-08
EA199800913A1 (en) 1999-06-24
CA2251331A1 (en) 1997-10-16
DE69733649D1 (en) 2005-08-04
BR9708632A (en) 2000-01-18
ATE298739T1 (en) 2005-07-15
CO4820431A1 (en) 1999-07-28
JP2001501584A (en) 2001-02-06
PL329314A1 (en) 1999-03-15
AU2607097A (en) 1997-10-29
DE69733649T2 (en) 2006-05-18
SA97180135B1 (en) 2006-06-12
CN1254465C (en) 2006-05-03

Similar Documents

Publication Publication Date Title
US6521667B1 (en) Calcilytic compounds
JP4431609B2 (en) Inorganic ion active compound
US6432656B1 (en) Calcilytic compounds
US6001884A (en) Calcium receptor-active molecules
EP0787122B9 (en) Calcium receptor-active compounds
US6335338B1 (en) Calcilytic compounds
US7202261B2 (en) Calcilytic compounds
US6818660B2 (en) Calcilytic compounds
US20070249702A1 (en) Calcilytic compounds
US6291459B1 (en) Calcilytic compounds
WO1998044925A1 (en) Calcilytic compounds
EP1258471B1 (en) Inorganic ion receptor-active compounds
EP1770083B1 (en) Inorganic ion receptor-active compounds
AU2004202208B2 (en) Inorganic Ion Receptor-active Compounds
CA2253407C (en) Inorganic ion receptor-active compounds
WO2006042007A2 (en) Chromenone compounds as calcilytics
AU2007221967A1 (en) Inorganic ion receptor-active compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97195368.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 332068

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2251331

Country of ref document: CA

Ref document number: 2251331

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/008327

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 1997 536327

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997917848

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 199800913

Country of ref document: EA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997917848

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1997917848

Country of ref document: EP